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1 INTRODUCTION
1 Introduction
1.1 Transmissible spongiform encephalopathies
Transmissible spongiform encephalopathies or prion diseases are neurodegenerative
disorders of the central nervous system (CNS) leading to motor dysfunctions, dementia
and death. Among animals the most prominent prion diseases are scrapie in sheep
and bovine spongiform encephalopathy (BSE) in cattle. Human prion diseases in-
clude Creutzfeldt-Jakob disease (CJD), Kuru, Gerstmann-Sträussler-Scheinker syn-
drome (GSS) and fatal familiar insomnia (FFI). Recently, a new variant of CJD (vCJD)
attracted the interest of the public as it was ascribed to the consumption of BSE-
contaminated products [Will et al., 1996] and to date has claimed 164 victims until
the 3rd August 20091.
Prion diseases show up with long incubation times and so far no therapy is available.
Moreover a progressive course of the disease is observed, including a slow destruc-
tion of the brain, which is accompanied by alterations in behavior, motor impairments
and cognitive decline. Beneath the characteristic neuropathological changes, such as
spongiform degeneration of the CNS, astrocytic gliosis and neuronal death, the accu-
mulation of amyloid deposits is found frequently but not necessarily in the brains of
infected individuals (Fig 1). Neither humoral nor cellular immune responses have been
detected in prion disease [Collinge, 2001; Prusiner , 2001].
In contrast to other disorders affecting the brain that are associated with accumu-
lation of aggregated proteins, such as Alzheimer’s or Huntington’s disease, transmis-
sibilty is another hallmark of prion diseases [Tateishi et al., 1996]. The transmission
of prion diseases was first demonstrated in 1936, when scrapie was experimentally
transmitted to healthy sheep and goats through inoculation [Cuillé and Chelle, 1936].
Thirty years later the human prion disease kuru was also shown to be transmissible
[Gajdusek et al., 1966] and in 1961 the infectious agent was successfully transmitted
to mice [Chandler , 1961], providing an animal model for prion disease research.
To date it is known that those amyloid deposits, which are found in the brains of prion
infected individuals mainly consist of an insoluble protein, designated PrPSc, which is
a misfolded isoform of the endogenous cellular prion protein (PrPC) [Prusiner , 1989].
Some decades ago most researchers postulated a ”slow virus” as the cause of the dis-
ease [Sigurdsson, 1954; Gajdusek et al., 1966; Gajdusek , 1977]. Then the remarkable
resistance of the infectious agent to conventional sterilization techniques, like exposure
to ultraviolet light, heat and even X-ray irradiation, led to the idea that the infectious
agent might be devoid of nucleic acids [Alper et al., 1966]. The revolutionary hypothe-
sis that a protein could be the pathogen was first formulated by Griffith in 1967 [Griffith,
1The National Creutzfeldt-Jakob Disease Surveillance Unit, www.cjd.ed.as.uk
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1967]. Later the protein-only hypothesis was further elaborated by Stanley B. Prusiner,
who defined the infectious agent as ”proteinaceous infectious particles” (prion). In
1982 he stated that prions are composed largely if not entirely of an abnormal protein
[Prusiner , 1982]. Indeed a host gene, encoding for the cellular form of the prion pro-
tein (PrPC), was discovered [Oesch et al., 1985; Chesebro et al., 1985; Basler et al.,
1986]. Over the years many studies, such as the generation of PrP knockout mice be-
ing resistant to prion infection [Büeler et al., 1992, 1993], contributed to the protein-only
hypothesis. In 1997 Prusiner was finally awarded for the Nobel prize in medicine ”for
his discovery of Prions - a new biological principle of infection”.
1.2 Prion disease of humans and animals
1.2.1 Animal prion diseases
Scrapie, a prion disease of sheep and goats, has been recognized in Europe for over
200 years and is still present endemically in many countries. Scrapie was first observed
in 1732 and later its experimental transmissibilty was shown [McGowan, 1922; Cuillé
and Chelle, 1936]. Typical symptoms of scrapie are changes in behavior, hypersensi-
tivity to touch and noise, changes in locomotion (e. g. ataxia of hind limbs), weight loss
as well as wool loss through rubbing and scratching [Gaiger , 1924].
Between 1920 and 1958 scrapie became a problem in the Suffolk breed, causing
immense financial loss [Bull and Murnane, 1958]. International trade with these sheep
was considered to be responsible for the worldwide spread of the disease and led
to an increase in scrapie research since the 1930s [Parry , 1962, 1983]. Although
scrapie is one of the best characterized prion diseases in animals, so far only little is
known about its natural transmission. Today it is generally believed that scrapie is a
transmissible disease, which is strongly influenced by host genetics as specific alleles
provide resistance or render sheep more susceptible [Belt et al., 1995; Hunter et al.,
1996].
Since the first case of bovine spongiform encephalopathy (BSE) was observed in
the United Kingdom (UK) in 1986 [Wells et al., 1987], BSE was confirmed in most
European countries as well as in Canada, Scandinavia, Israel, Japan and in the USA
and developed into a major epidemic. To date more than 184.000 cattle in the UK
and more than 5800 cattle worldwide were affected by BSE until the 30th June 20092,
provoking a severe food crisis and economic consequences. BSE may originate from
sheep scrapie by feeding cattle with inadequately heat-activated meat-and-bone-meal
(MBM) derived from scrapie-infected sheep [Wilesmith et al., 1988]. Alternatively, BSE
may have been a rare, sporadic disease of cattle, which spread extensively among
2World Organization for Animal Health, www.oie.int/eng/info/en_esbru.htm
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the cattle population after the technical protocol for MBM was changed to lower tem-
peratures in 1970 [Wilesmith et al., 1991]. Independent of the source, it is very likely
that MBM served as vehicle of transmission from cattle to cattle. As a consequence of
these findings ”The Ruminant Feed Ban of 18th July 1988” was concluded and export
of cattle from the UK to other European countries was forbidden in 1989. Simultaneous
to the BSE epidemic, new TSEs of ruminant species in zoos and also in domestic and
captive wild cats were identified. Some of these have been confirmed to be caused by
BSE-contaminated MBM [Jeffrey and Wells, 1988; Kirkwood et al., 1990]. Moreover
transmission of BSE to humans was described [Hill et al., 1997; Collinge, 2001] and
has caused about 164 cases of a new variant of CJD3. Although BSE seems to have
widely spread via the food chain, prion disease have never been observed in dogs or
birds [Matthews and Cooke, 2003] and feeding of pigs with BSE contaminated material
did not cause the disease [Dawson et al., 1990; Wells et al., 2003].
Beside scrapie and BSE, several other prion diseases of animals have been de-
scribed (Tab 1), including transmissible mink encephalopathy [Marsh and Hadlow ,
1992], chronic wasting disease of deer and elk [Williams and Young, 1980] and fe-
line spongiform encephalopathy in domestic cats [Wyatt et al., 1991]. All these prion
diseases present with alterations in behavior like enhanced aggressiveness, stereotyp-
ical scraping and motor impairments and most of them are most likely transmitted via
the oral route.
Table 1: Animal prion diseases.
Disease Species Transmission
Scrapie sheep
goat
oral
vertical, horizontal
sporadic (?)
Bovine spongiform encephalopathy
(BSE)
cattle
other ruminants
oral
sporadic (?)
Transmissible mink
encephalopathy (TME)
mink oral
(cattle MBM)
Chronic wasting disease (CWD) deer
elk
possibly similar to scrapie
Feline spongiform encephalopathy
(FSE)
domestic cats
wild cats (zoo)
oral
(cattle MBM)
3until 3rd August 2009; The National Creutzfeldt-Jakob Disease Surveillance Unit, www.cjd.ed.as.uk
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1.2.2 Human prion diseases
Human prion disease include Creutzfeldt-Jakob disease (CJD), Kuru, fatal familiar
insomnia (FFI) and Gerstmann-Sträussler-Scheinker syndrome (GSS). According to
their etiology, they are further divided into sporadic, acquired and inherited forms (Tab
2). Although prion diseases of humans are not contagious, the transmissibilty of human
prion disease was proofed experimentally. Kuru was transmitted by intracerebral inoc-
ulation of infected brain homogenates into chimpanzees [Gajdusek et al., 1966], later
transmission studies of CJD and GSS led to the concept of ”transmissible dementias”
[Gibbs et al., 1968; Masters et al., 1981]. In addition to transmissibilty and similar clini-
cal symptoms, human and animal prion diseases also share common neuropathologi-
cal features like spongiform vacuolization of the CNS, astrocytic proliferation, neuronal
loss and the presence of amyloid plaques (Fig 1).
Classical or sporadic Creutzfeldt-Jakob disease (sCJD) was first described in 1920
by H. G. Creutzfeldt and A. M. Jakob [Creutzfeldt , 1920; Jakob, 1921]. sCJD is the most
common human prion disease with an annual incidence of one per million [Masters
et al., 1979]. sCJD most frequently affects aged people of about 55-75 years, showing
a disease duration of less than one year. Typical symptoms of sCJD are a rapid,
progressive dementia with speech impairments, myoclonus, coordination dysfunctions
and seizures. How prions spontaneously evolve in sCJD patients is so far unknown.
Neither a genetic predisposition nor any signs of an infection were found [Collinge,
2001].
Figure 1: Characteristic neuropathological features of transmissible spongiform en-
cephalopathies. (A) Grey matter of the brain of a CJD patient stained with hema-
toxylin–eosin (HE) displaying the characteristic spongiform, vacuole-like morphology.
(B) Activation and proliferation of reactive, swollen astrocytes is visualized by stain-
ing with antibodies against glial fibrillary acidic protein (GFAP, brown). (C) Immuno-
histochemical staining using anti-PrP antibodies shows prion protein deposits (brown
colour). Adapted from [Glatzel and Aguzzi , 2001].
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Acquired human prion disease include Kuru, iatrogenic CJD (iCJD) and a recently
described new variant of CJD (vCJD). Kuru is a neurodegenerative disease character-
ized by progressive ataxia and dementia and long incubation periods (>40 years) [Gaj-
dusek and Zigas, 1957; Collinge et al., 2006]. It was observed among the Fore pop-
ulation living in the Eastern Highlands of Papua New Guinea in the 1950s. Kuru was
transmitted during cannibalistic feasts, when deceased Kuru-affected relatives were
consumed by the community [Gajdusek , 1977]. Kuru is believed to have originated
from a random, sporadic CJD case among the Fore [Alpers and Rail , 1971]. Conse-
quently the recycling of prions by cannibalism among the isolated population led to a
Kuru epidemic and was a major cause of death of Fore people.
Iatrogenic transmission of CJD occurred mainly from human to human via medical
accidents. Most of these cases are due to injection of cadaverous human growth hor-
mone and transplantation of dura mater [Brown, 1988; Brown et al., 2000]. However,
also transmission via transplantation of cornea, usage of prion-contaminated neuro-
surgical instruments and brain electrodes was described [Duffy et al., 1974; Bernoulli
et al., 1977].
Variant CJD (vCJD) was first described in 1995 and 1996, when some cases of
remarkably young CJD patients with an untypical clinical phenotype were identified
[Will et al., 1996]. In contrast to sCJD a prolonged disease duration of 13-14 month
is observed. Moreover the median age of disease onset with 28 years is reduced and
vCJD patients show predominantly psychiatric disturbances in comparison to sCJD.
Similar to the late phase of classical CJD, all vCJD patients develop ataxia, which is
followed by a progressive dementia [Zeidler et al., 1997a, b].
The sudden increase in CJD cases in the UK in the early 1990s, parallel to the
BSE epidemic, led to the idea that these cases might be related to BSE-exposure,
in particular to ingestion of BSE-contaminated food products [Will et al., 1996]. Later
this hypothesis was supported by lots of studies. It was shown that mice, sheep and
non-human primates can be experimentally infected by BSE-contaminated material by
the oral route [Maignien et al., 1999; Jeffrey et al., 2001; Ridley and Baker , 1996;
Bons et al., 1999]. Moreover transmission characteristics, incubation times and lesion
profiles as well as glycosylation pattern of vCJD and BSE in the same inbred mouse
strains are similar [Hill et al., 1997; Bruce et al., 1997; Scott et al., 1999], providing
strong evidence that the agent causing vCJD is the same as the agent causing BSE.
To date 164 cases of vCJD have been confirmed4. Although most of these cases are
related to consumption of BSE-infected material at least two vCJD cases have been
transmitted by blood transfusion [Llewelyn et al., 2004; Peden et al., 2004], leading
to a debate concerning the biosafety of medical products and to efforts of developing
adequate test systems.
4until 3rd August 2009; The National Creutzfeldt-Jakob Disease Surveillance Unit, www.cjd.ed.as.uk
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10% of all human prion diseases are inherited and related to different mutations
of the Prnp gene, encoding for the cellular prion protein. More than 50 point- and
missence mutations are known for Prnp, which are inherited autosomal dominantly
[J. Gerstmann, 1936]. Hereditary human prion diseases have various characteristics.
While GSS presents classically as a cerebellar ataxia and dementia around the age of
45 with a mean duration of about 5 years, familiar CJD (fCJD) shows a much shorter
disease duration [Haltia et al., 1979]. Massive sleep disturbances, neuronal loss and
gliosis in the thalamus are characteristic for FFI, a recently described inherited human
prion disease [Medori et al., 1992]. Various Prnp mutations are described for fCJD
[Kovács et al., 2002], while GSS frequently present a P102L mutation in addition to
various other Prnp mutations [Hsiao et al., 1989]. In FFI a D178N mutation together
with 129 M/M homozygosity is observed [Goldfarb et al., 1992; Medori et al., 1992].
Table 2: Human prion diseases.
Disease Etiology Transmission
sporadic Creutzfeldt-Jakob disease
(sCJD)
sporadic conversion of PrPC to PrPSc
iatrogenic Creutzfeldt-Jakob
disease (iCJD)
acquired iatrogenic transmission (contaminated
medical products and instruments)
familiar Creutzfeldt-Jakob disease
(fCJD)
hereditary various Prnp mutations
variant Creutzfeldt-Jakob disease
(vCJD)
acquired transmission by consumption of
BSE-contaminated products or from
human to human e.g. via blood
transfusion
Kuru acquired sporadic CJD case among the Fore;
transmission via endocannibalism
Gerstmann-Sträussler-Scheinker
syndrome (GSS)
hereditary various Prnp mutations (frequently
P102L)
fatal familiar insomnia (FFI) hereditary Prnp mutation D178N and 129 M/M
Protease-sensitive prionopathy
(PSPr)
unknown unknown
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Even in non-hereditary human prion disease the susceptibility of humans to prion
diseases is strongly influenced by the host genetics. In particular methionine / methion-
ine (M/M) homozygosity at codon 129 of the Prnp gene plays an important role in prion
susceptibility. 129 M/M homozygosity is found in most sCJD cases and is associated
with a shorter incubation time in Kuru [Lee et al., 2001; Windl et al., 1996]. In addition
almost all tested vCJD cases were 129 M/M homozygous [Collinge et al., 1996; Hill
et al., 1999].
Recently a new class of prion disease, called protease-sensitive prionopathy (PSPr)
was described. In comparison to other human prion disease, PSPr display a different
histopathology and only small amounts of misfolded PrP are found in brains of affected
individuals. According to the authors PSPr might have been overlooked so far and
classified as non-Alzheimer’ s dementias [Gambetti et al., 2008].
1.3 The prion concept
The nature of the infectious agent, responsible for prion disease, was ambiguous for a
long time. In 1936 transmission studies of the scrapie agent to healthy sheep and goats
were successful but very long incubation periods were observed [Cuillé and Chelle,
1936]. This led to the conclusion that the infection might be caused by a ”slow virus”
with long replication cycles [Sigurdsson, 1954; Gajdusek et al., 1966; Gajdusek , 1977].
On the contrary several studies proofed a remarkable resistance of the agent against
conventional sterilization techniques. The infectivity of the agent was not reduced by
procedures known to damage nucleic acids, such as ultraviolet light, X-ray irradiation
or treatment with nucleases. Surprisingly, procedures known to modify or hydrolyze
proteins, like treatment with urea, sodium hydroxide or digestion with proteinase K or
trypsin, led to an inactivation of the infectious agent [Alper et al., 1966, 1967; Prusiner
et al., 1981]. These findings led to the very unconventional hypothesis that the infec-
tious agent might be devoid of nucleic acids [Griffith, 1967]. In 1982 S. Prusiner purified
infectious material from scrapie infected hamster brain and showed that the extract was
capable of forming amyloid structures in vitro, which were very similar to the deposits
found in scrapie-infected brains [Bolton et al., 1982; Prusiner , 1982; McKinley et al.,
1983; DeArmond et al., 1985]. In order to distinguish this new class of pathogens
from viruses and bacteria, he introduced the term ”proteinaceous infectious particles”
(prion) and stated that the infectious agent is composed largely if not entirely of a sin-
gle protein that can replicate without the use of nucleic acids (”protein-only” hypothesis)
[Prusiner , 1982].
Shortly afterwards amino acid sequencing led to the identification of the N-terminal
sequence of the prion protein (PrP), which was extracted from infected brains [Prusiner
et al., 1984]. The usage of molecular gene probes finally led to the identification of
13
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a host encoded single-copy chromosomal gene, which was expressed to the same
extent in scrapie-affected as well as in healthy hamsters. Later the gene encoding for
PrP was also discovered in mice, human and many other mammalian species [Oesch
et al., 1985; Chesebro et al., 1985]. From these findings it was concluded that PrP
might exist in two different forms. Although no differences in the primary structure of
PrP, isolated from infected or healthy brains, was observed [Basler et al., 1986]. It
turned out that the infectious form of PrP was protease-resistant while the normal form
of PrP was not [Meyer et al., 1986]. Finally it became clear that the infectious form of
PrP is a variant of a cellular protein. Therefore the normal, healthy form of the prion
protein was called ”cellular PrP” (PrPC) and the infectious (protease-resistant) form
”PrP-scrapie” (PrPSc). Furthermore it was assumed that PrPC and PrPSc only differ in
their conformation and it was proposed that PrPSc acts as a template that promotes the
conversion of PrPC to PrPSc [Pan et al., 1993; Cohen et al., 1994].
The generation of PrP deficient (Prnp0/0) mice strongly supported the ”protein-only”
hypothesis. Prnp0/0 mice are completely resistant to prion infection, but the introduction
of a PrP encoding transgene can restore their susceptibility [Büeler et al., 1992, 1993;
Whittington et al., 1995; Fischer et al., 1996]. Thus, PrPC is required for prion propa-
gation. Moreover polyclonal antibodies, directed against PrP were found to neutralize
scrapie infectivity [Gabizon et al., 1988] and the conversion of PrPC into protease-
resistant PrPSc was shown in vitro after co-cultivation of both forms [Kocisko et al.,
1994]. Recently amyloid-like fibrils, consistent of recombinant PrP, caused scrapie-
typical symptoms in distinct transgenic mice. As the incubation period of these trans-
genic mice was extremely long and inoculation of wild-type mice did not cause a dis-
ease, it remains unclear if ”de novo” infectivity was really generated [Legname et al.,
2004]. To date, no prion-specific nucleic acid was identified [Bellinger-Kawahara et al.,
1987a, b].
Although the ”protein-only” hypothesis is widely accepted today, it does not explain
how a single pathogenic protein can encode for a variety of strain-specific characteris-
tics observed in prion disease. Those strain-specific characteristics include variation in
incubation periods, neuropathology and lesion profiles as well as differences in trans-
missibility and biochemical properties such as the glycoprofile of PrPSc or inactivation
behavior. Although most parameters are defined for each prion disease and species,
the molecular basis of prion strains remains elusive [Aguzzi et al., 2007].
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1.4 The cellular prion protein (PrPC) and its conversion into the
pathological isoform PrPSc
1.4.1 Primary structure and processing of PrPC
The cellular prion protein (PrPC) is highly conserved in mammals and is expressed
at high levels throughout adult life, predominantly in the CNS [Schätzl et al., 1995;
Wopfner et al., 1999]. PrPC is expressed in neurons [Kretzschmar et al., 1986] but
also in astrocytes and oligodendrocytes [Moser et al., 1995] as well as in non-neuronal
tissues including blood lymphocytes [Brown et al., 1999b; Burthem et al., 2001; Liu
et al., 2001], gastroepithelial cells [Morel et al., 2004], heart, kidney and muscle [Brown
et al., 1998]. PrP is encoded by a single-copy gene Prnp, which consists of 3 exons
and is located on chromosome 2 [Sparkes et al., 1986]. The coding sequence of Prnp
is restricted to exon 3. In case of murine Prnp, the translation of exon 3 results in a 254
amino acid (aa) protein (Fig 2) [Basler et al., 1986].
Figure 2: Primary structure of murine PrPC . Adapted from [Flechsig and Weissmann,
2004].
The translation of PrPC starts at the endoplasmatic reticulum (ER), from where it
proceeds to the Golgi apparatus and is finally exported to the cell surface. During
its biosynthesis, PrPC undergoes several post-translational modifications [Caughey ,
1991]. A leader sequence of 22 aa is cleaved off the N-terminus to translocate PrPC
into the ER [Oesch et al., 1985; Basler et al., 1986], where the asparagine residues
180 and 196 are glycosylated [Haraguchi et al., 1989] and a disulphide bond is formed
between the cysteines 178 and 213 [Hope et al., 1986; Safar et al., 1998]. Using
the secretory pathway, PrPC passes the Golgi apparatus and the protein reaches the
plasma membrane, where 24 hydrophobic residues of the C-terminus are removed
[Stahl et al., 1987]. Finally, PrPC is attached to the outer leaflet of the membrane by a
glycophosphatidylinositol anchor (GPI) [Stahl et al., 1987]. On the cell surface, PrPC
is enriched in distinct microdomains (lipid rafts) [Vey et al., 1996], which are charac-
terized by a high cholesterol content [Simons and Ikonen, 1997], or is associated with
clathrin-coated pits [Shyng et al., 1994]. From the cell surface PrPC is internalized by
endocytosis and again recycled to the cell surface or degraded [Shyng et al., 1993].
The relevance of this PrP recycling process is currently unknown and discussed con-
troversially. Mature PrPC exhibits a flexible, non-structured N-terminus and a globular
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C-terminal domain. Another characteristic feature, located in the flexible N-terminus,
is the presence of the so-called octarepeat domain (aa 51-91) [Brown et al., 1997].
The octarepeat domain contains five repetitive sequences (PQGGTWGQ) and is ca-
pable of binding copper ions. In addition a stop-transfer region (STE, aa 95-112) and
a hydrophobic trans-membrane sequence (TM, aa 112-126) are described [Nakahara
et al., 1994].
1.4.2 The physiological function of PrPC
PrPC is a highly conserved protein among mammals and other species. The presence
of PrPC in neuronal tissue and also in a variety of other tissues indicates an important
physiological function of the protein. Many approaches have been used to understand
the physiological function of PrPC , including identification of PrPC interaction partners,
human genetic studies of the Prnp gene, over-expression of PrPC in different cell types
and organisms and finally Prnp knockout strategies in mice [Linden et al., 2008].
The most strikingly phenotype of Prnp0/0 mice is their resistance to prion infec-
tion, which can be restored upon re-introduction of PrP encoding transgenes. From
these studies it became clear that PrPC expression is required for prion induced tox-
icity [Büeler et al., 1993, 1994; Sailer et al., 1994]. Apart from that, an altered circa-
dian rhythm and sleep disturbances were documented for Prnp0/0 mice [Tobler et al.,
1996, 1997]. These studies suggest that PrPC might be involved in the regulation
of sleep, as sleep deficits are also observed in several human prion diseases, like
sCJD and FFI [Lugaresi et al., 1998; Landolt et al., 2006]. Also different behavioral
phenotypes of Prnp0/0 mice were described. Beside cognitive defects and memory
impairment, increased locomotor and decreased anxiety were reported [Roesler et al.,
1999; Coitinho et al., 2003; Criado et al., 2005; Nico et al., 2005]. Moreover differ-
ences in neuronal excitability, such as impairments in long-term potentiation (LTP) and
increased susceptibility to seizures were reported in PrP deficient mice [Collinge et al.,
1994; Walz et al., 1999]. Later it was shown that neurons of the hippocampus are
disorganized and show diminished sensitivity to arriving action potentials, suggesting
a role for PrPC in calcium homeostasis [Colling et al., 1996].
Recently it was demonstrated that Prnp0/0 mice show an altered behavior in olfac-
tory tasks and a disrupted electrophysiology in the deep layers of the main olfactory
bulb. As both alterations could be rescued by transgenic neuronal specific expression
of PrPC , it was suggested that PrPC might be important in the normal processing of
sensory information by the olfactory system [Pichon et al., 2009].
Copper ions (Cu2+) are important co-factors for many enzymatic processes and
many cells have evolved a special mechanisms for Cu2+ uptake and transport. PrPC is
known to bind Cu2+ at the octapeptide region (histidine 96 and 111) and facilitates Cu2+
16
1.4 The prion protein (PrP) 1 INTRODUCTION
endocytosis [Jackson et al., 2001; Pauly and Harris, 1998]. Moreover a decreased
Cu2+ content was measured in Prnp0/0 mice [Brown et al., 1997]. Therefore it was
proposed that PrPC might play a role in copper metabolism.
A protective function of PrPC as Cu/Zn superoxide dismutase (SOD-1) was de-
scribed, suggesting that PrPC might be involved in defense against oxidative stress
[Brown et al., 1999a]. The study was confirmed by another group, showing that SOD-1
activity was reduced in Prnp0/0 mice [Wong et al., 2001]. However, Waggoner et al.
were not able to reproduce the results and mouse genetic experiments argue against
a SOD-like activity in vivo [Hutter et al., 2003; Waggoner et al., 2000].
As PrPC is a GPI-anchored cell surface protein, a function of PrPC in signal trans-
duction was proposed [Stahl et al., 1987]. Indeed, several interaction partners of PrPC
were identified. Using the yeast two-hybrid system, a direct binding of PrPC to a pre-
cursor of the laminin receptor was shown [Rieger et al., 1997; Gauczynski et al., 2006].
Alternative interaction partners are caveolin-1 [Mouillet-Richard et al., 2000] and the
cell adhesion molecule N-CAM, showing increased activity of Fyn kinase [Schmitt-
Ulms et al., 2001] and leading to enhanced axonal outgrowth in cell culture [Graner
et al., 2000; Santuccione et al., 2005]. Recently it was shown that oligomers of the
Alzheimers amyloid-β peptide (Aβ42) bind to PrPC with nanomolar affinity. Moreover
Aβ42 inhibited PrPC-dependent LTP, suggesting a Aβ42-PrPC signalling pathway re-
sponsible for synaptic plasticity [Laurén et al., 2009].
Further interaction partner of PrPC are the heat-shock protein STI-1 and Hsp60
[Edenhofer et al., 1996; Zanata et al., 2002] as well as to the anti-apoptotic factor Bcl-2
[Kurschner and Morgan, 1995]. Although a physiological relevance of these interac-
tions seem to be marginal because PrPC is not expressed in the same compartments
in vivo, a neuroprotective function of PrPC is discussed [Westergard et al., 2007].
Since it was demonstrated that PrPC is expressed on the surface of hematopo-
etic stem cells and a decreased proliferation of neuronal precursors was observed in
Prnp0/0 mice, a role for PrPC in stem and progenitor cell biology was proposed [Zhang
et al., 2006; Steele et al., 2006].
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1.4.3 Structural and biochemical properties of PrPC and PrPSc
Although PrPC and PrPSc exhibit identical primary structures and post-translational
modifications, they differ in their biochemical properties and display different secondary
protein structures (Tab 3). While PrPC is a non-infectious, soluble and protease-
sensitive protein of 33-35 kDa, the infectious isoform PrPSc shows a partial resistance
to proteinase K (PK) and is insoluble in non-ionic detergents [Cohen and Prusiner ,
1998]. The digestion of murine PrPSc with PK results in a 27-30 kDa fragment, as 90
aa are cleaved from the N-terminus [Oesch et al., 1985].
According to its size and partial PK-resistance this fragment is called PrP27−30 or
alternatively PrPres [Bolton et al., 1982]. Moreover PrPSc tends to aggregate, leading to
the formation of amyloid plaques. Upon purification and enrichment of infectivity from
prion infected hamster brain homogenates, the appearance of amyloid fibrils (”prion
rods”) is observed. Prion rods are insoluble in aqueous solutions as well as in organic
or non-ionic detergents [McKinley et al., 1991].
Furthermore PrPC and PrPSc show different secondary structures. Different spec-
troscopic techniques, like fluorescence emission, circular dichroism and infrared spec-
troscopy were applied to solve the structure of PrP. The data showed that PrPC is rich
in α-helical structure [Baldwin et al., 1994; Pan et al., 1993; Pergami et al., 1996], while
PrPSc has a higher β-sheet content [Gasset et al., 1993; Caughey and Raymond , 1991;
Safar et al., 1993]. The structure of recombinant PrPC , produced in Escherichia coli,
was also determined by nuclear magnetic resonance (NMR). The C-terminal region
consists of 3 α-helices and 2 anti-parallel β-sheets flanking helix 1, while the flexible
N-terminus of PrPC (aa 23-120) is random coiled (Fig 3) [Hornemann et al., 1997; Riek
et al., 1997]. It is likely that the N-terminus is stabilized upon binding of copper ions
[Jones et al., 2004; Leclerc et al., 2006].
Table 3: Biochemical and structural properties of different PrP isoforms.
PrPC PrPSc PrP27−30
Infectivity not infectious infectious infectious
Protease-resistance sensitive partial resistance resistant
Solubility soluble insoluble insoluble
Half-life time 2-4h > 24h > 24h
Molecular weight 33-35 kDa 27-35 kDa 27-30 kDa
State of aggregation monomer,
dimers,
oligomers
dimers,
aggregates
amyloid fibrils
Secondary structure 42% α-helical,
3% β-sheet
30% α-helical,
43% β-sheet
21% α-helical,
54% β-sheet
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Figure 3: Nuclear magnetic resonance (NMR) structure of PrPC (residues 121-231)
and the corresponding model of PrPSc. The structure of PrPC contains 3 α-helices
(red) and 2 β-sheets (blue). The disulphide bond, connecting helix 2 and 3 is shown
in yellow. PrPSc is rich in β-sheet structures. The model shows that helix 1 is replaced
by several β-sheets, which are coiled up to form a β-helix, while helix 2 and 3 remain
stable. Adapted from [Eghiaian, 2005].
Due to its extreme insolubility, an NMR-structure of PrPSc is still lacking. However, a
theoretical model of the structure of PrPSc exists. In this model, helix 1 is replaced by 4
β-sheets, while helix 2 and 3 are preserved [Huang et al., 1996]. Recent studies of 2D-
crystals, which were obtained from PrP27−30 molecules, revealed that helix 1 and both
related β-sheets (residues 98-175) are more likely changed into a left-handed β-helix.
In this model helix 2 and 3, which are connected via the disulphide bond are preserved
as well as the flexible N-terminus. Thus, three molecules are able to form a trimer with
β-helical structures in the center. Finally, several of these trimers can build up a fibril
or so-called ”prion-rod” (Fig 4) [Wille et al., 2002; Govaerts et al., 2004].
Figure 4: Model of PrPSc aggregation. (A) PrPSc monomer, displaying a β-helical
structure and two α-helices. (B) Formation of a PrPSc trimer. (C) PrPSc trimers build up
a fibril or so called ”prion-rod”. Adapted from [Govaerts et al., 2004].
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1.4.4 Models for prion replication
The replication of the pathological PrP isoform plays a central role in prion pathogen-
esis. Prions are believed to replicate by an autocatalytic, PrPSc dependent conversion
of PrPC to PrPSc [Prusiner , 1989]. To date the cellular localization of prion replication
is still elusive. Several studies suggest endosomal or lysosomal compartments, while
other findings propose lipid rafts inside the plasma membrane as site of prion replica-
tion [Mayer et al., 1992; Arnold et al., 1995; Baron and Caughey , 2003; Botto et al.,
2004; Marijanovic et al., 2009].
Currently, two different models are postulated for the conversion process. The re-
folding model or ”heterodimer” model (Fig 5a) postulates an interaction of exogenously
introduced PrPSc (e.g. upon prion infection) and endogenous PrPC . After binding of
PrPSc to a partially unfolded PrPC molecule, a heterodimer is formed and PrPC adapts
the conformation of PrPSc. The reaction scheme represents a linear autocatalysis with
an exponential formation rate of PrPSc. However, in normal conditions a spontaneous
conversion of PrPC into PrPSc is prevented by a high energy barrier [Prusiner , 1991].
This assumption would be in good agreement with the finding, that spontaneous prion
diseases are extremely rare. Furthermore the heterodimer model could explain the ex-
istence of inherited prion diseases, as a point-mutation could lower the energy barrier
and thus enhance the conversation frequency. Moreover a cellular factor X, display-
ing a chaperon-like function, was postulated to facilitate the conversion reaction, but to
date no factor X could be identified [Telling et al., 1995].
Another model for prion replication is the ”seeding” or nucleation-polymerization
model (Fig 5b). The seeding model assumes the existence of a thermodynamic equi-
librium between PrPC and PrPSc with PrPC being the favored state. Once a seed or
nucleus has been formed, the growth of the aggregates is faster than their dissocia-
tion rate. As a consequence, more and more PrPSc is formed and can aggregate to
infectious seeds and further to amyloid-like deposits. Finally a fragmentation of PrPSc
deposits increases the number of infectious seeds, leading to a chain reaction of repli-
cation [Come et al., 1993; Caughey et al., 1995].
The seeding model might explain the existence of different prion strains, each char-
acterized by an individual lesion profile, distinct incubation periods and neuropathology
[Aguzzi et al., 2007]. The specific properties of the different strains could be encoded
and transmitted by such polymerized aggregates. It was shown that the conversion of
recombinant PrP is possible in vitro, while strain-specific characteristics are preserved
[Bessen et al., 1995; Kocisko et al., 1994]. Moreover the protein misfolding cyclic am-
plification technique (PMCA) supports the seeding model. During PMCA, a brain ho-
mogenate of a healthy animal is once seeded with a small amount of PrPSc-containing
material. The seed initiates the replication of PrPSc. Each round of PMCA is termi-
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nated with a sonification step, leading to a fragmentation of formed PrPSc-aggregates
and the generation of new seeds. Thus, after several rounds of PMCA an exponential
multiplication is achieved without further addition of infectious material [Saborio et al.,
2001].
Figure 5: Models for the conversion of PrPC into PrPSc. (a) Due to the refolding model,
a spontaneous conversion of PrPC to PrPSc is inhibited by a high energy barrier. Upon
introduction of exogenous PrPSc, a heterodimer is formed and catalyzes the conversion
process. (b) According to the seeding model, PrPC and PrPSc are in an equilibrium with
PrPC as favored state. Once a seed has formed, the conformation of PrPSc is stabi-
lized and monomeric PrPSc is recruited, leading to an equilibrium shift and PrPSc ag-
gregation. Fragmentation of PrPSc deposits enhances the number of infectious seeds.
Adapted from [Aguzzi and Polymenidou, 2004].
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1.5 Prion Pathogenesis
1.5.1 Neuroinvasion of prions: the spread of prions from peripheral sites to the
CNS
Although the distribution of the infectious agent in the tissue of the infected host is quite
variable, the spread of prions through the body is characterized by several phases: af-
ter oral uptake prions spread from the intestine to lymphoid tissues and via the periph-
eral nervous system (PNS) the infectious agent ascends to the CNS. Prion replication
and accumulation in the CNS finally leads to neurodegeneration and clinical signs be-
come obvious. Furthermore a hematogenous spread of prions cannot be excluded
since vCJD-cases have been described, in which transmission probably occurred after
blood transfusion [Mabbott and MacPherson, 2006; Beekes and McBride, 2007].
After ingestion of contaminated material, prions have to cross the intestinal epithe-
lium, which is protected by a single layer of epithelial cells bound by tight junctions.
Within this epithelium microfold cells (M-cells) are located, which are specialized for
transepithelial transport. M-cells are also supposed to translocate TSE agents across
the gut epithelium [Heppner et al., 2001] but also denditic cells (DC) have been pro-
posed. Furthermore it was reported that partially digested fragments of PrPSc com-
plexed with ferritin can be translocated independently of M-cells [Rescigno et al., 2001;
Mishra et al., 2004].
Once crossed the gut epithelium, prions proceed to lymphoid tissues. Current data
suggest that an uptake of prions by migratory DCs and macrophages within the intra-
epithelial pocket, which is a large invagination of the basolateral membrane of M-cells,
is likely [Maignien et al., 2005; Huang et al., 2002].
The early accumulation of prions in lymphoid tissues occurs within the germinal
centers of B-cell follicles, on follicular dendritic cells (FDC) and within macrophages and
is essential for efficient neuroinvasion [Kitamoto et al., 1991; Sigurdson et al., 2002;
Mabbott et al., 2000; Jeffrey et al., 2000]. The absence of Peyer´s patches impairs
neuroinvasion of orally infected scrapie prions [Prinz et al., 2003] as well as removal of
the spleen before intraperitoneal inoculation [Fraser and Dickinson, 1970]. Moreover
the accumulation of prions in FDCs is crucial, as their absence delays neuroinvasion
and reduces disease susceptibility [Montrasio et al., 2000; Mabbott et al., 2003]. B-cells
provide different cytokines for FDC maturation, and consequently depletion of B-cells
also inhibits prion replication in lymphoid tissue [Mabbott et al., 2000; Klein et al., 1997;
Prinz et al., 2002].
How FDCs take up prions after they have been delivered to B-cell follicles is uncer-
tain. Many cell types, including DCs, lymphocytes, mast cells and platelets are able to
secrete exosomes [Denzer et al., 2000a; Fevrier et al., 2004] and it was reported that
FDCs are able to bind exosomes on their surface [Denzer et al., 2000b]. Therefore
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prion transport via vesicles seems possible. It was also hypothesized that prions might
become opsonised by FDCs via complement components [Klein et al., 2001; Mabbott
et al., 2001; Blanquet-Grossard et al., 2005].
Detailed analysis of PrPSc distribution in orally infected mice indicate that prions
spread from lymphoid tissues to the CNS via the PNS. It is believed that prions reach
their CNS target sites by spreading retrogradly along efferent fibers. Sympathetic nerve
fibers (e.g. the splanchic nerves) as well as parasympathetic (e.g. the vagus nerve)
seem to be involved. In contrast to sympathetic fibers, parasympathetic nerves enter
the CNS directly without passing the spinal cord. Thus prions can enter the CNS by
several routes (Fig 6) [Beekes and McBride, 2000; McBride et al., 2001; Beekes and
McBride, 2007].
How exactly prions spread from FDCs to the PNS is not known. A direct transfer
seems to be unlikely as FDCs and peripheral nerve fibers are anatomically separated
(Fig 6) [Felten, 1993; Defaweux et al., 2005]. Again DCs or exosomes have been pro-
posed as transport vehicles from FDCs to nerve fibers [Février et al., 2005]. Moreover
the transmission of prions within the PNS is dependent on PrPC expression [Blättler
et al., 1997; Glatzel and Aguzzi , 2000; Race et al., 2000]. Finally prions arrive at the
CNS, where their accumulation leads to neuronal damage accompanied by the typical
neuropathological changes [Mabbott and MacPherson, 2006].
Figure 6: Neuroinvasion of prions. (A) Innervation of the spleen by peripheral nerve
fibers. Nerve fibers are mainly associated with the capsule and the red pulp. Only
few nerve fibers enter the white pulp, where FDCs, B- and T-cells are located. (B)
Neuroinvasion of prions from lymphoid tissues and intestine to the CNS via sympathetic
and parasympathetic nerve fibers. DMNV: motor nucleus of the vagus nerve, GALT:
gut-associated lymphoid tissue. Adapted from [Mabbott and MacPherson, 2006].
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1.5.2 Prion-induced neurodegeneration
Spongiform changes, loss of neurons, activation of microglia and astrocytes as well
as the formation of amyloid plaques are classical neuropathological hallmarks of prion
diseases, which do not always correlate with clinical disease symptoms [Flechsig and
Weissmann, 2004]. Beside this, the molecular mechanisms of prion toxicity and the
chain of events leading to the clinical disease are still poorly understood, although
several hypothesis have been proposed.
In general two different mechanisms are proposed: 1. PrPSc may exhibit neurotoxic
properties, e.g. by initiating apoptotic pathways, disrupting synaptic functions, mechan-
ical damage or by impairing axonal transport mechanisms (→toxic gain-of-function). 2.
a toxic effect might also contribute to a loss of PrPC function. Here a loss of neuro-
protective properties of PrPC , such as anti-apoptotic or anti-oxidative features, might
be responsible for neuronal death (→ loss-of-function situation) [Collinge, 2001; Hetz
et al., 2003]. However, neither the former nor the later theory could be confirmed to
date and studies that intended to unravel the toxic mechanism of prions have often pro-
duced contradicting results. For instance changes in synaptic plasticity are a constant
finding of clinical prion disease [Clinton et al., 1993]. In addition, neuronal loss initiated
by apoptotic pathways was shown in different TSE animal models as well as in human
TSE cases [Giese et al., 1995]. However, apoptosis was not directly associated with
synaptic pathology and neither a loss of PrPC function nor accumulation of PrPSc can
sufficiently explain the observations [Park et al., 2000]. After intracerebral (i.c.) inoc-
ulation, wild-type mice (Prnp+/+) exhibit clinical signs at 158 days post infection (dpi),
while mice carrying only one allele of Prnp (Prnp+/0) develop scrapie symptoms at 290
dpi. Surprisingly both lines demonstrate a similar pathology at 140 dpi, suggesting that
large quantities of PrPSc can be tolerated for several months [Büeler et al., 1994]. On
the contrary the amount of brain-derived PrPSc did not correlate to the extent of prion
induced neuropathology, suggesting that a small amount of PrPSc might be sufficient
to induce neuropathological changes [Lasmézas et al., 1997]. Beside this, immunod-
eficient mice show neuropathological changes in the CNS but do not develop clinical
symptoms after prion infection [Frigg et al., 1999].
The fact that mice with PrPC-depletion show no major phenotype, first excluded
a simple loss-of-function concept [Büeler et al., 1992]. Later it was suggested that a
functional homologue of PrP might substitute PrPC function in early embryonic devel-
opment and consequently mice with postnatal PrP depletion were generated. Again
no phenotypic alterations were obvious but it turned out that depletion of PrP in prion
infected mice could reverse spongiform changes [Mallucci et al., 2002, 2003].
Another constant finding in prion disease are severe motor impairments at the late
stage of the disease. To date several studies point out a role for motor neurons (MN) in
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the clinical manifestation of prion disease. Kimberlin and Walker first postulated clinical
target areas (CTA), distinct neuronal populations in the brainstem and the spinal cord,
in which prions have to access and replicate to cause clinical prion disease [Kimberlin
and Walker , 1988]. More recently it was reported that transgenic mice expressing trun-
cated PrP∆32−93 demonstrate no detectable brain pathology upon prion challenge but
20% neuronal loss in the spinal cord [Flechsig et al., 2000]. Moreover application of
prions into the sciatic nerve of hamster led to the infection of spinal cord projecting neu-
rons. The infection of such neurons, which are connected to brain centers responsible
for motor control (e.g. nucleus ruber, nucleus lateralis vestibule and cortex), appeared
to be sufficient to cause clinical disease in hamster [Bartz et al., 2002]. From these
studies it was concluded that neuronal loss in the spinal cord is sufficient to cause clin-
ical disease. In addition impairments of axon functions such as synaptic degeneration,
protein accumulation and changes of microtubule distribution were detected in CJD
patients [Clinton et al., 1993; Kovács et al., 2005], animals and also in in vitro mod-
els of prion disease [Medrano et al., 2008; Novitskaya et al., 2007], suggesting axonal
transport defects in prion disease. Indeed it has been reported that impaired axonal
transport in MN of nucleus ruber and motor cortex correlate with the onset of clinical
disease. This observation was a constant finding in different mouse-models and upon
usage of different prion strains [Ermolayev et al., 2009a].
1.6 Dominant-negative effect of PrP polymorphisms
Numerous PrPC polymorphisms are known affecting genetic predisposition, the clinical
course of the disease as well as natural resistance and susceptibility to prion disorders
[Mead , 2006]. Epidemiological studies of sheep populations revealed the efficiency of
protective or dominant-negative Prnp alleles [Woolhouse et al., 2001]. Sheep homozy-
gous for glutamine at codon 171 (171 Q/Q) develop scrapie, while at least one arginine
at this position (171 R/Q or 171 R/R) provides resistance to the disease [Goldmann
et al., 1994; Westaway et al., 1994]. These results were later confirmed in infection
studies and as a consequence distinct breeding strategies were elaborated to gener-
ate scrapie-resistant sheep flocks [O’Rourke et al., 1997; Tuo et al., 2002]. Interest-
ingly such sheep are not completely resistant to intracerebral BSE-infection [Houston
and Gravenor , 2003]. Whether those sheep can be infected via the oral route remains
elusive. So far no infection after oral exposure to BSE was observed, although trans-
port of the infectious agent into lymph by crossing the intestinal barrier was described
[Bellworthy et al., 2005; Sales, 2006]. In general it is assumed that sheep carrying
protective polymorphisms are less susceptible to natural occurring TSEs [Díaz et al.,
2005]. In deer, leucine at codon 132 provides resistance to CWD, while methionine at
this position is associated with susceptibility [Browning et al., 2004].
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Polymorphisms are also described in human prion diseases (Fig 7). As mentioned
before, several Prnp mutations are associated with inherited prion disease, like GSS,
fCJD and FFI. Moreover a genetic predisposition is described even for non hereditary
human prion disease. Codon 129 strongly influences the susceptibility to sCJD, Kuru
and vCJD. Thus 129 M/M homozygosity is found in most sCJD cases and in almost
all tested vCJD patients [Collinge, 2001]. In contrast lysine at codon 219 (219 E/K or
219 K/K) seems to have protective properties in sCJD, as E/K heterozygosity was not
found in 85 autopsied sCJD cases [Shibuya et al., 1998].
The protective character of such polymorphisms is called dominant-negative effect
[Caughey , 2001]. The dominant-negative effect of different Prnp polymorphisms was
investigated in various in vitro and in vivo approaches and has been initially described
in cell culture in 1994 [Priola et al., 1994]. Especially the sheep polymorphism 171
Q/Q and the human polymorphism 219 E/K were investigated in prion-infected murine
cell lines. Codon 171 in sheep corresponds to 167 in mouse and 219 in human to 218
in mouse. It was shown that both Prnp mutants, namely Q167R and E218K, inhibited
prion propagation in cell culture and were not converted into PrPSc itself [Kaneko et al.,
1997b; Zulianello et al., 2000].
Figure 7: Human Prnp polymorphisms. Definite or suspected pathogenic mutations
are shown above this representation of the prion protein gene. Neutral or prion disease
susceptibility affecting polymorphisms are shown below. Adapted from [Mead , 2006].
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The murine PrnpQ167R mutant was further characterized in transgenic mice. Trans-
genic mice carrying PrnpQ167R or PrnpQ218K substitutions on a Prnp0/0 background,
were unable to replicate and propagate prion disease. After reinsertion of the wild-type
allele, the conversion of wild-type PrPC into PrPSc was dramatically slowed down and
correlated with an increase in incubation time [Perrier et al., 2002]. Moreover lentivi-
ral gene transfer of PrPQ167R and PrPE218K into prion infected cells efficiently inhibited
prion replication [Crozet et al., 2004]. Recently an effective gene therapy approach in
transgenic mice, using PrPQ167R virions, was described [Toupet et al., 2008].
The mechanism how dominant-negative PrP mutants counteract prion replication
is still under debate. For example it has been speculated that PrPQ167R and PrPC
compete for the binding site at PrPSc molecules. Therefore they can inhibit the con-
version without being transformed into an abnormal PrP isoform itself [Perrier et al.,
2002; Lee et al., 2007]. Another hypothesis is that dominant-negative PrP mutants
affect prion propagation by competing with PrPC for a putative cofactor, necessary for
prion replication [Kaneko et al., 1997b]. The remarkable inefficient generation of prion
infectivity in vitro suggests the existence of such additional factors [Legname et al.,
2004]. It was proposed that a cofactor might be associated with caveolae-like domains
of the cell surface or endosomes [Kaneko et al., 1997a; Nunziante et al., 2003]. Other
studies assumed polyanionic molecules such as nucleic acids. As the site of prion
replication is not identified yet, the nature and location of an auxiliary cofactor remains
speculative [Deleault et al., 2007]. The seeding model for prion replication provides
another theory for a dominant-negative mechanism. The hypothesis considers that
dominant-negative PrP molecules can be regarded as ”defective” monomers that can
not be converted into PrPSc but are recruited to growing seeds. Attached to the seed,
dominant-negative PrP provides no reactive interface for the recruitment and conver-
sion of additional monomers. Therefore the seed is effectively ”capped” and protected
from further growing [Horiuchi et al., 2000].
1.7 Cre/loxP system
The Cre-loxP technology was first introduced in the 1980s and is based on the enzy-
matic activity of Cre-recombinase (Cre). Cre is a 38 kDa family member of site-specific
integrases derived from bacteriophage P1 [Sternberg et al., 1981; Sauer and Hender-
son, 1988] and catalysis the recombination between two 34 bp palindromic loxP DNA
sequences (Fig 8). In vivo the function of Cre is to circularize the P1 genome dur-
ing infection and maintain the genome in a monomeric state for cell division. At least
two loxP sites and Cre itself are required for recombination. Beside this, no further
cofactors or sequences are needed, regardless of the cellular environment.
The number and orientation of loxP sites influences the recombination event. Thus
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Cre-recombination can either result in excision, inversion or translocation of the loxP-
flanked DNA (Fig 9) [Nagy , 2000]. However, too many loxP sites can lead to chromo-
somal instability [Lewandoski and Martin, 1997]. The mechanism of Cre-recombination
starts with the binding of two Cre monomers to each loxP site. Then a tetramer (”holi-
day” intermediate) is formed, bringing the two loxP sites together. Finally, recombina-
tion occurs within the spacer area [Voziyanov et al., 1999].
Today, Cre is widely used as a genetic tool to control site specific recombination
events in genomic DNA and has been successfully applied in mammalian cell cultures,
yeasts, plants, mice and other organisms [Araki et al., 1997]. Various approaches are
used to introduce Cre-recombinase into cells and organisms. For transient expression
in vitro, usually electroporation or calcium precipitation is used. In vivo approaches
include injection of Cre-RNA, the protein itself or viral delivery of Cre in a tissue- or cell-
specific manner. Another possibility is the establishment of transgenic mouse strains.
Typically Cre and loxP strains are developed separately and crossed to produce a
double-transgenic Cre-lox strain [Nagy , 2000].
Figure 8: Sequence of a loxP site containing two 13 bp palindromic repeats and a 8
bp spacer.
Recently it has been reported that Cre-expression can be toxic to cells in vitro
and in vivo and it was suggested that the mammalian genome contains so-called
pseudo loxP sites, serving as functional recognition sites for Cre. Thus recombina-
tion of these pseudo loxP sites leads to DNA strand breaks and chromosome rear-
rangements [Pfeifer et al., 2001; Silver and Livingston, 2001; Schmidt-Supprian and
Rajewsky , 2007]. Therefore a spatial and temporal control of Cre-expression is not
only important for the experimental setup but also to avoid Cre toxicity. Usually Cre-
expression is controlled by the design of the transgenic construct, e.g by a tissue-
specific promoter. Beside this a variety of strategies to overcome Cre-toxicity have
been developed, including self-silencing or self-deleting Cre expression vectors and
several inducible systems controlling Cre transcription or translation, e.g. by oral appli-
cation of steroids (tamoxifen or RU486) or doxycycline [Pfeifer et al., 2001; Silver and
Livingston, 2001; Mähönen et al., 2004].
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Figure 9: Cre-recombination is determined by the orientation and location of flanking
loxP sites. (A) If the loxP sites are oriented in opposite directions, Cre recombinase
mediates the inversion of the floxed segment. (B) If the loxP sites are located on dif-
ferent chromosomes (trans arrangement), Cre recombinase mediates a chromosomal
translocation. (C) If the loxP sites are oriented in the same direction on a chromo-
some segment (cis arrangement), Cre recombinase mediates a deletion of the floxed
segment. Adapted from (http://jaxmice.jax.org).
1.8 Adeno associated virus vectors
The human adeno associated virus (AAV) was discovered in 1965 as a contaminant
of adenovirus preparations [Atchison et al., 1965]. AAV is a small virus (22 nm cap-
sid), which infects humans and other primate species. AAV belongs to the family of
Parvoviridae, which is included into the genus of Dependovirus. Despite a high sero-
prevalence among humans (approximately 80% of the population are AAV2 positive),
the virus has not been linked to any human disease and has only limited capacity to
induce an immune response. AAV can infect a variety of dividing and non-dividing cells
and is able to incorporate its DNA into the host genome. These features make AAV a
highly attractive candidate for gene therapy [Grieger and Samulski , 2005; Gonçalves,
2005].
AAV has a single stranded DNA (ssDNA) of 4,7 kilobase pairs, that can be either
of positive or negative sense. Moreover the genome has two inverted terminal repeats
(ITR), which can form a T-shaped hairpin structure that is needed for DNA replication.
Two open reading frames encode for rep and cap proteins. Rep proteins are essential
for the AAV life cycle, while the later are needed for the formation of the capsid. AAV
does not encode a polymerase, depending instead on cellular polymerase activities for
DNA replication [Gonçalves, 2005; Carter , 2005].
To date 11 different serotypes have been described with serotype 2 (AAV2) being
the best characterized and therefore the most popular serotype in AAV research [Mori
29
1.8 Adeno associated virus vectors 1 INTRODUCTION
et al., 2004]. AAV2 shows natural tropism towards e.g. skeletal muscles, neurons, vas-
cular smooth muscle cells and hepatocytes [Bartlett et al., 1998; Manno et al., 2003;
Richter et al., 2000; Koeberl et al., 1997]. For host-cell infection, several cell surface re-
ceptors have been described. AAV2 attaches to heparan sulfate proteoglycan (HSPG),
while internalization is aided by the co-receptors αvβ5 integrin, fibroblast growth factor
receptor type 1 (FGFR-1) and hepatocyte growth factor receptor (c-Met). The use of
HSPG receptors may explain the broad tropism of the virus that include human, non-
human primate, canine, murine and avian cells [Summerford and Samulski , 1998; Qing
et al., 1999; Summerford et al., 1999; Kashiwakura et al., 2005].
After attachment to a receptor AAV is internalized most likely via clathrin-coated
pits and submitted to endosomal trafficking. Intracellular transport of AAV involves
microtubule and motor proteins. After escape from late endosomal or lysosomal com-
partments, AAV is translocated to the nucleus probably via the nuclear pore complex
[Gonçalves, 2005]. After entry to the nucleus, AAV can follow two interchangeable
pathways: the lytic or lysogenic. The lytic pathway only develops in presence of a
helper-virus, such as adeno (Ad) or herpes simplex virus (HSV) [Handa and Carter ,
1979]. In the absence of a helper-virus, AAV integrates into the host genome, targeting
a distinct integration site on human chromosome 19 [Surosky et al., 1997]. These fea-
tures also make AAV an attractive candidate for gene therapy. Because only a minimal
set of adenoviral genes is required for efficient generation of AAV particles, AAV can be
produced in a helper-virus free system [Matsushita et al., 1998]. Therefore plasmids
carrying the transgenic DNA, which is flanked by two AAV ITRs, and some additional
plasmids, encoding for helper functions, are co-transfected into the producer cell line
(Fig 13).
AAV vectors have already been used in several first- and second phase clinical
trials for treatment of cystic fibrosis, haemophilia and also in Parkinson’s disease. As
AAV showed good tolerance even in the central nervous system, other trials are in
process, e.g. gene therapy approaches for Canavan disease and muscular dystrophy
[Carter , 2005; Kaplitt et al., 2007]. Although AAV vectors seem to be a promising
tool, the vector system still needs further improved. More recently, double-stranded
AAV (dsAAV) have been used, showing enhanced gene expression in comparison to
single-stranded AAV vectors. dsAAV can be produced by mutating a distinct DNA motif
inside the ITR, called terminal resolution site (trs). A modified trs prevents the two DNA
strands from separation during the AAV replication cycle. As a consequence dsAAV
does not require the conversion of ssDNA to dsDNA, a relatively slow process that is
carried out by the cell machinery, providing faster and more effective gene expression
in the target cells [Wang et al., 2003].
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2 Aim of the study
The primary objective of the study was to examine if motor neurons (MN) are vul-
nerable cell populations for triggering the onset of clinical prion disease and whether
the protection of these cells against prion-induced dysfunctions can interfere with the
development of the disease on a subclinical level.
Towards this, we developed a conditional mouse model with expression of dominant-
negative PrPQ167R in the cells of interest. The MN-specific expression of protective
PrPQ167R was achieved by mating the novel transgenic line Tg floxed LacZ-PrPQ167R
to various Cre-strains. Expression of Cre under control of the Hb9 promoter led to
the deletion of the floxed LacZ marker gene and consequently to the expression of
PrPQ167R in MN of the spinal cord [Arber et al., 1999]. The NF-L promoter directed Cre-
expression to most neurons of the spinal cord as well as to various neurons of the brain
[Schweizer et al., 2002]. Transgenic mice and age-matched control littermates were
inoculated with mouse-adapted prions to investigate the effect of dominant-negative
PrPQ167R on incubation periods, survival and prion pathogenesis.
In a second part, a double-stranded AAV-2-Cre vector (dsAAV2-Cre) was used to
transfer Cre-recombinase into Tg floxed LacZ-PrPQ167R mice. It has been reported
that AAV2 is able to proceed retrogradly from muscle tissue to MN of the spinal cord
[Kaspar et al., 2003]. Therefore dsAAV2-Cre was injected into the hind limb muscles
of Tg floxed LacZ-PrPQ167R mice to target a broader cell population and thus enhance
expression levels of protective PrPQ167R in the spinal cord. Another goal of this strategy
was to avoid time consuming intercrossing of Tg floxed LacZ-PrPQ167R mice and Cre-
strains as well as optimizing PrPQ167R expression by variation of the virus titer or the
site of application.
In a last part we investigated if neurons and in particular MN are involved in the
early accumulation of PrPSc and prion infectivity in splenic tissue. Therefore a trans-
genic model with neuronal PrP depletion was established. Lox2+/− mice, carrying one
allele of floxed Prnp on a Prnp0/0 background [Rossi et al., 2001], were mated to Hb9-
Cre and NF-L-Cre strains to achieve a MN-specific or a pan-neuronal PrP knockout,
respectively. The resulting double-transgenic offsprings were inoculated with mouse-
adapted prions and the accumulation of PrPSc and prion infectivity in spleen and spinal
cord was analyzed at 50 days post inoculation.
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3.1 Laboratory equipment and software
Material Company
ABI PRISM 7500 Applied Biosystems
AIDA software Raytest Isotopenmessgeräte
Autoclav Müncher Medizin
Balance Satorius
Centrifuge Eppendorf, Hettich, Sorvall
Clean Bench Nuaire
Cryostat (CM 1900) Leica
Cuvettes (UV-ette) Eppendorf
Dark Box LAS 3000 Fuji Photo Film
Digital camera Diagnoistic instruments
Electrophorese chamber Institute of Virology
ELISA-Reader Molecular Devices
FACScalibur Becton-Dickinson
Fluorescence microscope Zeiss, Leica
Freezer Bosch
Hamilton syringe (33gauge) Hamilton
Humid chamber for IHC self made
Ice machine Scotsman
Image Reader software Fuji Photo Film
Incubator Heraeus
Isoflurane anesthesia chamber Institute of Virology
Magnetic stirrer Ika Werke
Metal plate (2x5x1mm) Institute of Virology, Würzburg
Micro Centrifuge Eppendorf
Micro pestle Eppendorf
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Microtome (SM 2000R) Leica
Microwave Severin
Mini Trans-Blot cell Biorad
Millex-GV (0,22µm) Millipore
Neubauer chamber Marienfeld
Optical tubes for PCR Applied Biosystems
Pap pen Dako
Parafilm Parafilm
pH meter Denver Instruments
Photometer Biorad
Pipetts Gilson, Eppendorf
Pipet controler, accu-jet Brand
Power supply Consort, Biometra
Prism 4.0 software GraphPad
PVDF membrane Roth
Shaker Heidolph
Super Frost Plus Slides for microscopy Langenbrinck Medizintechnik
Surgical instruments World Precision Instruments
SDS-Gels for PAGE (12% tris-glycine) Lonza
Thermocycler Eppendorf
Tissue Tek Sakura
Thermomixer Eppendorf
UV-system Intas
USP 5.0 Vicryl sutures Ethicon, Johnson & Johnson
Vortex Mixer neoLab
Whatman blotting paper Schleicher and Schüll
Water bath GFL
X-ray films Amersham
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Materials like cell culture flasks, petri dishes, pipette tips, falcon tubes, micro-
centrifuge tubes, cryo tubes, syringes and needles were ordered from Hartenstein
Laborbedarf, Greiner, Eppendorf, Nunc GmbH, BD Bioscience and Carl Roth GmbH.
3.2 Buffers and chemicals
Buffer/Reagent Composition Company
0,1% Sarkosyl 0,1 % (w/v) L-Leuroyl-Sarcosine in
PBS
Sigma
2xHeBs 50mM HEPES
280mM NaCl
AppliChem
AppliChem
4% NaPTA 4% (w/v) phosphotungstic acid
170mM MgCl2 in ddH2O
Sigma
Sigma
4% Sarkosyl 4% (w/v) L-Leuroyl-Sarcosine in
PBS
Sigma
500µl DNA-mix for
transfection of cells
50µl sterile 2,5M CaCl2
15µg of plasmid DNA
in Ampuwa
Sigma
Fresenius
50x TAE 2M Tris, pH 8.0
5,7% (v/v) Acetic acid
0,05M EDTA-Na2, pH 8.0
AppliChem
AppliChem
AppliChem
5x SDS sample buffer 250mM Tris/HCl, pH 6.8
30% (v/v) Glycerol
10% Sodium dodecyl sulfate (SDS)
5% (v/v) β-mercaptoethanol
0,005% (w/v) bromophenol blue
AppliChem
AppliChem
Sigma
Merck
Serva
Aceton 100% (v/v) AppliChem
AEC (3-Amino-9-
Ethylcarbazol)
tablets DCS
Agarose 1-2,5% (w/v) in 1xTAE AppliChem
Agarose (SeaKem
GTG)
0,8% (w/v) in 1x TAE Cambrex
Aquatex ready-to-use Merck
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ATV 0,05% Trypsin (1:250, Difco)
0,5mM EDTA
137mM NaCl
5,4mM KCl
0,058% NaHCO3
BD
Sigma
AppliChem
AppliChem
Sigma
Benzonase nuclease 321u/µl; diluted 1:10 in PBB Sigma
Bradford staining
solution
Biorad protein assay Biorad
Bovine serum
albumine (BSA)
1mg/ml in ddH2O Sigma
Cell lysis buffer 50mM Tris/HCl, pH 7.5
150mM NaCl
0,5% (v/v) Triton X-100
0,5% Desoxycholic acid
in PBS
AppliChem
AppliChem
Sigma
Sigma
Citrate-buffer 20mM Citric acid monohydrat
2g Sodium hydroxide pellets
dissolved in 1l ddH2O, pH 6.0
AppliChem
AppliChem
dNTP Mix (10mM) 1,25mM in sterile ddH2O Fermentas
Dimethyl sulfoxide
(DMSO)
100% (v/v) Sigma
Ethylenediamine
tetraacetic acid (EDTA)
in ddH2O Sigma
Entellan 100% (v/v) Merck
Eosin 1% (w/v) in ddH2O Merck
Ethidium bromide
(EtBr)
1µg/µl Ethidium bromid in 1xTEA Roth
Ethanol 100% (v/v) AppliChem
FACS buffer 10mM EDTA, pH 8.0
2% FCS
0,1% Sodium azid in PBS
Sigma
Biochrom
Sigma
Fix solution for cells 2% formaldehyde
0,2% glutaraldehyde in PBS
Roth
Roth
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Fluorescence mounting
medium
ready-to-use Dako
Formic acid 99-100% (v/v) AppliChem
Goat serum 100% (v/v) Zymed
Hydrogen peroxide 30% (v/v) AppliChem
IHC blocking-buffer 10% (v/v) CAS-Block in TBS-T Zymed
Isofluran 3-4% (v/v) in O2 for anesthesia Abbot
Ketanest/Rompun 7,5mg/ml Rompun
7,5mg/ml Ketanest
in sterile PBS
Bayer Leverkusen
Parke-Davis GmbH
Mayers Hemalaun ready-to-use Roth
Methanol 100% (v/v) AppliChem
OptiMEM growth
medium
OptiMEM Glutamax
10% Fetal Calf serum (FCS)
1% Penicillin/Streptavidin
Gibco
Biochrom AG
Sigma
Phosphate buffered
saline (PBS)
137mM NaCl
2,7mM KCl
4,3mM Na2HPO4
1,47mM KH2PO4
in sterile ddH2O, pH 7.4
AppliChem
AppliChem
Sigma
Sigma
PFA (4%, RotiHistofix) buffered, pH 7.5 Roth
Proteinase K 20mg/ml (50U/ml) Roche Diagnostics
Protease inhibitor,
Complete EDTA-free
tablets Roche Diagnostics
Rinse-buffer 5mM EGTA
0,01% (w/v) Desoxycholate
0,02% (v/v) Igepal CA-630
2mM MgCl2 in PBS
Sigma
Sigma
Sigma
Sigma
SDS-running buffer 25mM Tris
192mM Glycin
1% (w/v) Sodium dodecyl sulfate
(SDS) in ddH2O, pH 8.4
AppliChem
AppliChem
Sigma
Sodium Butyrate 500mM stock Sigma
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Stripping-buffer 0,2M Glycin
1mM EDTA-Na2
0,5M NaCl in ddH2O, pH 2.5
AppliChem
Sigma
AppliChem
TBS 10mM Tris
150mM NaCl in ddH2O, pH 7.6
AppliChem
AppliChem
TBST 10mM Tris
150mM NaCl
0,1% v/v Tween20, pH 7,6
AppliChem
AppliChem
AppliChem
TBS-T 0,4% (v/v) Trition-X 100 in TBS Sigma
TBS-T2 1% (v/v) Trition-X 100 in TBS Sigma
TBST/MP TBST + 5% (w/v) non-fat dry milk Biorad
Tissue lysis buffer 0,5% (w/v) Desoxycholic acid
0,5% (v/v) Igepal CA-630
protease inhibitor Complete
EDTA-free
in PBS
Sigma
Sigma
Roche
Transfer-buffer 25mM Tris
192mM Glycin
1% (w/v) Sodium dodecyl sulfate
(SDS)
20% (v/v) Methanol in ddH2O, pH
8.4
AppliChem
AppliChem
Sigma
AppliChem
Trypan blue 0,4% Sigma
X-Gal 1mg/ml
in Dimethylformamide
Roth
Sigma
X-Gal staining solution
for cells
2mM MgCl2
5mM K3[Fe(CN)]6
5mM K4[Fe(CN)]6
1mg/ml X-Gal
in PBS
Sigma
Sigma
Sigma
Roth
X-Gal staining solution
for mice
5mM K3[Fe(CN)]6
5mM K4[Fe(CN)]6
1mg/ml X-Gal in Rinse-buffer
Sigma
Sigma
Roth
Xylol 100% (v/v) Roth
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3.3 Enzymes and synthetic oligonucleotides
Enzymes were purchased from New England Biolabs GmbH. Synthetic oligonucleotides
were obtained from Sigma-Aldrich and Invitrogen.
Primer Sequence 5’→ 3’ Target gene
Actin_for AGC CAT GTA CGT AGC CAT CC mouse Actb (β-actin)
Actin_rev
GCT GTG GTG GTG AAG CTG
TAG
mouse Actb (β-actin)
Cre_for AAA TGC TTC TGT CCG TTT GC
Cre gene of Enterobacteria phage
P1
Cre_rev ATT GCT GTC ACT TGG TCG TG
Cre gene of Enterobacteria phage
P1
LacZ_ROSA_for ATC CTC TGC ATG GTC AGG TC LacZ gene of Escherichia coli.
LacZ_ROSA_rev CGT GGC CTG ATT CAT TCC LacZ gene of Escherichia coli.
LoxP1_for CAG AGC TGT TGT GGT CAG G transgene floxed LacZ-PrPQ167R
LoxP2_PrP_rev CCA CTA GGA AGG CAG AAT GC transgene floxed LacZ-PrPQ167R
Nco TAT TGC ATG GTT GTT ACG CC Prnp lox2 allele
P3
ATT CGC AGC GCA TCG CCT
TCT GCC
mouse Prnp−/−(neo) allele
P3´NC
CCC TCC CCC AGC CTA GAC
CAC GA
mouse Prnp
P5
GCT TTC TTC AAG TCC TTG
CTC CTG CTG TAG
Prnp lox2 allele
P10
GTA CCC ATA ATC AGT GGA ACA
AGC CCA GC
mouse Prnp
3’loxP3
GGG CAG GAG AAA CAG TTT
GG
Prnp lox1 allele (Zürich II)
PrP_167_For GAT CCA TTT TGG CAA CGA C mouse Prnp, exon3
PrP_167_Rev TCA TCT TCA CAT CGG TCT CG mouse Prnp, exon3
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3.4 Antibodies
Primary antibody Company
monoclonal mouse anti-β-actin (clone AC-15) Sigma
mouse anti-β-galactosidase Sigma
monoclonal mouse anti-PrP (clone 3F4) Chemicon
monoclonal mouse anti-PrP SAF32 Spibio
anti-PrP B2-43 AG Klein
monoclonal mouse anti-Cre Sigma
biotin-conjugated mouse anti-NeuN Chemicon
biotin conjugated anti-WFA Sigma
rabbit anti-GFAP Dako
Secondary antibody Company
HRP-rabbit anti-mouse IgG1 Zymed
HRP-rabbit anti-mouse IgG2a Zymed
Alexa Fluor 488 Fab2 rabbit anti-mouse IgG Molecular Probes
Streptavidin-Texas Red Dianova
Polylink secondary Ab (biotin-conj.) DCS
Label streptavidin label (HRP-conj.) DCS
3.5 Kits
Kit Company
ABsoluteTMQPCR Green Low ROX Mix ABgene
AEC Kit DCS
DNeasy Blood & Tissue Kit Qiagen
GoTaq Flexi DNA polymerase PCR kit Promega
Link and Label system DCS
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Qiaquick gel extraction Kit Qiagen
Kits for plasmid preparation Qiagen
SuperSignal West Pico Chemoluminescent substrate Pierce
3.6 DNA and Protein molecular weight markers
Marker Company
Gene ruler 1kb DNA ladder Fermentas
Gene ruler 100bp DNA ladder Fermentas
MagicMarkTM XP Western Protein Standard (20-220kDa) Invitrogen
PageRulerTM Prestained Protein ladder Fermentas
3.7 Cells
Human embryonic kideny cells (HEK or 293T cells), immortalized with the Ad5 E1A
protein expressing the large SV40 T-antigen [Graham et al., 1977] were used to test
the expression of plasmids.
3.8 Mouse strains
3.8.1 C57BL/6
C57BL/6 is the most widely used wild-type inbred strain. The C57BL/6 strain was
created by Dr. CC Little in 1921 from Miss Abbie Lathrop´s stock.
3.8.2 Prnp0/0(Zürich I knockout)
Prnp0/0 or Zürich I knockout mice are devoid of PrPC because the open reading frame
(ORF) of exon 3 was disrupted by insertion of a neomycin (neo) cassette. The neo
gene replaces codon 3 to 188, therefore PrPC is not expressed and consequently
Prnp0/0 mice are resistent to prion infection. Prnp0/0 mice were generated on a wild-
type C57BL/6 129/Sv background (Fig 10). Although Prnp0/0 mice are devoid of PrPC ,
they display normal development and behaviour [Büeler et al., 1992, 1993].
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Figure 10: Stucture of the wild-type murine Prnp gene and the disrupted open reading
frame (ORF) in Prnp0/0 mice. The Prnp gene consists of three exons (E1-E3) and two
introns (I1, I2) under control of the endogenous Prnp promoter. In Prnp0/0 mice the
ORF of E3 is disrupted by a neomycin (neo) cassette, therefore these mice are devoid
of PrPC . Adapted from [Weissmann and Flechsig, 2003].
3.8.3 Prnp lox2
Prnp lox2 (Lox2) mice were obtained during the generation of a second Prnp-knockout
strain called Zürich II. In Lox2 mice exon 3 of the Prnp gene was flanked by two loxP
sites to enable a selective deletion of exon 3 by Cre-recombinase. Lox2 mice carry 2
alleles of floxed Prnp under control of the endogenous Prnp promoter. Further breeding
of these mice to distinct Cre-strains leads to a selective PrPC-knockout similar to the
situation in Zürich II (Fig 11) [Rossi et al., 2001].
Figure 11: Structure of the Prnp lox2 allele. Exon 3 (E3) was flanked by two loxP sites
leading to a deletion of E3 upon Cre-recombination. Adapted from [Rossi et al., 2001].
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3.8.4 Tga20
Tga20 mice express approximately 5 to 8-fold of PrPC as compared to wild-type under
control of the endogenouse Prnp promoter. Tga20 mice were generated on a Prnp0/0
background. Due to the overexpression of PrPC these mice develop scrapie at 60-62
days post intracerebral infection with RML prions (dose: 3x105LD50) [Fischer et al.,
1996].
3.8.5 Tg(SHaPrP) (Tg(SHaPrP)3922-Prnp0/0)
Tg(SHaPrP) mice express approximately 20-fold of syrian hamster PrPC under control
of the syrian hamster Prnp-promoter on a Prnp0/0 background [Scott et al., 1989].
3.8.6 NF-L-Cre
NF-L-Cre mice express Cre-recombinase of bacteriophage P1 under control of the
human neurofilament light chain (NF-L) promoter. Therefore Cre is expressed in facial
and spinal motor neurons and in various neuronal populations of the brain. NF-L-Cre
mice were bred on a CD-1 background and backcrossed to C57BL/6 [Schweizer et al.,
2002].
3.8.7 Hb9-Cre (B6.129S1-Mnx1tm4(Cre)Tmj/J)
In Hb9-Cre mice the expression of Cre-recombinase is directed to motor neurons of the
spinal cord. While mice heterozygous for Hb9-Cre are viable and fertile, homozygous
Hb9-Cre mice die at or soon after birth. Hb9-Cre mice were generated on a 129/Sv
background and backcrossed to C57BL/6 [Arber et al., 1999; Yang et al., 2001].
3.9 Scrapie inoculum
As inoculum the mouse-adapted Rocky Mountain Laboratory (RML) scrapie strain
[Chandler , 1961] passaged in Swiss-CD-1 mice (Charles River Laboratories) was used.
RML was diluted in PBS containing 5% BSA. The titer of this standard inoculum was
8.6 log LD50 units/ml of a 10% (w/v) brain homogenate.
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4.1 Animal methods
4.1.1 Generation of Tg floxed LacZ-PrPQ167R mice
Cloning. The plasmid pLL4 was based on the pLL3.7 vector [Rubinson et al., 2003],
in which the U6 and eGFP genes were replaced by a multiple cloning site between
ApaI and PciI of pLL3.7. The transgenic DNA consisted of a floxed LacZ gene and
the coding sequence of a murine dominant-negative Prnp gene, mutated at codon
Q167R as well as at L108M and V111M (3F4-tag) [Kascsak et al., 1987]. The trans-
gene including the entire polyA site of murine Prnp was introduced into the NotI/SphI
cloning site. The human ubiquitin C (UbiC) promoter and a murine β-globin intron
were inserted upstream of the transgenic DNA via PacI/AscI and EcoRI, respectively.
The floxed LacZ gene was originally cloned from a transgene designated Fabpl 4 at-
132/loxP ß-gal/hGH [Saam and Gordon, 1999], while the UbiC promoter was derived
from a plasmid designated FUW [Lois et al., 2002].
Purification. The transgenic DNA was released from the backbone by PacI/SphI di-
gestion. 18µg DNA per preparation were digested for 2h at 37°C by 50units of PacI and
SphI using appropriate buffer conditions and BSA concentrations as recommended by
the manufacturer. After digestion the DNA was heated for 10min at 50°C to stop the
enzymatic reaction and afterwards purified twice by electrophoresis through a 0,8%
SeaKem GTG agarose gel. The 9,3kb construct was isolated from the gel and ex-
tracted using the Qiaquick Gel Extraction kit. To increase the purity of the final DNA
fragment, all buffers of the kit were filtered through a 0,22µm Millex-GV prior to use.
Microinjection. The purified construct was injected into the male pronucleus of fertil-
ized oocytes obtained from C57BL/6 mice. The microinjection was performed by Prof.
Dr. T. Rülicke at the Institute of Laboratory Animal Science, Vienna. Transgene pos-
itive founders were identified by PCR, mated to C57BL/6 and analyzed for transgene
expression. The transgenic line was called Tg floxed LacZ-PrPQ167R.
4.1.2 Mating of Tg floxed LacZ-PrPQ167R mice to Hb9-Cre and NF-L-Cre strains
Further breeding to Hb9-Cre mice or to NF-L-Cre mice revealed double transgenic
Tg floxed LacZ-PrPQ167R/Hb9-Cre or Tg floxed LacZ-PrPQ167R/NF-L-Cre mice on a
Prnp+/+ mixed C57BL/6 x 129/Sv background.
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4.1.3 Mating of Lox2 mice to Hb9-Cre and NF-L-Cre strains
Lox2 mice carry two alleles of loxP flanked murine Prnp under control of the endoge-
nous Prnp promter. Lox2 mice were mated to Prnp0/0 mice (Zürich I) in order to ob-
tain heterozygous lox2+/− mice. Hb9-Cre mice and NF-L-Cre mice were also estab-
lished on a Prnp0/0 background and further breeding of these Cre-strains to lox2+/−
mice resulted in double transgenic lox2+/−/Hb9-Cre and lox2+/−/NF-L-Cre mice with
Prnp0/0 background. Thus a selective knock-out of PrPC was achieved in cells with
Cre-expression.
4.1.4 Tail biopsy and earmarks
Generally mice were weaned at the age of 18-21 days. At the same time earmarks
were placed and tail biopsies were taken for genotyping. Tails were immediately frozen
on dry ice and stored at -20°C until use.
4.1.5 Intramuscular application of AAV-Cre vectors
For intramuscular (i.m.) application of AAV-Cre vectors, Tg floxed LacZ-PrPQ167R mice
were anaesthetized with 40mg/kg Ketanest/Rompun and both hind limb muscles were
exposed by a short skin cut. A volume of 30µl per side was injected slowly into the
muscle tissue using a 0,3ml insulin syringe. After injection the skin was closed with
resorbable USP 5.0 vicryl sutures. At various time points mice were sacrificed and
organs were recovered to check Cre-recombination by PCR and western blot analysis.
4.1.6 Scrapie inoculation of mice
All animal experiments were performed according to the german governmental and in-
stitutional guidelines. As inoculum the mouse-adapted RML scrapie strain [Chandler ,
1961] passaged in Swiss-CD-1 mice (Charles River Laboratories) and diluted in PBS
containing 5% BSA was used. The titer of this standard inoculum was 8.6 log LD50
units/ml of a 10% (w/v) brain homogenate. For intracerebral (i.c.) inoculations a 30µl
volume was injected using a high-dose (3*105LD50) of RML inoculum. For intraperi-
toneal (i.p.) inoculations a 100µl volume was injected containing either a high-dose
(106LD50) or a low-dose (103LD50) of RML. Intranerval (i.n.) inoculations were per-
formed as described in [Ermolayev et al., 2009b]. Briefly, animals were anaesthetized
with 40mg/kg Ketanest/Rompun. The right sciatic nerve was surgically exposed by
dislodging M. gluteus superficialis and M. biceps femoris, placed on a metal plate
(2x5x1mm) and 1µl of high-dose (104LD50) RML was injected using a 33-gauge Hamil-
ton syringe over a period of 5min. Great care was taken to visually control and assure
accurate uptake of the inoculum into the nerve. After inoculation, the sciatic nerve was
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repositioned and the lesion was closed with resorbable USP 5.0 vicryl sutures. Follow-
ing inoculation, the neurological status of the mice was assessed three times a week
according to typical scrapie criteria as previously described [Carlson et al., 1986] and
animals were sacrificed on the day of onset of clinical signs of terminal prion disease.
4.1.7 Bioassay to determine prion infectivity
Scrapie infected lox2+/−, lox2+/−/NF-L-Cre and lox2+/−/Hb9-Cre mice were sacrificed
50 days post inoculation (dpi) and 1% (w/v) spleen homogenates were prepared. 30µl
of each 1% (w/v) spleen homogenate was intracerebrally injected into 4 to 5 Tga20
indicator mice. The incubation time until development of terminal scrapie sickness was
determined and infectivity titers were calculated according to the relationship [Prusiner
et al., 1982]:
y = −0, 0657 ∗ x+ 10, 308
y = log LD50
x = incubation time (days) to terminal disease
4.1.8 Statistics
Results were analysed using Graph Pad Prism software. Kaplan-Meier curves were
utilized to display survival data. One-way ANOVA followed by Bonferroni´s post-hoc
multiple comparison test and Kruskal-Wallis test followed by Dunn´s post-hoc multiple
comparison test were applied when appropriate. The null hypothesis was rejected
on the basis of P < 0,05. Results are given as mean incubation time in days ± SD.
Asymptomatic animals/survivors were excluded from statistic.
4.2 Molecular biology techniques
4.2.1 Isolation of genomic DNA from tissue samples
Genomic DNA from mouse tail biopsies, brain, spinal cord and pancreatic tissue was
isolated using the DNeasy Blood & Tissue kit. Genomic DNA from tail biopsies was
extraced according to the manufacturers protocol and dissolved in 100µl elution buffer
provided by the kit. To facilitate lysis of brain, spinal cord and pancreas samples,
300µl of lysis buffer/Proteinase K mixture was added and the tissue was homogenized
through 19-23gauge needles prior to overnight digestion. After tissue lysis the DNA
was isolated according to the provided protocol. DNA from brain, spinal cord and
pancreas samples was eluted in 50µl to increase the final DNA concentration.
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4.2.2 Determination of the nucleic acid concentration
The concentration and quality of double-stranded DNA (dsDNA), in particular contam-
ination with salts and proteins, was estimated by measuring the absorption (optical
density, OD) of the samples at 260nm and 280nm using a photometer. The concen-
tration and quality was determined according to the equations given below. A pure
dsDNA sample without protein contamination will give a ration of 1,7 to 2.
c(dsDNA)
[
µg
µl
]
= [OD260nm∗50∗f ]
1000
p(dsDNA) = [OD260nm]
[OD280nm]
c = concentration of dsDNA in µg/µl
OD = optical density in nm
f = dilution factor
p = purity of dsDNA in µg/µl
4.2.3 Polymerase chain reaction (PCR)
The polymerase chain reaction allows rapid amplification of specific nucleic acid se-
qences in a complex pool of DNA. The specificity of the amplified sequence is achieved
by two synthetic oligonucleotides (primers) that are complementary to the 5’- or 3’-
end of the template sequence. Depending on the primer-design the heatstable Taq-
polymerase catalyses the sythesis of a new DNA strand in sense or antisense direc-
tion. This process leads to the production of the specific DNA region flanked by the
two primers. Each round of amplification multiplies the amount of the target DNA [Saiki
et al., 1988].
4.2.3.1 Genotyping of transgenic mice by PCR. The genotypes of all transgenic
mice were analysed by PCR. For amplification of the specific allele, genomic DNA was
isolated from tail biopsies and PCR reactions were performed in a total volume of 25µl
using an automatic thermocycler. After amplification 15µl of all PCR products were
analysed by agarose gel elctrophoresis.
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Table 10: Composition of a 25µl standard PCR mix
Reagent Stock conc. 1x Vol.
5x GoTaq Flexi Buffer 5x 5µl
dNTPs 1,25mM 5µl
MgCl2 25mM 1,5µl
DMSO 100% 1,3µl
Primer 1 (forward) 50pmol/µl 0,3µl
Primer 2 (reverse) 50pmol/µl 0,3µl
GoTaq DNA polymerase 5U/µl 0,2µl
ddH2O 9,4µl
Genomic DNA ca. 200-500ng 2µl
Table 11: PCR amplification conditions
Genotype Primer
Product
size
Amplification
conditions
Tg floxed
LacZ-PrPQ167R
LacZ_ROSA_for
LacZ_ROSA_rev
314bp
95°C 5min
95°C 30s
60°C 30s 33cyles
72°C 40s
72°C 5min
Tg floxed
LacZ-PrPQ167R
PrP_167_for
PrP_167_rev
203bp
95°C 5min
95°C 30s
60°C 30s 33cyles
72°C 30s
72°C 5min
NF-L-Cre
Hb9-Cre
Cre_for
Cre_rev
206bp
95°C 5min
95°C 30s
56°C 30s 33cyles
72°C 30s
72°C 5min
Lox2 (floxed Prnp) P5
Nco
370bp
95°C 5min
95°C 40s
61°C 40s 33cyles
72°C 40s
72°C 5min
Prnp −/−
Prnp +/−
P3
P10
P3’ NC
Prnp0/0:
362bp
Prnp0/+:
568bp
95°C 5min
95°C 30s
60°C 30s 33cyles
72°C 40s
72°C 5min
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4.2.3.2 PCR analysis of Cre-recombination. Cre mediated recombination of the
DNA in different tissues of double transgenic mice was checked by PCR. Genomic DNA
from brain and spinal cord tissue was isolated and PCR reactions were performed in
a total volume of 25µl using the same mastermix composition as listed in table 10.
Primers, PCR conditions and product sizes for the analysis of Cre-recombination in
the different transgenic mice are given in table 12. After amplification 15µl of all PCR
products were analysed by agarose gel elctrophoresis.
Table 12: PCR conditions to analyse Cre-recombination
Genotype Primer
Product
size
Amplification
conditions
Tg floxed LacZ-PrPQ167R/
NF-L-Cre or Hb9-Cre
LoxP1_for
LoxP2_PrP_rev
226bp
95°C 5min
95°C 30s
58°C 30s 35cyles
72°C 30s
72°C 5min
lox20/+/NF-L-Cre or
Hb9-Cre
P5
3’loxP3
360bp
95°C 5min
95°C 40s
61°C 40s 33cyles
72°C 40s
72°C 5min
4.2.4 Copy number studies in Tg floxed LacZ-PrPQ167Rmice
Quantitative real time PCR (qrtPCR) is a technique based on the polymerase chain
reaction that allows amplification and simultaneous quantification of a target nucleic
acid. A common method of dsDNA quantification is the use of fluorescent dyes such
as SYBR Green I. Binding of SYBR Green I to dsDNA causes fluorescence of the dye.
Each round of amplification leads to an increase in PCR-product and therefore to an
increase in fluorescence intensity. A certain threshold is set at the beginning of the log-
linear phase. The first clear increase in flourescence intensity can be measured, when
the amplification passes into the exponential phase. At this timepoint the fluorescence
signal reaches the threshold value and the cycle number is given as the Ct-value. The
Ct-values of the sample and a reference are compared, allowing DNA concentrations
to be quantified [Higuchi et al., 1993]. Target neucleic acids can be quantified using ei-
ther absolute or relative quantification. Absolute quantification determines the absolute
amount of a target nucleic acid by relating the PCR signal to a standard curve, whereas
relative quantification estimates the ratio between the amount of target nucleic acid to
a reference.
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In this work transgene copy numbers of different Tg floxed LacZ-PrPQ167R mice were
measured by relative quantification. The 2−∆∆Ctmethod [Livak and Schmittgen, 2001;
Ferreira et al., 2006] was used to estimate copy numbers of the Prnp gene in each
sample of genomic DNA. This method requires two main pre-requisites. The first is
the existence of at least one calibrator sample consisting of template DNA with known
copies of the studied gene. The second is the need to have a house-keeping gene
of constant copy numbers in each sample permitting normalization of the quantitative
data.
Figure 12: Typical amplification plot of a real time PCR. Adapted from Qiagen hand-
book.
In this study genomic DNA from Prnp+/+-mice or Prnp+/0-mice and were taken as
calibrators, mouse Actb served as house-keeping gene. Samples from Prnp0/0-mice
and samples without DNA were used as negative controls.
Absolute copies were calculated as follows:
∆∆Ct = (CtPrnp − CtActb)unknown sample − (CtPrnp − CtActb)calibrator
n fold = 2−∆∆Ct
absolute copies = n fold ∗ copies calibrator
Genomic DNA was isolated from tail biopsies and the DNA concentration was ad-
justed to 10ng/µl. Individual real-time PCR reactions were carried out in 20µl volumes
in Optical Tubes containing 10µl ABsoluteTM QPCR SYBR Green Low ROX Mix, 8,2µl
ddH2O, 0,8µl Primer Mix (stock: 10pmol/µl) and 10ng genomic DNA. For the amplifi-
cation of Prnp the primers PrP_167_for and PrP_167_rev and for the amplification of
Actb the primers Actin_for and Actin_rev (3.3) were utilized. Real-time PCR was per-
formed in the ABI PRISM 7500 with 15min of pre-incubation at 95°C (activation of the
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polymerase) followed by 35cyles at 95°C for 30s (denaturation), 60°C for 30s (anneal-
ing of the primers) and 72°C for 40s (elongation and flourescence read-out) followed
by 10min at 72°C (termination). In addition melting-curve analysis were performed at
the end of each PCR assay to control the specificity of the reaction. Specific reactions
should result in a single melting peak corresponding to the PCR product being ampli-
fied. Each individual sample was run in doublets and the Ct-value of each tube was
recorded. The average and standard deviation (SD) was determined and the average
value was accepted if the failure rate was ≤5% [Ferreira et al., 2006]. Absolute gene
copy numbers were calculated according to the equations given above and rounded to
a whole number.
4.2.5 Restriction enzyme digestion of DNA
Restriction enzymes are a class of bacterial endonucleases that protect bacteria from
viral infections by cleaving foreign DNA molecules. Restriction endoncleases are clas-
sified into three diffrent types depending on their subunit composition, cofactor require-
ment etc. Type II restiction enzymes are the only class used in the laboratory for DNA
analysis and gene cloning. They cut DNA at defined positions close to or within their
recognition sequence, usually a short (4-8bp) palindromic DNA sequence [Roberts,
1976].
Restriction enzyme digestion of DNA fragments was performed by incubating ds-
DNA with an appropriate amount of restriction enzyme in its respective buffer condi-
tions as recommended by the supplier. Standard digestions include 2-10U of restriction
enzyme per 1µg od DNA or 22µl of PCR product. The reaction was incubated for 1-3h
at 37°C.
4.2.6 Agarose gel electrophoresis of DNA
Agarose gel electrophoresis is used to separate nucleic acid fragments according to
their size. Larger fragments move more slowly through the gel matrix than smaller ones
when an electric field is applied. Depending on the size of the DNA fragments 0,8-3%
agarose gels in 1xTAE were prepared. Depending on the agarose concentration, an
constant electric field of 80-180V was applied to seperate the DNA fragments. After
electrophoresis the gel was stained in EtBr-solution and analysed in ultraviolet light.
50
4.2 Molecular biology techniques 4 METHODS
4.2.7 Production of adeno-associated virus vectors (dsAAV2-Cre) expressing
Cre-recombinase
The double-stranded recombinant adeno-associated virus vector expressing Cre- re-
combinase (dsAAV2-Cre) was cloned and produced in the lab of Prof. T. Cathomen.
The structure and a schematic overview of the virus production in cell culture are given
in Fig. 13. The recombinant dsAAV2-Cre vector consisted of 2 inverted terminal re-
peats (ITR), a cytomegalo virus (CMV) promoter and the Cre gene of Enterobacteria
phage P1. For better dectection of Cre expression and to direct Cre-recombinase into
the cell nucleus of the target cells, a haemagglutinin tag (HA) and a nuclear localization
signal (NLS) were introduced upstream of the Cre open reading frame. Because of a
special modification in the terminal resolution site (trs) of the ITR, the viral DNA remains
double-stranded, leading to enhanced gene expression in eukaryotic cells. Morevover
a bovine growth hormone polyadenylation signal (bGH PolyA) was placed downstream
of Cre in order to increase gene expression and protein production in transgenic mice.
dsAAV2-Cre was produced in a helper virus free system. Briefly 293T-cells were
co-transfected with the recombinant dsAAV2 DNA encoding for Cre-recombinase, a
plasmid carrying rep/cap packaging signals and a helper plasmid providing distinct
adenovirus gene products necessary for dsAAV2-production. Two days after 293T
cell transfection, supernatants containing dsAAV2-Cre virions were harvested. Fur-
thermore dsAAV2-Cre was purified and concentrated via dialysis and the virus titer
(genomic particles/ml) of each batch was determined by real time PCR.
Figure 13: Structure and production of recombinant ds-AAV-Cre particles. a) structure
of the recombinant pD-dsAAV2-Cre vector, b) dsAAV-Cre production in a helper-free
system. Adapted from Invitrogen handbook.
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4.3 Cell culture techniques
4.3.1 Culture conditions, passaging and seeding of cells
Human embryonic kidney cells (293T) were kept in T75 culture flasks containing Op-
tiMEM growth medium. Cells were cultured at 37°C in a humidified incubator in 5%
CO2. Cells were passaged at 70-80% confluency. Therefore cells were washed twice
with sterile PBS and covered with 2ml ATV. After 1min ATV was removed and cells
were incubated at 37°C for 3min before 10ml of growth media was added and cells
were resuspended in the medium. A 1:10 dilution of cells in growth medium was made
and cells were replaced in a fresh culture flask. For counting of cells, 15µl of cell sus-
pension was mixed with 15µl of trypan blue and cell counting was performed using a
Neubauer chamber. For transient transfection, 106 cells were seeded in a 10cm culture
dish.
cells/ml = mean(cell count of 4 squares) ∗ dilution factor ∗ 104
4.3.2 Transient calcium-phosphate transfection of 293T cells
106 293T cells were seeded in a 10cm culture dish. A culture flask containing OptiMEM
growth medium was kept o/n at 37°C in the incubator to allow equilibration. The next
day the medium was replaced by 4ml of equilibrated medium. For each transfection
a 500µl DNA-mix, containing 15µg of plasmid DNA and 50µl 2,5M CaCl2 in Ampuwa
water, was prepared and 2ml of 2xHeBs buffer was placed in a FACS tube. The 500µl
DNA-mix was added dropwise to the 2xHeBs buffer, while air was bubbled through
the solution in order to enhance the formation of CaCl2 crystals [Wigler et al., 1979].
The DNA/2xHeBs mix was incubated for 30min at room temperature and then added
dropwise to the plated cells. The next day 200µl sodium butyrate was added and cells
were incubated at 37°C for 4-12h. After butyrate treatment the medium was replaced
and cells were harvested for FACS analysis or western blot.
4.3.3 Fuorescence-activated cell sorting (FACS)
Fluorescence-activated cell sorting (FACS) is a method for sorting and characteriza-
tion of individual cells by a fast quantitative recording of fluorescent signals. Proteins
on the cell surface, which are labeled by antibodies coupled to fluorescent dyes can
be analyzed. In this study FACS analysis was performed to study the expression of
PrPQ167R on the cell surface of 293T-cells after transfection with PrPQ167R expressing
plasmids.
Therefore transfected 293T cells were washed 2x with 10ml PBS (4°C) and incu-
bated in 5ml PBS/20mM EDTA at 37°C for 2min to detach the cells from the surface.
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Cells were collected, counted and and 105 cells were transferred into a FACS tube.
2ml of FACS buffer was added and cells were centrifuged at 1300rpm for 5min. The
supernatant was discarded and the 1stantibody, diluted in 250µl was added to the cell
pellet. Cells were incubated on ice for 1h. 3ml FACS buffer was added and cells cen-
trifuged at 1300rpm for 5min. The 2nd antibody in 250µl was added to the pellet and
cells were again incubated on ice for 1h. After washing 3x with 3ml of FACS buffer,
cells were resuspended in 250µl FACS buffer and the fluorescence was measured in a
FACScalibur system.
Table 13: Antibodies for immunodetection in FACS analysis
Primary antibody Stock Dilution
monoclonal mouse anti-PrP (clone 3F4) 2mg/ml 1:500 in FACS buffer
anti-PrP B2-43 1mg/ml 1:500 in FACS buffer
Secondary antibody
goat anti-mouse IgG/FITC 1mg/ml 1:100 in FACS buffer
4.3.4 X-Gal assay to detect β-galactosidase in 293T cells
X-Gal (C14H15BrCINO6) is an organic compound consisting of galactoside linked to
indole that is cleaved by the bacterial enzyme β-galactosidase (β-gal). The cleavage
results in a dark blue precipitate. X-Gal can be used to indicate whether β-gal, which
is encoded by the LacZ gene, is expressed in cells or a certain tissue. 2 to 3 days
after transfection, 293T cells were washed with PBS and 5ml of fix solution was added.
Cells were incubated at 4°C for 5min, washed 3x with PBS, covered with 5ml of staining
solution and incubated at 37°C for 2h. Cells were rinsed with PBS and analysed by light
microscopy or stored at 4°C.
4.3.5 293T cell lysis for western blot analysis
Transfected cells were washed with icecold PBS, collected and centrifuged at 1300rpm
for 5min. The pellet was resuspended in 1ml PBS and centrifuged again at 2000rpm
for 5min. 200µl of lysis buffer was added and the pellet was incubated on ice for 5min.
After centrifugation at 1000rpm for 1min, the supernatant was collected and stored at
-20°C for western blotting.
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4.4 Biochemical methods
4.4.1 Preparation of tissue homogenates
To prepare 10% (w/v) brain and spinal cord homogenates, 9 volumes of lysis buffer
were added to the tissue. 10% (w/v) spleen homogenates were prepared in 9 vol-
umes of sterile PBS + protease inhibitor. Brains were passed through 18-25gauge nee-
dles, spinal cords and spleens were homogenized using a micro-pestle prior to pass-
ing the tissue through 18-25gauge needles. Finally homogenates were centrifuged at
2000rpm for 5min and the supernatants stored at -20°C unitl use.
4.4.2 Bradford assay to determine of protein concentrations
Protein concentrations of 10% (w/v) tissue homogenates were quantified using the
photometric bradford protein assay. This assay is based on the observation that the
absorbance maximum of Coomassie blue G-250 shifts from 494nm to 595nm when the
dye binds to a protein [Bradford , 1976].
Three dilutions of each sample (200x, 400x and 500x) were mixed with Bradford
staining solution and the absorption at 595nm was compared to a straight calibration
line obtained from a standard BSA dilution series (125-12,5µg/ml). After determination
of protein concentrations, 10% homogenates were adjusted to 8mg/ml.
4.4.3 Proteinase-K digestion
For the differentiation between the cellular and the pathogenic form of PrP, a pro-
tein digestion with Proteinase K (PK) was performed prior to SDS polyacrylamid gel
elctrophoresis. Therefore usually 80µg of total protein from 10% (w/v) tissue ho-
mogenates were digested with 1,6µg PK for 30min at 37°C. An appropriate amount
of 5x SDS sample buffer was added and the samples were boiled at 95°C for 10min in
order to stop the enzymatic digestion, denature the proteins and disrupt the disulfide
bonds.
4.4.4 Peptide-N-glycosidase F (PNGase F) digestion
Pepetide-N-glycosidase F (PNGase F) is an enzyme used for deglycosylation of gly-
coproteins, such as PrPC . The glycosidase digestion of brain and spinal cord ho-
mogenates with PNGase F was performed as indicated by the manufacturer. After
digestion an appropriate amount of 5x SDS sample buffer was added and samples
were boiled at 95°C for 10min.
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4.4.5 Sodium phosphotungstic acid (NaPTA) precipitation of PrPSc
The precipitation of PrPSc from spleen and spinal cord homogenates was done accord-
ing to the protocol published in [Safar et al., 1998]. 10% (w/v) tissue homogenates
were prepared, protein concentrations were determined and samples were adjusted
to 8mg/ml. To 1000µg/200µg of total protein 125µl/25µl 4% sarkosyl was added and
samples were incubated at 37°C for 15min. For the removal of nucleic acids, samples
were digested with 5µl/1µl benzonase and 5µl/1µl 50mM MgCl2 was added. Samples
were incubated at 37°C for 30min. In order to specifically percipitate PrPSc, samples
were treated with PK. To 1000µg total protein 27,5µl PK (0,215mg/ml) was added and
digestions were carried out at 37°C for 30min. 200µg samples remained untreated.
Afterwards samples were treated with 25µl/5µl 4% NaPTA and 47,5µl/9,5µl protease
inhibitor was added. Samples were incubated again at 37°C for 30min and then cen-
trifuged for 30min at 14000rpm (18°C) before the pellets were resuspended in 15µl
0,1% sarkosyl and boiled in 5x SDS sample buffer at 95°C for 10min.
4.4.6 SDS polyacrylamid gel electrophoresis
Sodium dodecyl sulfate polyacrylamid gel electrophoresis (SDS-PAGE) is a technique
used to separate proteins according to their electrophoretic mobility [Laemmli , 1970].
The proteins are denatured and rendered monomeric by boiling in the presence of
disulfide bond reducing agents (e. g. β-mercaptoethanol) and anionic detergents like
SDS. SDS unfolds the structure of a protein and applies a uniform negative charge
along the length of the polypeptide. The distance a SDS-denatured protein migrates
though the gel during electrophoresis can be directly related to its molecular mass.
Protein samples were denatured at 95°C for 10min in 5x SDS sample buffer and
separated through a 12% Tris-Glycine gel in SDS running buffer, applying a constant
current of 150V for ca. 1h. The SDS-PAGE was performed in a Mini Trans-Blot cell.
4.4.7 Western blotting and immunodetection of proteins
Western blot is an analytical technique used to analyse specific proteins in a given
sample by antibody detection. It uses gel electrophoresis for protein separation before
the proteins are transferred to a membrane where they are immobilized and can be
probed with antibodies specific to the target protein [Towbin et al., 1979].
After SDS-PAGE, proteins were transferred to a polyvinylidene difluoride membrane
(PVDF). Prior to blotting the PVDF membrane was activated in 100% methanol and im-
mersed in transfer buffer. Proteins were blotted according to the wet blot method for
1,5h applying a constant current of 350mA (Mini Trans-Blot cell). The blotted mem-
brane was blocked over night at 4°C in TBST/MP. After blocking the membrane was
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incubated for 1h at room temperature in TBST/MP containing the primary antibody
in an appropriate dilution (table 14), then washed 2x 10min in TBST and afterwards
incubated 1h at room temperature in TBST/MP containing the respective secondary
antibody conjugated to horseradish peroxidase. Excess antibodies were removed by
washing the membrane 4x 10min in TBST. Membranes were developped on X-ray films
using the SuperSignal West Pico Chemoluminescent substrate according to the sup-
pliers protocol.
Table 14: Antibodies for immunodetection in western blot
Primary antibody Stock Dilution
monoclonal mouse anti-β-actin (clone AC-15) 1mg/ml 1:20 000 in TBST/MP
mouse anti-β-galactosidase 1mg/ml 1:5000 in TBST/MP
monoclonal mouse anti-PrP (clone 3F4) 2mg/ml 1:5000 in TBST/MP
monoclonal mouse anti-PrP SAF32 1mg/ml 1:5000 in TBST/MP
anti-PrP B2-43 1mg/ml 1:10 000 in TBST
monoclonal mouse anti-Cre 2mg/ml 1:10 000 in TBST/MP
Secondary antibody
HRP-rabbit anti-mouse IgG1 1mg/ml 1:10 000 in TBST/MP
HRP-rabbit anti-mouse IgG2a 1mg/ml 1:10 000 in TBST/MP
4.4.8 Stripping and re-exposure of western blot membranes
If necessary membranes were stripped to allow exprosure of a different set of antibod-
ies. Therefore membranes were washed 3x 10min in stripping buffer and 2x 10min in
TBST to readjust the pH value. Afterwards membranes were probed again with primary
and secondary antibody.
4.4.9 Densitometric analysis of protein signals
For quantification of PrP signals in brain and spinal cord homogenates of transgenic
mice, PVDF membranes were analysed in a LAS-3000 Darkbox. Digital images of
chemoluminescent signals were obtained using the Image Reader LAS-3000 software.
Signal intensities ratios were quantified using the AIDA software. As an internal control
PrP signals were normalized to β-actin prior to quantification.
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4.5 Histological techniques
4.5.1 Tissue preparation for histological analysis
4.5.1.1 Tissue preparation for X-Gal assay. One-day old transgenic offsprings
were sacrificed, the tail was removed for genotyping and the body immediately trans-
ferred into 50mL 4% buffered PFA and stored for 48-72h at 4°C. After fixation the tissue
was embedded in Tissue TeK and frozen on dry ice. The embedded tissue was kept for
24h in -20°C before 30µm head and body section were prepared on SuperFrost Plus
microscope slides using a CM 1900 cryostat. Sections were stored at -20°C until use.
4.5.1.2 Tissue freezing and preparation of frozen sections. Mice were sacrificed
and native tail, brain, spinal cord, spleen and pancreas tissue for western blot or PCR
analysis was immediately frozen on dry ice and stored at -20°C or -80°C until use.
Native brain and spinal cord tissue for immunohistochemical analysis was placed in a
cryo tube, embedded in Tissue TeK and frozen on dry ice. The frozen tissue was stored
at -20°C until use. 10µm thick sections were prepared on SuperFrost Plus slides using
a CM 1900 cryostat. Sections were stored at -20°C until use.
4.5.1.3 Paraffin embedding and preparation of paraffin sections. Mice were
sacrificed and brain, spinal cord and spleen tissue was recoverd and immediately trans-
ferred into a 15ml falcon tube containing 15ml 4% buffered PFA. The tube was sealed
and stored for at least 24h. Prion-infected material was inactivated for 1h in 98-100%
formic acid, again rinsed in 4% PFA before the dehydration process was accomplished
by passing the tissue through a series of increasing EtOH concentrations (70-100%).
The dehydrated tissue was embedded in paraffin wax and 5µm sections were prepared
using a microtome. Sections were floated in a 40°C water bath to allow spreading and
subsequently transferred onto SuperFrost Plus slides. Dried sections were stored at
room temperature until further use.
4.5.2 X-Gal assay to detect β-galactosidase (β-gal)
After thawing 30µm head and body sections were shortly air dried and washed 3x for
15min at room temperature in rinse buffer. For X-Gal staining slides were incubated
over night in the dark at 37°C in staining solution. X-Gal was diluted from a 40mg/ml
stock in dimethylformamide. The staining solution was pourred off and slides were
washed in PBS. To intensify the blue staining slides were stored for several hours in
PBS at 4°C. Finally sections were mounted with Aquatex and analysed by light mi-
croscopy.
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4.5.3 Immunohistochemistry (IHC)
4.5.3.1 IHC of β-gal and neuron-specific nuclear protein (NeuN). To show the
expression of the marker gene LacZ in neurons of the brain and spinal cord of Tg
floxed LacZ-PrPQ167R mice, a co-staining of β-gal and the NeuN was accomplished.
Frozen sections were marked with PAP-pen and fixed for 2min in ice-cold aceton. After
fixation and 3x 5min of washing in TBS-T, sections were blocked in IHC blocking-buffer
for 1h at room temperature in a humid chamber. Blocking was followed by an over-
night incubation at 4°C (humid chamber) with primary antibodies, mouse anti-β-gal
and biotin-conjugated mouse anti-NeuN. After washing 3x 5min in TBS, sections were
incubated for 1h at room temperature with secondary antibodies, Alexa Fluor 488 Fab2
rabbit anti-mouse IgG and Streptavidin-Texas Red (table 14). Sections were washed
again 3x 5min in TBS-T before they were covered with fluorescent mounting medium.
4.5.3.2 IHC of β-gal and wisteria floribunda agglutinin (WFA). To detect the ex-
pression of LacZ in the red nucleus (Nucleus ruber) of Tg floxed LacZ-PrPQ167R mice,
an IHC co-staining of β-gal and WFA was performed on 10µm native cryo brain sec-
tions. WFA is a lectin that labels selectively N-acetylgalactosamines beta 1 residues of
glycoproteins within the extracellular matrix of distinct neuron populations, e. g. neu-
rons of the red nucleus. Frozen brain sections were marked with PAP-pen and fixed for
2min in ice-cold aceton. After fixation and 3x 5min of washing in TBS, sections were
blocked for 1h at room temperature in a humid chamber using IHC blocking-buffer.
Blocking was followed by an over-night incubation at 4°C (humid chamber) with pri-
mary antibodies mouse anti-β-gal and biotin-conjugated anti-WFA. After washing 3x
5min in TBS, sections were incubated for 1h at room temperature with secondary anti-
bodies Alexa Fluor 488 Fab2 rabbit anti-mouse IgG and Streptavidin-Texas Red (table
15). Sections were washed 3x for 5min in TBS and covered with fluorescent mounting
medium.
4.5.3.3 IHC of 3F4 tagged PrPQ167R. For IHC detection of PrPQ167R frozen brain and
spinal cord sections were marked with PAP-pen and fixed for 10min in ice-cold aceton.
After fixation and washing (3x 5min TBS-T2), sections were blocked for 1h at room
temperature in a humid chamber using IHC blocking-buffer. Blocking was followed by
an over-night incubation at 4°C (humid chamber) with the primary antibody mouse anti-
PrP-3F4. After washing 1x 5min in TBS-T2 and 2x 5min in TBS, sections were probed
at room temperature for 1h with the secondary antibody Alexa Fluor 488 Fab2 rabbit
anti-mouse IgG (table 15). Sections were washed 1x 5min in TBS-T2 and 2x 5min in
TBS and covered with fluorescent mounting medium.
58
4.5 Histological techniques 4 METHODS
4.5.3.4 Hematoxylin-eosin (HE) staining. To remove the paraffin wax, paraffin
sections were washed 2x 10min in xylol and then passed through an EtOH serial with
decreasing concencrations (100%, 96% and 70%, 2x 5min each). Afterwards sections
were shortly rinsed in ddH2O and stained for 15min in Mayers hemalaum solution. The
stained sections were rinsed for 10min in running tap water, washed 1min in ddH2O
and were co-stained for 1-5min in 1% (w/v) eosin. After eosin staining, sections were
dehydrated by washing 1x 1min in 96% EtOH, 2x 2min in 100% EtOH and 2x 10min in
xylol before they were mounted with Entellan.
4.5.3.5 Glial fibrillary acidic protein (GFAP) immunohistochemistry. A GFAP
staining was performed on paraffin brain sections to visualize activated astrocytes in
brains of scrapie affected mice. Sections were washed 2x 10min in xylol and then
passed through an EtOH serial with decreasing concencrations (100%, 96% and 70%,
2x 5min each). To reexpose the antibody epitopes in the fixed tissue, sections were
boiled for 5min in citrate-buffer and then cooled down in TBS for 10min. After a short
rinse in ddH2O, the endogenous peroxidase was inactivated by a 15min treatment in
0,7% (v/v) hydrogen peroxide. The sections were washed in TBS, blocked for 30min
in 10% (v/v) goat serum and incubated over night at 4°C (humid chamber) with the
primary antibody rabbit anti-GFAP (table 15). For the detection of rabbit anti-GFAP,
the Link and Label system was used according to the suppliers instructions. Sec-
tions were washed in TBS and developed with 3-Amino-9-Ethylcarbazol (AEC) and
co-stained with hemalaum.
Table 15: Antibodies for IHC detection
Primary antibody Stock Dilution
mouse anti-β-galactosidase 1mg/ml 1:250 in IHC-blocking buffer
biotin-conjugated mouse anti-NeuN 1mg/ml 1:250 in IHC-blocking buffer
biotin conjugated anti-WFA 1mg/ml 1:750 in IHC-blocking buffer
mouse anti-PrP 3F4 2mg/ml 1:2000 in IHC-blocking buffer
rabbit anti-GFAP 1mg/ml 1:300 in 10% goat serum
Secondary antibody
Alexa Fluor 488 Fab2 rabbit anti-mouse
IgG
1mg/ml 1:1000 in IHC-blocking buffer
Streptavidin-Texas Red 1mg/ml 1:1000 in IHC-blocking buffer
Polylink secondary Ab (biotin-conj.) ready-to-use
Label streptavidin label (HRP-conj.) ready-to-use
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5 Results
5.1 Transgenic mice with inducible expression of dominant-
negative PrPQ167R in motor neurons
5.1.1 Generation and characterization of Tg floxed LacZ-PrPQ167R mice
Structure and recombination of transgenic DNA for nuclear injection. The trans-
genic DNA for nuclear injection consists of the human ubiquitin C (UbiC) promoter fol-
lowed by a floxed lacZ marker gene and the dominant-negative Prnp mutant PrnpQ167R.
For optimal expression in transgenic mice, a murine ß-globin intron was introduced
downstream of the promoter and a polyadenylation signal (poly-A) was inserted. To
distinguish between PrnpQ167R and endogenous wild-type Prnp, a PvuI restriction site
was generated simultaneously to the Q→R mutation at codon 167. Moreover, the
hamster-specific 3F4-tag [Kascsak et al., 1987] was introduced into PrnpQ167R by a
L→M and V→M mutation at codon 108 and 111, respectively. Therefore the PrPQ167R
protein can be detected by the monoclonal anti-PrP-3F4 antibody, which does not react
with wild-type mouse PrP (Fig 14).
Figure 14: Structure and recombination of the transgenic DNA used for pronuclear
microinjection. Cre-recombination can be detected on DNA level. The recombinant
DNA yields a 226bp PCR product.
In Tg floxed LacZ-PrPQ167R mice LacZ is expressed ubiquitously, the dominant-
negative PrnpQ167R mutant remains silent. Expression of PrPQ167R is achieved by mat-
ing Tg floxed LacZ-PrPQ167R mice to a Cre-strain, with Cre-recombinase under control
of a tissue specific promoter. Cre belongs to an integrase family of site-specific re-
combinases and catalysis the recombination between two palindromic loxP recognition
sites [Nagy , 2000]. Depending on the expression pattern of Cre, the loxP-flanked LacZ
marker gene is deleted, leading to the expression of PrPQ167R in the cells of interest.
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Functionality of the transgenic construct in cell culture. Expression and recom-
bination of the transgenic construct pLL4-UbiC-floxed-LacZ-PrPQ167R-3F4 (pLL4-Tg)
was verified in cell culture. Human embryonic kidney cells (293T cells), which are per
se devoid of PrP, were co-transfected with pLL4-Tg and a Cre-expressing vector desig-
nated pMC-Cre [Gu et al., 1993]. X-gal staining of pLL4-Tg transfected cells revealed
strong expression of enzymatically active β-galactosidase (β-gal) as indicated by a blue
precipitate (Fig 15A).
FACS analysis of transfected 293T cells exhibited PrPQ167R expression only in the
presence of Cre. As PrPQ167R was detectable by several anti-PrP antibodies, target-
ing different epitopes of PrP (anti-PrP-3F4: aa 108-111; anti-PrP B2-43: aa 146-151),
we assumed that transgenic PrPQ167R had normal conformation and was functionally
exposed on the cell surface of 293T cells. The expression level of PrPQ167R after Cre-
recombination was comparable to a control plasmid (pCG-CMV-PrPQ167R-3F4), pro-
viding PrPQ167R under control of a strong viral promoter derived from cytomegalovirus
(CMV). 293T cells transfected with pLL4-Tg alone, were PrP-negative as compared to
cells expressing β-gal from pAD-MD-CMV-LacZ (Fig 15B).
In order to investigate Cre-recombination on DNA-level, genomic DNA was isolated
from transfected cells and checked for recombinant DNA by PCR. The recombinant
allele yielded a PCR product of 226bp, while the transgenic DNA including the LacZ
gene yielded a 380bp product (Fig 14). Recombinant DNA was found exclusively in
cells, which were co-transfected with pLL4-Tg and pMC-Cre (Fig. 15C).
Expression of PrPQ167R was restricted to 293T cells co-transfected with pLL4-Tg and
pMC-Cre, as shown by western blot. No leaky expression of PrPQ167R from pLL4-Tg
was found. Moreover, western blot analysis confirmed the specificity of the anti-PrP-
3F4 antibody to the 3F4-epitope and thus to PrPQ167R as anti-PrP-3F4 was unable to
detect wild-type PrPC in a brain homogenate of C57BL/6 mice (Fig. 15D).
In summary, the results obtained from cell culture experiments proved the function-
ality of the transgenic construct pLL4-UbiC-floxed-LacZ-PrPQ167R-3F4. Consequently,
the transgenic DNA for pronuclear injection UbiC-floxed-LacZ-PrPQ167R-3F4 was re-
leased from the vector backbone by PacI/SphI digestion and purified for nuclear injec-
tion.
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Figure 15: Co-expression of pLL4-UbiC-floxed-LacZ-PrPQ167R-3F4 (pLL4-Tg) and Cre-
recombinase in 293T cells. (A) X-gal staining of 293T cells, transfected with pLL4-Tg,
revealed strong expression of the LacZ marker gene (blue precipitate). (B) FACS anal-
ysis of 293T cells, transfected with pLL4-Tg and pMC-Cre. PrPQ167R was detected at
the cell surface only in the presence of Cre-recombinase and was recognized by differ-
ent anti-PrP antibodies. (C) Genomic DNA of 293T cells, co-transfected with pLL4-Tg
and pMC-Cre, was analyzed by PCR. Recombinant DNA was only found in the pres-
ence of Cre and yielded a PCR product of 226bp. (D) Western blot analysis of 293T
cell lysates. PrPQ167R was expressed after Cre-recombination and could be detected
by different anti-PrP antibodies.
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Generation and characterization of Tg floxed LacZ-PrPQ167R mice. The trans-
genic DNA was injected into the male pronucleus of fertilized oocytes obtained from
C57BL/6 mice. The resulting offsprings were screened for the presence of transgenic
DNA by a PCR directed at LacZ and PrnpQ167R. The LacZ PCR resulted in a 314 bp
product, while the 203 bp product, amplified from both PrnpQ167R and wild-type Prnp,
needed further PvuI digestion. The unique restriction site introduced into transgenic
PrnpQ167R resulted in a two-band pattern of the digested PCR product, confirming the
presence of the transgenic DNA (Fig 16).
Figure 16: Identification of founder mice obtained from nuclear injection of UbiC-
floxed-LacZ-PrPQ167R-3F4. Offsprings were screened by PCR for the presence of the
marker gene LacZ and PrnpQ167R. Transgenic PrnpQ167R was distinguished from wild-
type Prnp by PvuI digestion.
In total 22 founders, carrying the transgenic DNA were identified and further mated
to C57BL/6 on a wild-type Prnp+/+ background. Due to random integration, the expres-
sion of pronuclear injected transgenes is often highly variable between different lines
containing an identical construct. These position effects are caused by integration of
the transgene into transcription control elements of a host gene, a region of imprint-
ing, a non-transcribed heterochromatin region or X and Y chromosomes [Rülicke and
Hübscher , 2000]. Therefore each founder line is unique, even if harboring an identical
transgene and has to be characterized separately.
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F1 progenitors obtained from 22 transgenic lines (Tg115-136) were screened for
expression of the marker gene LacZ by an enzymatic X-gal assay. Expression of func-
tional β-gal was visualized by a blue precipitate on head and body sections derived
from one-day-old offsprings. β-gal expression was evaluated by X-gal staining intensi-
ties and related to a relative scale ranging from + to +++++ . Six out of 22 transgenic
lines expressed the marker gene LacZ. The highest expression levels of β-gal in brain
and spinal cord were observed in Tg117 and Tg127. These lines exhibited ubiquitous
β-gal expression and the strongest X-gal staining intensities in the nervous tissue (Fig
17).
Figure 17: Expression pattern of β-gal and transgene copy numbers in F1 progenitors
of different Tg floxed LacZ-PrPQ167R lines. (A) Schematic representation indicating the
sectional plane for X-gal analysis. a: head sections, b: body sections (B) Overview of
transgenic lines: relative marker gene expression in brain and spinal cord was mea-
sured by X-gal assay; total Prnp copy numbers were calculated by quantitative real
time PCR. (C) Comparison of marker gene expression in the different transgenic lines.
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In detail, X-gal staining on serial, coronal brain sections of Tg117 and Tg127 dis-
played strong β-gal expression in cerebellum, various regions of the mid-brain, hip-
pocampus and cortex (Fig 18).
Figure 18: X-gal staining on serial, coronal brain sections of Tg117 and Tg127.
Moreover, total transgene copy numbers were measured by quantitative real time
PCR (qrtPCR) using relative quantification and the 2-44Ct method [Ferreira et al.,
2006; Livak and Schmittgen, 2001]. Genomic DNA of Prnp+/+ and Prnp+/0 mice were
taken as calibrators, mouse Actb served as house-keeping gene for normalization.
DNA of Prnp0/0 mice was used as negative control (Fig 19). An average value of 4
Prnp copies was measured for Tg117 and also for Tg127. Considering that transgenic
mice were bred on a Prnp+/+ background, both lines carried two copies of PrnpQ167R
(Fig 17).
Figure 19: Example of a copy number study in Tg127. (A) Amplification plot and dis-
sociation curve of Prnp in different DNA samples. (1) no template control, (2) Prnp0/0,
(3) Prnp+/0, (4) Prnp+/+, (5) Tg127 #1, (6) Tg127 #2. (B) Amplification plot and dis-
sociation curve of Actb. The Ct value of the different aliquots is in the same range,
indicating equal DNA concentration of the analyzed samples. Rn, normalized reporter
signal.
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Stable inheritance of the transgene is important with regard to consistent experi-
mental conditions. While most transgenic lines showed stable inheritance, transgene
segregation into two different gene cluster was observed in line Tg136, suggesting
multiple transgene integration sites (Fig 17B). Although all transgenic mice displayed
normal behavior, differences in fertility and lifespan were obvious and led to an exclu-
sion of several lines for further analysis and experiments. For example mice of Tg119
tended to develop tumors at the age of about 40 weeks, suggesting that the transgene
integrated into a tumor suppressor or oncogene. Mice of Tg129 bred inefficiently with
average litter sizes of only 2-3 offsprings, while β-gal expression in Tg124 mice was too
weak. Finally, lines Tg117 and Tg127 were chosen for further experiments, because
they displayed normal phenotype and behavior, reproduced at high rate heterozygoti-
cally and the transgene segregation followed the expected Mendelian inheritance (Tab
16).
Table 16: Breeding efficiencies and transgene inheritance of Tg117 and Tg127 mice.
Breeding litters (n) pups/litter Tg pups/litter TgxCre pups/litter
mean ± SD mean ± SD mean ± SD
Tg117 x C57BL/6 7 6,9 ± 2,7 3,7 ± 1,8
Tg117 x Hb9-Cre 18 10,2 ± 5,1 4,7 ± 3,8 2,0 ± 1,8
Tg117 x NF-L-Cre 22 9,5 ± 4,4 5,1 ± 3,5 2,2 ± 2,0
Tg127 x C57BL/6 9 9,4 ± 4,7 4,8 ± 2,5
Tg127 x Hb9-Cre 21 10,4 ± 4,9 4,7 ± 3,3 2,1 ± 2,3
Tg127 x NF-L-Cre 21 10,7 ± 2,8 5,5 ± 2,2 2,8 ± 1,3
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Immunofluorescence analysis revealed co-localization of β-gal and the neuronal
marker NeuN in different brain areas responsible for motor control, e.g. in nucelus ruber
(Fig 20) and motor cortex (Fig 21) as well as in the hippocampus (Fig 22). Nucleus
ruber was labeled by wisteria floribunda agglutinin (WFA). The lectin WFA selectively
labels distinct residues of glycoproteins inside the extracellular matrix of neurons and
can therefore be used to identify functionally different neuronal populations, e.g. in
nucleus ruber or cortex [Brückner et al., 1996]. While nucleus ruber controls tonicity
and posture, the motor cortex is involved in the control and execution of voluntary motor
functions. Both are connected to each other and to the spinal cord.
In addition expression of the marker gene LacZ was observed in neurons of the
dorsal and ventral horn of the spinal cord (Fig 23), as indicated by colocalization of
β-gal and NeuN (Fig 23).
Figure 20: Expression of β-gal in nucleus ruber of transgenic mice. Immunofluores-
cence showed β-gal (green) in neurons of nucleus ruber in Tg117 and Tg127 mice.
Due to the expression pattern of Cre, β-gal expression was diminished in Tg/NF-L-
Cre mice but not in Tg/Hb9-Cre. Nucleus ruber was visualized by wisteria floribunda
agglutinin (WFA, red), a marker for perineuronal nets. Scale bar: 50µm.
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Figure 21: Immunofluorescent labeling exposed co-localization of β-gal (green) and
the neuronal marker NeuN (red) in neurons of the motor cortex in Tg117 and Tg127
mice.
Figure 22: Expression of β-gal (green) in neurons (NeuN, red) of the hippocampus of
Tg117 and Tg127 mice, visualized by immunofluorescent staining. Scale bar: 50µm.
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Figure 23: Neuronal expression of β-gal in the spinal cord of Tg117, Tg127 and wild-
type mice. Immunofluorescence revealed co-localization of β-gal (green) and NeuN
(red) in the dorsal and ventral horn of the spinal cord.
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Expression of dominant-negative PrPQ167R after inter-crossing of Tg floxed LacZ-
PrPQ167R mice to Cre-strains. Expression of dominant-negative PrPQ167R in motor
neurons (MN) was achieved by mating Tg floxed LacZ-PrPQ167R mice to Hb9-Cre or
NF-L-Cre strains. Cre expression in the cells of interest led to a deletion of the marker
gene LacZ in MN of the spinal cord (Hb9-Cre) or in various neurons in brain and spinal
cord (NF-L-Cre), inducing expression of protective PrPQ167R on a Prnp+/+ background
(Fig 14).
Cre-mediated recombination of genomic, transgenic DNA was detected by PCR in
brain and spinal cord of Tg/NF-L-Cre and to a lesser extent restricted to the spinal cord
in Tg/Hb9-Cre, suggesting that Cre-recombination was successful on DNA level in both
transgenic lines (Fig 24).
Figure 24: Cre-recombination on DNA level was analyzed by PCR of genomic DNA,
isolated from brain and spinal cord tissue of transgenic mice. Recombinant DNA
yielded a product of 226bp. Positive controls: DNA of 293T cells, co-transfected with
pLL4-Tg and pMC-Cre.
In order to distinguish dominant-negative PrPQ167R from endogenous, wild-type PrPC
on the protein level, a specific 3F4-epitope (aa 109-112) [Kascsak et al., 1987] was
introduced into the coding sequence of PrnpQ167R. Western blot analysis using the
monoclonal anti-PrP-3F4 antibody revealed PrPQ167R expression in brain and spinal
cord of Tg/NF-L-Cre mice, while Tg/Hb9-Cre mice showed PrPQ167R expression ex-
clusively in the spinal cord. As brain and spinal cord tissue homogenates also con-
tained non-neuronal Cre-negative cells, the expression of β-gal was found throughout
all genotypes, although to a lesser extent in Tg/NF-L-Cre.
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Due to different glycosylation states, PrPQ167Rin brain and spinal cord of Tg117/NF-
L-Cre and Tg127/NF-L-Cre mice exhibited the typical three band pattern. However
only little amounts of mainly mono-glycosylated and predominately unglycosylated
PrPQ167Rwere found in the spinal cord of Tg117/Hb9-Cre and Tg127/Hb9-Cre mice,
respectively. The results suggest that the Hb9 promoter targeted only a distinct subset
of MN during embryonic development (Fig 25).
Figure 25: Expression of β-gal and PrPQ167R in uninfected transgenic mice. Western
blot exhibited expression of β-gal in brain and spinal cord of transgenic mice. Due
to Cre-recombination, β-gal signals were weaker in Tg/Cre samples. The expression
of PrPQ167R was detected in brain and spinal cord of Tg/NF-L-Cre and restricted to the
spinal cord in Tg/Hb9-Cre. Controls: wild-type and Syrian hamster brain homogenates;
normalization with β-actin; 100µg total protein/lane.
In addition, glycosylation of PrPC and PrPQ167R in brain and spinal cord of trans-
genic mice was analyzed by a N-glycosidase F (PNGase F) treatment. PNGase F is
an amidase that hydrolyzes nearly all types of N-glycan chains from glycopeptides. Di-
gestion of homogenates with PNGase F resulted in a single band pattern in western
blot analysis, confirming the removement of two sugar residues from wild-type PrPC
and transgenic PrPQ167R (Fig 26).
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Figure 26: N-glycosidase F (PNGase F) treatment of brain and spinal cord samples
of transgenic mice. Upon PNGase F digestion sugar residues of the di- and monogly-
cosilated forms of PrPC and PrPQ167R were cleaved off, reducing the typical three band
pattern of PrP to a single protein signal.
In order to quantify PrPQ167R in Tg/NF-L-Cre and Tg/Hb9-Cre mice, densitometric
analysis of western blots were performed and analyzed using the AIDA software. The
concentration of brain and spinal cord homogenates was carefully adjusted and equal
amounts of total protein were blotted on a PVDF membrane. Endogenous wild-type
PrPCas well as transgenic PrPQ167R was visualized by an antibody recognizing the N-
terminal region of PrP (anti-PrP SAF32), which is identical in both forms of the protein.
Total PrP levels were quantified by comparing PrP signal intensities of transgenic mice
to PrP signals of wild-type littermates. As internal control PrP signals were normalized
to β-actin. Because Tg/NF-L-Cre and Tg/Hb9-Cre mice express PrPQ167R on a Prnp+/+
background, the difference in total PrP signal intensities (as compared to wild-type) was
considered to reflect the amount of PrPQ167R in brain and spinal cord. Total PrP levels
were elevated about 20% in brain and 20-30% in spinal cord of Tg117/NF-L-Cre. In
Tg127/NF-L-Cre an increase of total PrP of 5% in brain and 30-40% in spinal cord
was measured in comparison to wild-type. No differences in total PrP were observed
in brains of Tg117/Hb9-Cre and Tg127/Hb9-Cre. Spinal cord of Tg117/Hb9-Cre and
Tg127/Hb9-Cre exhibited an increase of PrP of 10% and 20%, respectively (Fig 27).
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Figure 27: Quantification of PrPQ167R in transgenic mice. (A) Example of densitomet-
ric analysis of western blots. Brain and spinal cord homogenates of transgenic mice
were blotted and endogenous wild-type PrPC as well as transgenic PrPQ167R was vi-
sualized by anti-PrP-SAF32. PrP signal intensities were measured in a defined area
(blue rectangle) and normalized to β-actin (red rectangle), which served as internal
control. 30µg total protein/lane. (B) Comparison of relative PrP amounts in brain and
spinal cord of Tg117 and Tg127 mice. PrP signals of wild-type Prnp+/+ mice were set
as 100%. Columns display mean ± standard deviation (SD); n = number of measure-
ments. (C) Summary of relative PrP amounts in Tg117 and Tg127 mice in comparison
to wild-type mice.
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The expression of PrPQ167R in brain and spinal cord of Tg117 and Tg127 after mat-
ing to Cre-strains was also analyzed by immunohistochemistry (IHC). IHC analysis of
PrPQ167R expression was performed on native brain sections. In the brain PrPQ167R
expression was observed in the hippocampus and motor cortex of Tg117/NF-L-Cre as
well as in Tg127/NF-L-Cre mice. A weaker expression of PrPQ167R was detected in the
brain of Tg117/Hb9-Cre and Tg127/Hb9-Cre (Fig 28).
Figure 28: Immunofluorescent labeling of PrPQ167R in the hippocampus and motor cor-
tex of Tg/Cre mice. The strongest expression of PrPQ167R was detected in Tg117/NF-
L-Cre and Tg127/NF-L-Cre. Weaker signals were observed in Tg117/Hb9-Cre and
Tg127/Hb9-Cre. Scale bar: 100µm.
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In addition, IHC analysis of native spinal cord sections exposed PrPQ167R expression
in the ventral and dorsal horn of double-transgenic Tg117/NF-L-Cre and Tg117/Hb9-
Cre mice (Fig 30). Comparable expression of PrPQ167R in the spinal cord was observed
for Tg127/NF-L-Cre and Tg127/Hb9-Cre, while transgenic mice without Cre-allele, did
not exhibit any PrPQ167R expression (Fig 29).
In comparison to the expression of β-gal and NeuN, which was located in the cytosol
and in neuronal nuclei, the expression pattern of PrPQ167R showed a diffuse distribution.
Therefore we assumed that PrPQ167R was mainly located on the neuronal surface as
previously seen in cell culture.
In summary IHC analysis of brain and spinal cord sections of transgenic mice were
in good agreement with previous western blot results and confirmed that the expression
of PrPQ167R was switched on as expected after Cre-recombination.
Figure 29: Expression of PrPQ167R in the spinal cord of Tg127/Cre transgenic mice.
The strongest PrPQ167R signals were detected in the dorsal and ventral horn of
Tg127/NF-L-Cre and in the ventral horn of Tg127/Hb9-Cre in comparison to Tg127
mice. Positive control: spinal cord sections of Tg(SHaPrP) mice, expressing 20-fold
hamster PrP on a Prnp0/0 background. Scale bar: 100µm.
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Figure 30: Expression of PrPQ167R and NeuN in the spinal cord of Tg117/Cre trans-
genic mice. Consistent with the expression of Cre, the strongest PrPQ167R signals were
detected in the dorsal and ventral horn of Tg117/NF-L-Cre and in the ventral horn of
Tg117/Hb9-Cre as compared to Tg117. In contrast to the allocation of NeuN, the dis-
tribution of PrPQ167R was diffuse due to the expression of PrPQ167R on the cell surface.
Spinal cord sections of Tg(SHaPrP) mice served as positive control for anti-PrP-3F4
staining.
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5.1.2 Survival and pathology of transgenic mice upon prion infection
Prion challenge of Tg floxed LacZ-PrPQ167R/Cre mice via different inoculation
routes. To investigate whether the expression of PrPQ167R had an effect on survival
and pathogenesis, transgenic mice and age-matched control littermates were inoc-
ulated with mouse-adapted prions of the Rocky Mountain Laboratory strain (RML)
[Chandler , 1961].
In general, the shortest incubation periods in prion disease are observed upon
intracerebral prion infection. On the contrary, naturally occurring prion diseases are
typically initiated by peripheral infection, e.g. by consumption of infected material or
by iatrogenic transmission. Therefore transgenic mice were challenged with RML pri-
ons via different inoculation routes, including intracerebral (i.c.), intraperitoneal (i.p.)
or intranerval (i.n.) inoculation into the right sciatic nerve. After prion infection, all
transgenic mice presented scrapie-like symptoms similar to those of wild-type mice,
including ataxia, hind limb paresis and kyphosis at the late stage of the disease and
independent of the inoculation route.
Susceptibility of Tg floxed LacZ-PrPQ167R/Cre mice after prion infection. All mice
of both transgenic lines, infected either i.c., i.n. or i.p. with a high dose of RML (i.c.
3x105; i.n. 104; i.p. 106 LD50), developed terminal scrapie. No significant differences in
survival were observed when compared to control groups. I.c. inoculated mice reached
the terminal stage of the disease at 150-165 days post infection (dpi), i.n. infection led
to an incubation time of 170-180 dpi and mice i.p. inoculated with a high dose of
infectivity displayed terminal scrapie symptoms at about 200 dpi (Fig 31, Fig 32).
In contrast, low dose i.p. infection (103 LD50) resulted in prolonged survival of
Tg117/ NF-L-Cre mice, expressing protective PrPQ167R in the spinal cord and in var-
ious neurons of the brain. Tg117/NF-L-Cre exhibited clinical symptoms at 265 dpi,
showing a statistically significant delay of 33 dpi (15%) in incubation time when com-
pared to Tg117 littermates (P<0.0001). Moreover, two mice of this inoculation group
remained free of clinical symptoms and did not develop scrapie until 304 dpi, when the
experimental observation was terminated and mice were excluded from the statistics.
Tg117/Hb9-Cre mice displayed a slightly enhanced incubation time (3,5%) and suc-
cumbed to clinical prion disease at 238 dpi, which was not significantly different from
control groups, suggesting that PrPQ167R expression exclusively in Hb9-positive MN
was not sufficient to inhibit prion replication and spread to the central nervous system
(CNS) (Fig 31).
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Figure 31: Survival analysis of Tg117 mice upon prion infection. (A) Kaplan-Meier
survival plots of transgenic mice inoculated with RML prions via different routes using
different doses of infectivity. ***, P<0.0001. (B) Tabular overview of the different ex-
perimental groups. The mean survival time after prion infection is displayed as mean
days post inoculation (dpi) ± standard deviation (SD). RML doses are given in units/ml.
n/n0, number of scrapie affected mice / number of inoculated mice.
Surprisingly, the survival of Tg127/NF-L-Cre was not prolonged upon low dose i.p.
infection. Tg127/NF-L-Cre mice succumbed to terminal scrapie at 227 dpi, which was
comparable to control groups. However, several mice in this inoculation group did not
develop clinical scrapie symptoms until the experiment was terminated at 315 dpi. In
contrast to line Tg117, survivors were observed in several inoculations groups, sug-
gesting an unexpected position effect of the transgenic DNA (Fig 32).
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Figure 32: Survival analysis of Tg127 mice upon prion infection. (A) Kaplan-Meier
survival plots of transgenic mice inoculated with RML prions via different routes using
different doses of infectivity. (B) Tabular overview of the different experimental groups.
The mean survival time after prion infection is displayed as mean days post inoculation
(dpi) ± standard deviation (SD). RML doses are given in units/ml. n/n0, number of
scrapie affected mice / number of inoculated mice.
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To investigate PrPSc accumulation in brain and spinal cord of transgenic mice, tis-
sue homogenates were prepared, treated with PK and analyzed in western blot. Trans-
genic mice, i.c., i.n. or i.p. inoculated with a high dose of RML, displayed comparable
amounts of PK-resistant PrPSc at the terminal stage of the disease in the brain as well
as the in spinal cord. Total PrPSc was labeled using the anti-PrP B2-43 antibody. In
addition, no PK-resistant PrPQ167R was detected using the monoclonal anti-PrP-3F4
antibody, pointing out that PrPQ167R was not converted into its pathological isoform and
did not contribute to total PrPSc amounts. However, weak signals were detected by
anti-PrP-3F4 in samples of i.n. inoculated transgenic mice. These signals were likely
due to an unspecific antibody-reaction as they were also present in wild-type controls
(Fig 33, Fig 34).
Figure 33: Western blot analysis of proteinase-K (PK)-resistant PrPSc in terminally
scrapie affected mice after high dose intranerval (i.n.) and intracerebral (i.c.) infection
with RML prions. Tg117/Cre mice and corresponding control littermates were ana-
lyzed. No differences in total PrPSc (anti-PrP B2-43) and no transgenic, PK-resistant
PrPQ167R (anti-PrP-3F4) was detected in the brain or spinal cord. Controls: i.c. and
non-infected C57BL/6 mice.
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Figure 34: Western blot analysis of PK-resistant PrPSc in terminally scrapie affected
mice after high dose intraperitoneal (i.p.) infection with RML prions. Tg117/Cre mice
and corresponding control littermates were analyzed. No differences in total PrPSc
(anti-PrP B2-43) and no transgenic, PK-resistant PrPQ167R (anti-PrP-3F4) was detected
in the brain or spinal cord. Controls: i.c. and non-infected C57BL/6 mice.
Similar results were observed for terminal scrapie-sick mice after low dose i.p. prion
infection. Even terminal Tg117/NF-L-Cre mice, displaying an extended survival of 15%,
accumulated PrPSc in brain and spinal cord to the same extent as their wild-type litter-
mates. Again no transgenic, PK-resistant PrPQ167R was detected.
In contrast, Tg117/NF-L-Cre mice that did not develop the disease and remained
completely free of clinical signs failed to replicate PrPSc until 304 dpi after low dose
i.p. infection. In these mice we did not find any evidence for PrPSc accumulation in the
brain or spinal cord. It seemed that in these mice PrPSc replication was inhibited by
the expression of PrPQ167R, blocking the disease at a sub-clinical level (Fig 35). Similar
results were obtained by western blot analysis of terminal scrapie-affected Tg127/Cre
mice (data not shown).
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Figure 35: Western blot analysis of PK-resistant PrPSc in terminally scrapie affected
mice after low dose i.p. infection with RML prions. No differences in total PrPSc (anti-
PrP B2-43) and no transgenic, PK-resistant PrPQ167R (anti-PrP-3F4) was detected in
the brain or spinal cord. Asymptomatic Tg117/NF-L-Cre mice did not accumulate
PrPSc. Controls: i.c. and non-infected Tg(SHaPrP) mice.
Immunohistochemistry (IHC) of the glial fibrillary acidic protein (GFAP) and hema-
toxylin-eosin (HE) staining of brain and spinal cord sections of terminally scrapie af-
fected mice revealed no differences in pathology, despite different genotypes and incu-
bation times. Upon the terminal stage of the disease, all transgenic animals developed
pronounced astrogliosis in the hippocampus and in the spinal cord. No alterations of
astrogliosis were found in Tg117/NF-L-Cre and Tg117/Hb9-Cre in comparison to their
wild-type littermates (Fig 36). Similar results were obtained for Tg127/Cre (data not
shown).
HE staining displayed the typical spongiform changes with vacuolization most promi-
nently in the white matter of the spinal cord, in the hippocampus and in the thalamus.
No differences in vacuolization pattern or intensities were observed for Tg117/NF-L-
Cre or Tg117/Hb9-Cre. In agreement with western blot results, we did not find any
evidence for neuropathological changes in Tg117/NF-L-Cre mice that did not develop
scrapie after low dose i.p. infection. These mice did not show any signs of astroglio-
sis or vacuolization in brain and spinal cord (Fig 37). Again, comparable results were
observed for Tg127/Cre (data not shown).
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Figure 36: Immunohistochemistry (IHC) of the glial fibrillary acidic protein (GFAP). Low
dose i.p. infected Tg117/Cre mice displayed comparable astrogliosis in hippocampus
and in the ventral horn of the cervical spinal cord. Asymptomatic Tg117/NF-L-Cre mice
remained free of astrogliosis until 304 dpi.
Figure 37: Hematoxylin-eosin (HE) staining of coronal sections of the hippocampus,
thalamus and the cervical spinal cord obtained from low dose i.p. infected Tg117/Cre
mice. Comparable vacuolization was observed in all scrapie affected mice, despite
of the different genotypes and prolonged survival of Tg117/NF-L-Cre. Asymptomatic
Tg117/NF-L-Cre mice remained free of vacuolization until 304 dpi (right column).
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5.2 Transfer of Cre-recombinase into Tg floxed LacZ-PrPQ167R mice
by adeno-associated viral vectors (AAV-Cre)
After intramuscular (i.m.) application adeno-associated virus vectors (AAV) can enter
the peripheral nervous system (PNS) and are transported into distinct brain areas (e.
g. to nucleus ruber and motor cortex) where the encoded gene is efficiently expressed
(Fig 38A) [Kaspar et al., 2003]. A successful transfer of Cre into the CNS of transgenic
mice using AAV or lentiviral vector systems has already been described [Kaspar et al.,
2002; Ahmed et al., 2004].
For the transfer of Cre into Tg floxed LacZ-PrPQ167R mice, double stranded AAV type
2 vectors, expressing Cre under control of a CMV promoter were used (dsAAV2-Cre).
Because of a special modification of the terminal resolution site (trs), the viral DNA
remains double stranded, providing a faster delivery and expression of the transgene
in comparison to single stranded AAV vectors [Wang et al., 2003].
Figure 38: Intramuscular (i.m.) application of dsAAV2-Cre into Tg floxed LacZ-
PrPQ167R mice. (A) Application scheme: viral vectors were injected into the hind limb
muscles of transgenic mice, from where they were retrogradly transported to the spinal
cord. Adapted from [Kaspar et al., 2003]. (B) Structure and recombination of the trans-
genic DNA in Tg floxed LacZ-PrPQ167R mice upon expression of Cre-recombinase. (C)
Tabular overview of dsAAV2-Cre inoculated mice. L, left side. R, right side.
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Two independent dsAAV2-Cre batches with different viral titers were used. A vol-
ume of 30µl dsAAV2-Cre, was injected bilaterally into the hind limb muscles of Tg floxed
LacZ-PrPQ167R mice. Mice were sacrificed at different time points and brain, spinal cord
and muscle tissue was analyzed by PCR and western blot in order to detect recom-
binant DNA and expression of PrPQ167R or Cre in Tg floxed LacZ-PrPQ167R mice (Fig
38B).
All mice inoculated with dsAAV2-Cre vectors displayed normal behavior and re-
mained healthy up to 107 days post AAV infection. Tg floxed LacZ-PrPQ167R mice,
treated with batch 1, were sacrificed at 22 dpi and 107 dpi, respectively. Because no
recombinant DNA was detected by PCR in the brain or spinal cord at the different time
points, all mice were checked for the presence of viral DNA by a PCR directed at Cre.
No Cre DNA was detected in the brain and spinal cord, suggesting that either the ap-
plied viral titer was too low for a PCR detection of Cre or that the foreign, viral DNA was
already degraded before functional Cre was expressed and recombination could take
place. The genotype of transgenic mice was confirmed by a LacZ PCR. The transgene
was present in all tested samples (Fig 39).
Figure 39: PCR analysis of Tg floxed LacZ-PrPQ167R mice treated with dsAAV2-Cre
of batch 1. (A) No recombinant DNA (226bp) was detected in brain or spinal cord of
dsAAV2-Cre treated mice at 22 or 107 dpi. (B) A LacZ PCR confirmed the genotype
of Tg floxed LacZ-PrPQ167R mice. No viral Cre DNA was detected in the analyzed
samples. DNA derived from 293T cells co-transfected with pLL4-Tg and pMC-Cre
served as positive, C57BL/6 brain tissue as negative control.
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Consequently, a second dsAAV2-Cre batch (batch 2) providing a higher virus titer
was used and treated mice were sacrificed at 12 dpi. PCR analysis revealed recombi-
nant, transgenic DNA as well as Cre DNA in hind limb muscle tissue but not in the brain
or spinal cord of dsAAV2-Cre inoculated mice. The presence of recombinant DNA in
the muscle tissue confirmed the expression of functional Cre at least at the site of virus
application (Fig 40).
Figure 40: PCR analysis of Tg floxed LacZ-PrPQ167R mice treated with dsAAV2-Cre of
batch 2. (A) Recombinant DNA (226 bp) was detected exclusively in the muscle tissue
of dsAAV2-Cre treated mice at 12 dpi. (B) A LacZ PCR confirmed the genotype of Tg
floxed LacZ-PrPQ167R mice. Viral Cre DNA was detected only in muscle tissue. DNA
derived from 293T cells co-transfected with pLL4-Tg and pMC-Cre as well as DNA of
Tg117/NF-L-Cre mice served as positive, C57BL/6 as negative control.
On the protein level, no transgenic PrPQ167R was detected by the monoclonal anti-
PrP-3F4 antibody in any of the analyzed tissues, regardless of Tg floxed LacZ-PrPQ167R
mice were treated with dsAAV2-Cre of batch 1 or 2. A second anti-PrP antibody, recog-
nizing PrPQ167R as well as wild-type PrPC , confirmed that enough protein was loaded
onto the gel as strong PrP signals appeared in the brain and spinal cord.
In addition, western blots were probed with a monoclonal anti-Cre antibody. In
agreement with PCR results, Cre was detected in small amounts in muscle tissue of Tg
floxed LacZ-PrPQ167R, infected with dsAAV2-Cre of batch 2. As the molecular weight of
Cre is 38 kDa and no evidence exist that Cre undergoes further processing, additional
bands around 50-60 kDa were considered as an unspecific reaction of the anti-Cre
antibody (Fig 41).
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Figure 41: Western blot analysis of Tg floxed LacZ-PrPQ167R mice, inoculated with dif-
ferent dsAAV2-Cre batches. (A) Strong signals of total PrP in the different samples
showed that enough protein was loaded onto the gel. Positive control: C57BL/6 and
Tg117. (B) No expression of PrPQ167R in the brain, spinal cord or muscle tissue was
observed after intramuscular application of dsAAV2-Cre vectors. Positive control: Syr-
ian hamster and Tg117/NF-L-Cre mice. (C) The 38 kDa Cre protein was detected in
small amounts selectively in muscle homogenates of Tg floxed LacZ-PrPQ167R mice
inoculated with dsAAV2-Cre of batch 2. Positive control: cell lysate transfected with
pMC-Cre. 100µg total protein/lane; b: brain, CL: cell lysate; spc: spinal cord; m: mus-
cle.
In summary the results suggest that dsAAV2-Cre vectors express functional Cre-
recombinase, when applicated at high titers (≥5*1010GP/ml), but further improvement
of the vector system is needed to achieve efficient transport from the site of application
to the CNS and induce expression of PrPQ167R in Tg floxed LacZ-PrPQ167R mice.
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5.3 Accumulation of PrPSc and prion infectivity in splenic tissue
of neuronal PrP deficient mice
Although prion infectivity in splenic tissue is associated with follicular dendritic cells
(FDC) and B- and T-lymphocytes [Raeber et al., 1999; Kitamoto et al., 1991], it is
still unknown if those cell types are able to replicate the infectious agent or if other PrP
expressing cell types, such as neurons innervating the LRS are involved. To investigate
if neurons and in particular MN participate in the replication of prion infectivity in splenic
tissue, we generated neuronal PrP deficient mice and studied the accumulation of
PrPSc and prion infectivity in spleens at an early time point after prion infection.
Towards this, we established double-transgenic mice carrying one allele of floxed
Prnp (lox2+/−) [Rossi et al., 2001] and either one allele of Hb9-Cre or NF-L-Cre on
a Prnp0/0 background. Because of the expression pattern of Cre in these mice, a
conditional PrP knockout was achieved in MN of the spinal cord (Hb9-Cre) [Arber et al.,
1999; Yang et al., 2001] and in various neuronal populations of the spinal cord and brain
(NF-L-Cre) [Schweizer et al., 2002]. Heterozygous PrP-levels in lox2+/− mice ensured
high Cre-recombination efficiencies in the target cells.
5.3.1 Characterization of neuronal PrP deficient mice
Cre-mediated recombination of the floxed Prnp allele was detected by PCR in brain,
spinal cord and tail of lox2+/−/NF-L-Cre and to a lesser extent in brain, spinal cord
and tail of lox2+/−/Hb9-Cre suggesting that Cre-recombination was successful on DNA
level in both transgenic lines, while the DNA remained unaltered in lox2+/− without Cre
allele (Fig 42). In contrast to Tg floxed LacZ-PrPQ167R/Hb9-Cre, recombinant DNA was
also found in brain lysates of lox2+/−/Hb9-Cre mice. This may be due to a higher Cre-
recombination efficiency in heterozygous mice or to a more sensitive PCR reaction.
Figure 42: Cre-recombination on DNA level was analyzed by PCR of genomic DNA,
isolated from brain, spinal cord and tail tissue of transgenic mice. Recombinant DNA
yielded a product of 360 bp. t: tail, b: brain, spc: spinal cord.
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Quantification of total PrPC in double transgenic lox2+/−/Hb9-Cre and lox2+/−/NF-
L-Cre mice was estimated by densitometric analysis of western blots. PrPC was vi-
sualized by anti-PrP B2-43 (epitope aa 144-151), normalized to β-actin and signal
intensities were measured using AIDA software and compared to signals of wild-type
(Prnp+/+) mice. In lox2+/− a reduction in PrPC of approximately 40% in brain and 60%
in spinal cord was measured. A further reduction in PrPC of about 20% was observed
for lox2+/−/NF-L-Cre in brain and spinal cord, respectively. The results were in good
agreement with data obtained for Tg floxed LacZ-PrPQ167R/NF-L-Cre.
In contrast lox2+/−/Hb9-Cre mice did not exhibit any further reduction in PrPC when
compared to lox2+/−, rather a slight enhancement in PrPC was observed (Fig 43).
These contradictory results may be due to the fact that Hb9-Cre is expressed only in a
subset of MN and therefore alterations in PrPC content are under detection limit.
Figure 43: Quantification of PrPC in lox2+/−/Cre transgenic mice. (A) Comparison of
relative PrPC amounts in brain and spinal cord of different transgenic mice. PrPC sig-
nals of wild-type (Prnp+/+) mice were set as 100%. Columns display mean ± standard
deviation (SD) (B) Summary of relative PrPC amounts in lox2+/−/Cre transgenic mice
in comparison to wild-type mice; n = number of measurements.
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5.3.2 Accumulation of PrPSc in spleen and spinal cord of neuronal PrP deficient
mice
To investigate PrPSc levels in spleen and spinal cord of lox2+/−, lox2+/−/Hb9-Cre and
lox2+/−/NF-L-Cre mice, age-matched littermates of each genotype were inoculated
with RML prions [Chandler , 1961]. Mice were intracerebrally (i.c.) infected with a
high dose of prions (3x105LD50). Intraperitoneal (i.p.) inoculation was performed using
either a high dose or a low dose of prions (106 or 103 LD50). At 50 days post inoculation
(dpi), spleen and spinal cord tissue was collected and a sodium phosphotungstic acid
(NaPTA) precipitation of PrPSc with subsequent PK-treatment and analysis by western
blot was performed (Fig 44).
Figure 44: Sodium phosphotungstic acid (NaPTA) precipitation of PrPSc in spleen and
spinal cord of lox2+/−, lox2+/−/Hb9-Cre and lox2+/−/NF-L-Cre mice at 50 dpi. Mice
were i.c. or i.p. inoculated with different RML doses as indicated. Protein amounts
for NaPTA precipitation: 1000µg total protein for PK-treated samples; 200µg of total
protein for samples without PK-digestion. Spleen and spinal cord material of uninfected
and terminally scrapie-affected C57BL/6 mice served as controls.
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At 50 dpi no PrPSc was detected in spinal cord tissue of lox2+/−, lox2+/−/Hb9-
Cre and lox2+/−/NF-L-Cre mice, independent on inoculation route and RML dose as
indicated by PK digestion. Moreover, PK-untreated spinal cord samples of lox2+/−,
lox2+/−/Hb9-Cre and lox2+/−/NF-L-Cre mice exhibited comparable PrP amounts of
about half the quantity of C57BL/6 (Prnp+/+).
I.c. and i.p. inoculation with a high dose of RML resulted in PrPSc accumulation in
spleens of lox2+/− and lox2+/−/Hb9-Cre but not in lox2+/−/NF-L-Cre mice. In addition
all mice that were i.p. inoculated with a low dose of RML, did not accumulate PrPSc in
the spleen until 50 dpi (Fig 44).
The results suggest that PrPSc replication in the spleen is impaired in mice with
pan-neuronal PrPC-depletion such as lox2+/−/NF-L-Cre. A PrP-knockout in subsets of
MN does not influence the replication of PrPSc in spleen.
5.3.3 Determination of prion infectivity titers in spleen of neuronal PrP deficient
mice
Prion infectivity titers in spleens of lox2+/−, lox2+/−/Hb9-Cre and lox2+/−/NF-L-Cre
mice were determined in a bioassay using Tga20 indicator mice. Therefore 1% spleen
homogenates of lox2+/−, lox2+/−/Hb9-Cre and lox2+/−/NF-L-Cre mice (previously i.c.
or i.p. infected with either a high or a low dose of RML) were prepared and intracere-
brally inoculated into Tga20 mice. The infectivity titer of each spleen homogenate was
calculated from Tga20 incubation times [Prusiner et al., 1982].
Lox2+/−, lox2+/−/Hb9-Cre and lox2+/−/NF-L-Cre mice, inoculated with a high dose
of RML, accumulated infectivity titers of 4-6 log LD50 in the spleen until 50dpi. In these
groups all Tga20 indicator animals developed terminal scrapie.
Spleens of low dose i.p. infected lox2+/− mice exhibited infectivity titers of 4,3
log LD50, which was sufficient to cause terminal scrapie in all Tga20 indicator mice.
Spleens of lox2+/−/Hb9-Cre mice with MN-specific PrP depletion showed a reduced
infectivity titer of 2,44 log LD50. In this group only 3 out of 4 Tga20 mice succumbed to
terminal scrapie. The lowest infectivity titer of 1,56 log LD50 was measured in spleens
of lox2+/−/NF-L-Cre mice. As the infectivity titer in spleens of lox2+/−/NF-L-Cre mice
was nearly under detection limit and only 2 out of 5 Tga20 mice developed scrapie, it
seemed that pan-neuronal depletion of PrP inhibited the accumulation of prion infectiv-
ity in spleen at 50 dpi. Therefore the results suggest that accumulation of prions in the
spleen is dependent on PrPC expression in the nervous tissue (Fig 45).
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Figure 45: Tga20 bioassay. (A) Kaplan-Meier survival plots of Tga20 mice, inoculated
with 1% spleen homogenates derived from i.c. (RML dose: 3x105LD50) or i.p. (RML
dose: 106LD50 or 103 LD50) infected lox2+/−, lox2+/−/Hb9-Cre and lox2+/−/NF-L-Cre
mice. *: P<0.01. (B) Determination of prion infectivity titers of spleen homogenates.
Symbols underneath the dotted line represent prion titers below the detection thresh-
old (indicator mice did not develop scrapie). Each dot represents one individual. (C)
Tabular overview of prion infectivity titers and mean survival time of Tga20 mice after
prion infection with 1% spleen homogenates. n/n0, number of scrapie affected mice /
number of inoculated mice.
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6 Discussion
6.1 Transgenic mice with inducible expression of dominant-
negative PrPQ167R in motor neurons
Several neurodegenerative diseases have been related to a selective impairment of
distinct neuronal populations. In Parkinson´s disease a selective loss of dopaminergic
neurons is described [Beal , 2001] and selective degeneration of motor neurons (MN)
is found in amyotrophic lateral sclerosis [Cleveland and Rothstein, 2001].
The identification of vulnerable cell populations in the nervous system, responsible
for triggering the onset of clinical prion disease, is still elusive. Beside the typical clini-
cal symptoms like trembling, paresis and finally severe ataxia, several studies point out
a role for MN in the clinical manifestation of prion disease. Kimberlin and Walker first
postulated clinical target areas (CTA), distinct neuronal populations in the brainstem
and spinal cord in which prions have to access and replicate to a certain threshold to
cause clinical prion disease [Kimberlin and Walker , 1986, 1988]. It was shown that
early clinical symptoms are consistent with neuronal damage in brain areas that con-
trol motor functions [Bartz et al., 2002] and recently we reported that impaired axonal
transport in MN of nucleus ruber and motor cortex correlates with the onset of clinical
prion disease [Ermolayev et al., 2009a].
As an experimental approach to strengthen these points we developed a novel
mouse model with Cre-mediated expression of dominant-negative PrPQ167R. Mating
of Tg floxed LacZ-PrPQ167R to Hb9-Cre mice [Arber et al., 1999; Yang et al., 2001]
led to the expression of PrPQ167R in MN of the spinal cord while NF-L-Cre [Schweizer
et al., 2002] directed PrPQ167R expression at a broader set of spinal MN as well as to
several neuronal populations of the brain. The model takes advantage of the natural
dominant-negative properties of a sheep PrP polymorphism [Goldmann et al., 1994].
PrPQ167R inhibits the conversion from PrPC to PrPSc in vitro and in vivo, probably by a
competitive interaction between PrPQ167R and PrPC for PrPSc, thus slowing down PrPSc
accumulation and providing prolonged survival [Kaneko et al., 1997b; Perrier et al.,
2002].
The transgenic DNA for nuclear injection consists of a UbiC promoter, a floxed
LacZ marker gene followed by the dominant-negative PrnpQ167R mutant, including a
PvuI restriction site as well as a specific antibody epitope designated 3F4-tag. The
specific characteristics of PrnpQ167R enabled us to discriminate between endogenous
wild-type PrP and PrPQ167R, which was important as Tg floxed LacZ-PrPQ167R mice
were generated on a wild-type Prnp+/+ background to ensure normal prion propagation
outside the cells of interest.
Experiments using PrP deficient 293T cells proofed the functionality of the trans-
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genic DNA in cell culture. In the absence of Cre, enzymatically active β-galactosidase
(β-gal) was expressed from the LacZ marker gene, while co-transfection with a Cre-
expressing plasmid led to the expression of PrPQ167R on the cell surface. PrPQ167R
was present in a di- mono- and unglycosylated form and detectable by several anti-PrP
antibodies, including the specific anti-PrP-3F4. Therefore a correct processing and
post-translational modification of PrPQ167R can be assumed.
Microinjection of the transgenic DNA led to 22 founder lines that were efficiently
identified by a PCR directed against LacZ. An additional PCR was performed to show
the presence of dominant-negative PrnpQ167R. The unique PvuI restriction site of
PrnpQ167R ensured a definite identification of Tg floxed LacZ-PrPQ167R mice. Further
analysis of transgenic offsprings by a X-gal screening assay revealed that only 6 out of
22 lines expressed β-gal in brain and spinal cord. This phenomenon can be explained
by the integration characteristics of pronuclear injected transgenes.
Depending on the size of the transgene, each fertilized oocyte receives ten to sev-
eral hundred DNA molecules. Those DNA molecules can recombine to large tandemly
arranged concatamers before the DNA integrates into the host chromosome. Thus,
multi-copy arrays can influence the expression of the transgene [Bishop and Smith,
1989]. Integration sites for transgenic DNA are randomly distributed [Brinster et al.,
1989] and can cause severe side effects. For example integration of the transgene
into oncogenes or tumor suppressor genes is a frequent observation in transgenic ap-
proaches. In this case, transgenic mice may be viable and fertile but develop tumors
at a young age. Transgenic mice derived from line Tg119 tended to develop tumors at
the age of 40 weeks and were therefore excluded from further experiments.
In addition position effects can influence the spatial and temporal expression char-
acteristics of the transgene. Position effects can be caused by integration of the trans-
gene into the direct vicinity of transcription control elements, a region of imprinting or a
non-transcribed heterochromatin region as well as into X- and Y-chromosomes [Rülicke
and Hübscher , 2000]. Frequently, an inactivation of transgenes by de-novo methylation
of DNA has been observed for stable transfected cells as well as for transgenic mice
[Li et al., 1993]. It has been reported that especially transgenes containing viral se-
quences are susceptible to this process, suggesting that de-novo methylation of DNA
might be a defense mechanism against the activity of foreign genes in a host genome
[Wienhues and Doerfler , 1985]. If multiple transgene insertion sites are located on dif-
ferent chromosomes, a segregation of the transgenic cluster upon breeding is possible,
leading to different transgene expression patterns of the resulting offsprings [Rülicke
and Hübscher , 2000]. To ensure a stable inheritance of the transgenic cluster and to
identify multi-copy arrays, transgene copy numbers of each transgenic line were de-
termined by quantitative real time PCR. Indeed, a transgenic line Tg136, carrying a
double-insertion of transgenic DNA, was identified.
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Further strategies to control integration events of transgenic DNA have been de-
scribed. It was reported that position effects can be eliminated for transgenes harboring
a cis-regulatory element called locus control region (LCR). LCRs are short stretches
of DNA, characterized by stable DNase-I hypersensitive sites, which provide an open
chromatin structure to neighboring sequences even when the transgene is integrated
into heterochromatin regions of a chromosome [Grosveld et al., 1987]. In addition to
that, matrix/scaffold attachment regions are thought to be important for the organization
of chromatin into functional genetic domains [Bode et al., 1992] and an element from
the cytosine-phosphate-guanine (CpG) island sequence of the hamster adenine phos-
phoribosyl transferase (APRT) locus was identified that may reduce de-novo methyla-
tion of flanking sequences [Siegfried et al., 1999].
Finally, transgenic lines Tg117 and Tg127 were selected for further experiments,
because they exhibited the strongest expression of β-gal in brain and spinal cord, dis-
played a normal phenotype and behavior and reproduced efficiently.
In detail, expression of the marker gene β-gal was found in the cerebellum, various
regions of the midbrain, in the hippocampus and cortex. Further immunohistochemical
(IHC) analysis exposed β-gal expression in neurons of the nucleus ruber and motor
cortex as well as in the dorsal and ventral horn of the spinal cord. The results confirmed
that transgene expression in Tg floxed LacZ-PrPQ167R mice was present in the spinal
cord as well as in brain regions essential for motor control.
While MN are predominately located in the ventral horn, the dorsal horn of the spinal
cord mainly contains sensory neurons. MN are connected to higher brain centers either
via the pyramidal or the extrapyramidal system. In contrast to humans and primates,
where the pyramidal tract plays an important role in motor control, the extrapyramidal
system is more important in other mammalian species such as rodents. Important
brain regions for motor control are the motor cortex and nucleus ruber. The motor
cortex is involved in the planning, control, and execution of voluntary motor functions
and connected to various cranial nerve nuclei in the brain stem, such as oculomotor,
trochlear, motor nucleus of the trigeminal nerve, abducens, facial, accessory and hy-
poglossal nucleus. In addition a majority of motor cortex fibers extends directly to the
spinal cord. The nucleus ruber is an important member of the extrapyramidal tract in
rodents that controls tonicity and posture. Neurons of the nucleus ruber project to neu-
rons in the spinal cord, which are involved in reflexes, locomotion, complex movements,
and postural control. Lesions of nucleus ruber in non-primates have been related to
contra-lateral paresis as well as to ataxia [Poirier , 1974; Armand , 1984].
Sucessful recombination of transgenic DNA in Tg floxed LacZ-PrPQ167R mice mated
to Cre-strains was demonstrated by PCR analysis. Moreover PrPQ167R expression was
detected in brain and spinal cord homogenates of Tg/NF-L-Cre mice, while transgenic
mice carrying an additional Hb9-Cre allele exhibited PrPQ167R expression exclusively
95
6.1 Transgenic mice with conditional expression of PrPQ167R 6 DISCUSSION
in the spinal cord. Beside this, IHC stainings confirmed the expression of PrPQ167R
after Cre-recombination. In contrast to β-gal, which was located inside the neuronal
cytosol, PrPQ167R showed a diffuse distribution. A diffuse distribution of PrPC is also
observed in Tg(SHaPrP) mice, overexpressing hamster PrPC on a Prnp0/0 background
and argues for the presence of PrPQ167R on the neuronal cell surface (probably on
axons). Taken together, the results show that the expression of PrPQ167R is dependent
on Cre-expression, which was controlled by the NF-L or Hb9 promoter.
To investigate whether the expression of PrPQ167R had an effect on survival and
pathogenesis, transgenic mice and age-matched control littermates were inoculated
with mouse-adapted prions of the Rocky Mountain Laboratory strain (RML). In addition
to an intracerebral (i.c.) prion infection, prions were also applied from the periphery
by intraperitoneal (i.p.) or intranerval (i.n.) inoculation. In case of i.p. prion infection,
two different doses of infectivity were used. After prion infection, all transgenic mice
that succumbed to the disease displayed typical scrapie symptoms similar to those of
wild-type mice and independent of the inoculation route.
Infection with a high dose of RML led to an unaltered susceptibility of Tg117/Cre
and Tg127/Cre mice, suggesting that the expression levels of PrPQ167R were too low to
significantly slow down PrPSc replication. Several strategies could enhance PrPQ167R
expression levels. For instance an increase in Cre-expression by establishing homozy-
gous Cre-strains would be possible. While NF-L-Cre mice are viable, homozygous
Hb9-Cre mice die at or soon after birth. Therefore a second strategy would be the us-
age of different strains with stronger MN-specific Cre-expression, such as Isl1-Cre mice
[Srinivas et al., 2001], application of Cre-expressing viral vectors or a direct injection of
Cre-RNA [Ahmed et al., 2004].
In addition, expression levels of PrPQ167R also dependent on the regulation of the
UbiC promoter. In the literature it was reported that the human UbiC promoter directs
high ubiquitous expression of transgenes in spleen, liver, heart, lung, ovary, stomach,
intestine, kidney, brain, mammary gland, uterus and skin of mice [Schorpp et al., 1996].
Although the activity of the UbiC promoter was impressively demonstrated in the X-
gal screening assay, the expression strength may vary between distinct subsets of
neurons. Therefore it might be that neurons exhibiting a strong expression of Cre
shown only low UbiC promoter activity.
In contrast low dose i.p. prion infection resulted in a prolonged survival of Tg117/NF-
L-Cre mice. Tg117/NF-L-Cre mice exhibited clinical symptoms at 265 dpi, showing
a statistically significant delay of 33 dpi (15%) in incubation time when compared to
Tg117 littermates (231 dpi). Moreover, a subset of these mice remained completely
free of clinical symptoms and did not develop scrapie until 304 dpi, when the exper-
imental observation was terminated and the mice were excluded from the statistic.
Interestingly, Tg117/Hb9-Cre mice displayed only a slightly enhanced incubation time
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and succumbed to clinical prion disease at 238 dpi, which was not significantly different
from control groups. The limited protective effect of PrPQ167R in Tg117/Hb9-Cre may
be explained by the expression pattern of the Hb9 promoter.
In the mammalian spinal cord, the homeobox gene Hb9 is expressed by developing
embryonic MN, predominately during embryonic stage E9 - E9.5 until E10,5 - E11. Its
encoded homeodomain protein Hb9 has an essential role in MN development and MN
fate [Arber et al., 1999; Thaler et al., 1999]. Hb9 expression is present in cholinergic
MN with ventral projections but has not been detected above the level of the abducens
motor nucleus or in dorsal sensory neurons such as the spinal accessory or vagus
nerve [Thaler et al., 1999].
In contrast, the NF-L promoter targets a broader set of neurons as it regulates
the expression of light chain neurofilament proteins. The expression of NF-L correlates
with the development of the mouse CNS and PNS and continues in postmitotic neurons
[Yazdanbakhsh et al., 1993]. Thus, the NF-L promoter directs Cre expression to dorsal
sensory as well as to ventral MN of the spinal cord. In the brain, NF-L-Cre expression
is found e.g. in the cerebral cortex, the ammon´s horn of the hippocampus as well
as in several motor and sensory cranial nerve nuclei, including the trigeminal nerve
nuclei, the facial nucleus, the ventral cochlear nucleus, the hypoglossal nucleus and
the reticular nucleus [Schweizer et al., 2002]. However, both promoters are inactive in
interneurons and glia.
Moreover, prolonged survival was observed in Tg117/NF-L-Cre only after peripheral
prion infection pointing out the relevance of prion neuroinvasion via parasympathetic
nerve fibers (e.g. nervus vagus) [McBride et al., 2001] as this route is “blocked” in
Tg117/NF-L-Cre mice but not in Tg117/Hb9-Cre.
Surprisingly, Tg127/NF-L-Cre mice did not exhibit a prolonged survival upon low
dose i.p. prion infection. In comparison to Tg117/NF-L-Cre, Tg127/NF-L-Cre mice
exhibited a weaker expression of PrPQ167R in the brain, while PrPQ167R levels in the
spinal cord were almost equal in both transgenic lines. If the protection of CTA in
the brain would be more efficient than a protection of spinal cord MN, a diminished
expression of PrPQ167R in the brain of Tg127/NF-L-Cre could account for a limited effect
on the survival of Tg127/NF-L-Cre mice.
In this context, an interesting time table was outlined in a previous study, that aimed
to investigate the spread of TME prions from the sciatic nerve to the brain in a Syrian
hamster model. It was reported that PrPSc was first detected in the spinal cord at 4
weeks post infection in those segments that correspond to the sciatic nerve. PrPSc was
first detected in the brain at 6 weeks post infection in the nucleus ruber as well as in
the lateral vestibular nucleus and interposed nucleus of the cerebellum. At 9 weeks
post infection, PrPSc was present in the hind limb motor cortex [Bartz et al., 2002]. It is
remarkable that all of these structures are involved in the control of motor functions, in-
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cluding balance and coordination. Recently, it was demonstrated that impaired axonal
transport in MN correlated with the onset of clinical prion disease in different mouse
models. After inoculation of prions into the sciatic nerve, 30-45% of neurons in the nu-
cleus ruber and 94% of neurons in the motor cortex showed axonal transport defects
at the onset of clinical prion disease [Ermolayev et al., 2009a]. Both studies confirm
that nucleus ruber is an early entry site of prions that may play an important role in the
clinical manifestation of prion disease.
Despite different incubation times no differences in total PrPSc amounts and pathol-
ogy in transgenic mice were obvious at the terminal stage of scrapie. In contrast,
Tg/NF-L-Cre mice that remained free of clinical signs did not accumulate PrPSc in the
CNS and did not display scrapie-typical neuropathological changes, such as astroglio-
sis or vacuolization. It can be assumed that in these mice the disease was blocked at
a subclinical level, supporting the hypothesis that clinical signs appear when neuronal
damage in the CTA reaches a certain threshold [Kimberlin and Walker , 1988].
In a previous study, transgenic mice with ubiquitous expression of dominant-negative
PrPQ167R were generated either on a Prnp0/0 and on a Prnp+/+ background. Upon i.c.
prion infection, Tg (MoPrP, Q167R)/Prnp0/0 did not develop scrapie for more than 550
days, while Tg (MoPrP, Q167R)/Prnp+/+ mice succumbed to the disease at 447 dpi
[Perrier et al., 2002]. The fact that Tg (MoPrP, Q167R) mice exhibited ubiquitous ex-
pression of PrPQ167R at the same level as wild-type PrP might explain the extended
survival of these mice in comparison to our transgenic model.
In analogy to our conditional mouse model, terminal Tg (MoPrP, Q167R) /Prnp+/+
mice displayed widespread vacuolization and severe astrogliosis at the terminal stage
of scrapie. In contrast Tg (MoPrP, Q167R)/Prnp0/0 mice did not display a typical scrapie
pathology [Perrier et al., 2002]. In conclusion neuropathological changes in terminal
Tg floxed LacZ-PrPQ167R mice can be attributed to the co-expression of PrPQ167R and
wild-type PrP.
Moreover it was reported that PrPQ167R can not be converted into PrPSc [Kaneko
et al., 1997b], consequently we did not detect any PK-resistant PrPQ167R in scrapie
affected transgenic mice. Similar to our results no PK-resistant PrP was observed in
Tg (MoPrP, Q167R)/Prnp0/0 mice, while Tg (MoPrP, Q167R) /Prnp+/+ mice exhibited
PrPSc accumulation in the brain at the late stage of the disease [Perrier et al., 2002].
Transgenic PrPQ167R in Tg (MoPrP, Q167R) mice did not contain a specific antibody
epitope. Therefore it was not distinguishable from wild-type PrPC but it is likely that
also in these mice PrPQ167R did not contribute to PrPSc levels. Recently, several new
dominant-negative PrP mutants, such as S221P and Y217C, were identified by gen-
eration of a PrP library. These new dominant-negative PrP mutants were capable to
inhibit prion replication in prion infected murine neuroblastoma cells (N2a) [Ott et al.,
2008] and it will be of interest to investigate the properties of these new PrP mutants in
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vivo.
In summary, our findings demonstrate that the protection of neurons inside brain
areas that are responsible for motor control delays the appearance of clinical symptoms
after low dose peripheral prion infection. Expression of protective PrPQ167R exclusively
in a subset of spinal MN did not influence the clinical course of scrapie. Therefore
the results suggest CTA upstream of the abducens motor nucleus, e.g. in nucleus
ruber, which is in agreement with other studies [Flechsig et al., 2000; Bartz et al.,
2002; Ermolayev et al., 2009a]. Furthermore our data confirms earlier results, showing
that neuronal depletion of PrPC in prion infected mice prevented progression to clinical
prion disease [Mallucci et al., 2003].
A detailed characterization of brain centers and neuronal populations that are in-
volved in prion accumulation and pathogenisis has important implications for the devel-
opment of therapeutical concepts. Considering the various possibilities of the Cre/loxP
technology, the new mouse model with inducible expression of PrPQ167R offers a great
potential to identify new CTA responsible for the manifestation of clinical prion disease.
After identification of such defined vulnerable cell populations, therapeutical strategies
can be applied in a more focused and therefore more effective way. Moreover an ad-
vance in therapeutics can only be achieved, when intervention occurs at an early stage
of infection before massive replication and accumulation of the infectious agent and
clinical signs are obvious. A sucessful gene therapy approach in a mouse-model of
prion disease has already been published. In this study a lentiviral gene transfer was
used to deliver PrPQ167R into prion infected wild-type mice resulting in a prolonged lifes-
pan of the treated mice [Toupet et al., 2008]. In addition several approaches using RNA
interference techniques as well as antibody-based immunotherapies and attempts aim-
ing at the identification of new anti-prion molecules are under investigation [Sakaguchi ,
2009; White and Mallucci , 2009; Relaño-Ginés et al., 2009]. Thus, a detailed knowl-
edge of CTA might contribute to the development of promising strategies against prion
diseases.
6.2 Transfer of Cre-recombinase into Tg floxed LacZ-PrPQ167R mice
by adeno-associated viral vectors (AAV-Cre)
A strategy to enhance expression levels of protective PrPQ167R in the spinal cord of
Tg floxed-LacZ-PrPQ167R mice is the transfer of Cre by adeno-associated virus vectors
(dsAAV2-Cre). It was reported that AAV2 vectors efficiently spread retrogradly from
muscle tissue via muscle-innervating neurons into the spinal cord and from there pro-
ceed to connected brain centers, where the encoded transgene is efficiently expressed
[Kaspar et al., 2003].
Therefore dsAAV2-Cre was injected into the hin -limb muscles of Tg floxed-LacZ-
99
6.2 Transfer of dsAAV2-Cre into Tg floxed LacZ-PrPQ167R mice 6 DISCUSSION
PrPQ167R mice. At different time points after dsAAV2-Cre application, brain, spinal cord
and muscle tissue of transgenic mice was collected and analyzed for Cre-recombination
and expression of PrPQ167R by PCR and western blot. Moreover, two different dsAAV2-
Cre batches, exhibiting different viral titers were used.
In a number of previous studies a toxic effect of Cre-expression was observed in
cell culture as well as in transgenic mice. Cells lacking ectopic loxP sites died after
application of lenti-Cre vectors, while a massive tissue damage was found 3 weeks
after viral transfer of Cre into the brain of reporter mice. It was concluded that the
mammalian genome contains pseudo loxP sites, which serve as functional recognition
sites for Cre. As a consequence, recombination of these pseudo-loxP sites leads to
chromosome rearrangements [Silver and Livingston, 2001; Pfeifer et al., 2001]. In this
study, the application of dsAAV2-Cre had no deleterious effect on behavior and fitness
of Tg floxed-LacZ-PrPQ167R mice until 107 dpi. Thus, the results do not confirm recent
reports of Cre-toxicity.
In Tg floxed-LacZ-PrPQ167R mice, treated with dsAAV2-Cre of batch 1, no recom-
binant DNA and consequently no expression of PrPQ167R was observed. Therefore a
second batch of dsAAV2-Cre, providing a higher virus titer of 5x1010 genomic particles
per ml (GP/ml) was used. In addition to that, mice treated with dsAAV2-Cre of batch
2 were sacrificed at an earlier time point. In these mice, recombinant DNA as well as
viral Cre DNA was detected in the muscle tissue. No recombinant DNA was found in
the spinal cord or in the brain. The results confirm that functional Cre was expressed
at least at the site of virus application. Unfortunately, no expression of PrPQ167R protein
was observed in muscle, spinal cord or brain. The results suggest that even a virus
titer of 5x1010 GP/ml was not sufficient to induce the expression of PrPQ167R. Although
expression of PrPQ167R under control of the UbiC promoter was observed in brain and
spinal cord as discussed before, it remains elusive if UbiC directs expression to skeletal
muscle.
Several hypothesis may explain the poor efficiency of dsAAV2-Cre vectors to induce
recombination in Tg floxed-LacZ-PrPQ167R mice. It has to be considered that the virus
titer of both batches was calculated from quantitative real time PCR analysis. Therefore
the virus titer is only a physical titer and does not characterize the ability of dsAAV2-
Cre to infect cells in vivo. Thus, the biological titer of both dsAAV2-Cre batches may be
clearly lower than 5x1010 GP/ml.
However, it was reported that a dose of 1x1010 viral particles (vp) of single-stranded
AAV-GFP was sufficient to achieve transport of AAV from the hind limb quadriceps to
the lumbar spinal cord [Kaspar et al., 2003] and application of 0,8 µl of ssAAV2-Cre (bi-
ological titer: 1x108 vp/ml) into the brain of transgenic mice induced Cre-recombination
[Ahmed et al., 2004]. Furthermore, several studies proofed a superior and accelerated
transduction of dsAAV in vitro and in vivo as well as an increase in transgene expres-
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sion as compared to ssAAV vectors [Wang et al., 2003; Chen et al., 2007]. A stable
and efficient expression of dsAAV-GFP after i.m. injection of a 30 µl volume, exhibiting
a virus titer of 1x1011 GP/ml, resulted in strong expression of GFP already at 7 dpi
[Wang et al., 2003].
The total packaging capacity of AAV is about 5 kb [Gonçalves, 2005]. Consequently
it was suggested that in case of dsAAV vectors, the entire AAV vector genome should
not exceed 2,5 kb so that a dimer molecule can be packed within the viral capsid [Wang
et al., 2003]. As the size of dsAAV2-Cre was 5,135 kb a correct packaging of Cre-DNA
into the AAV capsid can not be assured and may lead to defective viral particles.
The fact that dsAAV2-Cre was expressed in muscle tissue but not in the spinal cord
or brain may also be related to an inefficient dsAAV2-Cre transport. It is possible that
AAV particles were not able to enter muscle innervating nerve fibers. As a conse-
quence, dsAAV2-Cre was not transported into MN of the spinal cord or to spinal cord
projecting neurons of the brain. In order to enhance the uptake of AAV into nerve fibers
and to improve retrograde transport of viral particles, a modification of capsid proteins
would be required. Alteration of the virus tropism can be achieved by chemical, im-
munological or genetic means. For example a chemical modification of the AAV capsid
using bispecific antibodies with specificity for the virion of AAV2 and the cell surface re-
ceptor αIIb β3 enabled AAV2 to transduce human megakaryoblast cells [Bartlett et al.,
1999]. In addition, insertion of foreign epitopes that mediate binding to specific cell
receptors into the capsid coding region may be an approach to enhance virus uptake
into distinct cell populations [Rabinowitz and Samulski , 2000].
To summarize, the results suggest that the current dsAAV2-Cre vector system
needs further improvement to achieve efficient transport from the site of application
to the CNS and to induce expression of PrPQ167R in Tg floxed LacZ-PrPQ167R mice. In
general, an efficient dsAAV2-Cre vector system would be desirable as it could avoid
time-consuming breeding of transgenic mice to Cre-strains.
6.3 Accumulation of PrPSc and prion infectivity in splenic tissue
of neuronal PrP deficient mice
The lethal journey of prions through the body of infected individuals involves numerous
cell types and tissues. After oral uptake prion spread from the intestine to lymphoid
organs from where they ascend to the CNS, most likely by traveling along tissue inner-
vating fibers that are connected to neurons of the spinal cord or directly to neurons of
the brain [Beekes and McBride, 2007]. An accumulation of prions in the lymphoretic-
ular system (LRS) seems to be essential for an efficient delivery of prions to the CNS.
In particular the spleen was identified as an early site of prion replication [Fraser and
Dickinson, 1970; Mould et al., 1970; Kimberlin and Walker , 1989]. However, it remains
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unclear if splenic lymphocytes or follicular dendritc cells (FDC) themselves are capable
to replicate the infectious agent or if other PrP-expressing cell types, such as neurons
innervating the LRS are involved.
To answer this question and investigate if such neurons and in particular MN are
involved in the accumulation of prions in splenic tissue, we established a double trans-
genic mouse model, carrying one allele of floxed Prnp (lox2+/−) [Rossi et al., 2001] and
either one allele of Hb9-Cre or NF-L-Cre on a Prnp0/0 background. The recombination
of transgenic DNA was demonstrated by PCR, while quantification of western blots
revealed diminished PrP levels in brain and spinal cord of double- transgenic mice,
suggesting that the expression of Cre in these mice led to a conditional PrP knockout
in a subset of MN of the spinal cord (Hb9-Cre) [Arber et al., 1999; Yang et al., 2001] or
in various neuronal populations of brain and spinal cord (NF-L-Cre) [Schweizer et al.,
2002].
Lox2 mice originate from a cloning strategy that aimed to generate a Prnp knockout
strain called Prnp0/0 Zürich II. Cre-mediated deletion of loxP flanked Prnp alleles, led
to a knockout of the entire PrP encoding region and its flanking sequences in Prnp0/0
Zürich II mice. It is known that these mice develop a cerebellar syndrome, which is
attributed to a severe loss of Purkinje cells starting at the age of ∼ 6 month. Symptoms
of this cerebellar syndrome include tremor and a trembling gait [Rossi et al., 2001]. Al-
though Cre-mediated recombination in neurons of lox2+/−/NF-L-Cre and lox2+/−/Hb9-
Cre mice established a PrP knockout similar to Prnp0/0 Zürich II, the phenotype and
behavior of double-transgenic mice was not distinguishable from wild-type mice.
After intracerebral (i.c.) and intraperitoneal (i.p.) inoculation of double-transgenic
mice with prions, the accumulation of PrPSc and prion infectivity in splenic tissue and in
the spinal cord was investigated at 50 days post inoculation (dpi). No accumulation of
PrPSc was detected in the spinal cord in any of the inoculated mice, confirming that 50
dpi represents indeed an early time point of the infection before the CNS is affected.
While PrPSc accumulation in the spleen was unaltered in PrP heterozygous (lox2+/−)
and MN-specific PrP deficient mice (lox2+/−/Hb9-Cre mice), mice with PrP depletion in
spinal cord and brain (lox2+/−/NF-L-Cre) failed to replicate PrPSc in splenic tissue. In
addition, these mice exhibited a clearly reduced prion infectivity titer in comparison to
lox2+/− and lox2+/−/Hb9-Cre mice as shown in a bioassay using PrP overexpressing
Tga20 indicator mice.
Therefore the results demonstrate that PrPSc accumulation as well as the accumu-
lation of prion infectivity titers in the spleen at an early time point of prion infection is
dependent on pan-neuronal PrP expression. In contrast a MN-specific PrP depletion
did not influence splenic PrPSc replication, suggesting that nerve fibers located in the
direct vicinity of splenic tissues are responsible. Therefore it might be possible that
after prion infection the agent multiplies in neuronal tissue, which seggregates PrPSc
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and prion infectivity to lymphoid components. In those components such as follicular
dendritic cells (FDC) or B- and T-lymphocytes, prions can be stored and accumulate to
a certain threshold.
It was reported that the expression of light neurofilaments, which is controlled by
the NF-L promoter, occurs in the mouse central and in the peripheral nervous system
(PNS) [Cochard and Paulin, 1984]. In addition to that it was shown that the NF-L pro-
moter can also initiate muscle-specific transgene expression [Yaworsky et al., 1997].
So far no direct evidence for NF-L promoter activity in splenic tissue or in spleen in-
nervating neurons was found, raising the question how NF-L positive nerve fibers can
influence prion accumulation in the spleen. Therefore a detailed mapping of the NF-L
promoter activity using highly sensitive approaches such as real time PCR, hybridiza-
tion or high resolution microscopy should be carried out.
Nevertheless, our results are in good agreement with previous studies investigat-
ing neuron-specific PrP expression in prion pathogenesis. It is clear that PrPC is re-
quired for prion replication as Prnp0/0 mice are resistant to prion infection [Büeler et al.,
1993]. PrP expression is also necessary for the transfer of prions from the periphery
to the CNS [Blättler et al., 1997]. Moreover, neuron-specific expression of hamster
PrP in transgenic mice was sufficient to render mice susceptible to hamster scrapie
[Race et al., 1995]. Another conditional PrP knockout model was described in 2002
[Mallucci et al., 2002]. Similar to lox2, MloxP mice possess floxed Prnp alleles on a
Prnp0/0 background. Upon breeding of MloxP to a strain with Cre expression under
control of the neurofilament heavy chain (NF-H) promoter, a neuronal PrP depletion
was achieved and it turned out that these mice were resistant to scrapie infection.
Later it was demonstrated that depletion of neuronal PrPC in mice with established
prion infection even reversed early spongiform changes and prevented neuronal loss
as well as progression to clinical disease [Mallucci et al., 2003]. However, if these mice
accumulate PrPSc and prion infectivity in the spleen was not investigated.
Although neuronal expression of PrPC seems to be crucial to sustain scrapie infec-
tion, non-neuronal cells may also contribute to the disease development as expression
of hamster PrP exclusively in astrocytes rendered Prnp0/0 mice susceptible to hamster
scrapie [Raeber et al., 1997]. Furthermore a hematogenous spread of prions cannot
be excluded since vCJD-cases have been described, in which transmission probably
occurred after blood transfusion [Llewelyn et al., 2004; Peden and Ironside, 2004].
As peripheral prion accumulation occurs at an early phase of the disease progres-
sion before neuronal damage and clinical signs become obvious, the involvement of
non-neuronal cells has been studied extensively. It was shown that in splenic tissue
prion infectivity is associated with B- and T-lymphocytes as well as with the stroma
[Raeber et al., 1999] and prion replication in the spleen seems to depend on PrPC
expressing FDCs [Montrasio et al., 2000; Mabbott et al., 2003]. In contrast, prion in-
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oculation experiments with mice lacking FDCs revealed that other cell types were also
capable of replicating prions [Prinz et al., 2002], but it is remains unclear which other
lymphoreticular cells are involved. Futhermore it is still elusive, how prions proceed
from FDCs to the PNS. Because of the microarchitecture of lymphoid organs, a direct
transfer from FDCs to peripheral nerve fibers seems to be unlikely as both are located
in separated compartments [Felten, 1993; Defaweux et al., 2005]. In this context motile
dendritc cells (DC) as well as exosomes have been proposed as prion transport vehi-
cles [Février et al., 2005]. It was already demonstrated that FDCs are able to bind
as well as to secrete exosomes [Denzer et al., 2000a, b]. Whether those exosomes
contain prion infectivity and if they are capable to fuse with the neuronal membrane of
peripheral nerves remains to be investigated. In addition it would be very interesting to
study if peripheral nerves are able to secrete exosomes that contain prion infectivity.
Prion disease show up with very long incubation periods. During the course of the
disease clinical signs appear at a late stage of the disease, when neuronal damage
is already widespread and non-reversible. Therefore the mechanisms of early prion
accumulation, which preceed neuronal dysfunctions have to be studied extensively
in order to develop effective diagnostic tools as well as new strategies against prion
replication and spread. In contrast to the CNS, which is separated by the blood-brain
barrier, peripheral sites such as lymphoreticular organs are much easier accessible. In
this context peripheral sites are of outstanding interest for the development of anti-prion
therapies.
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7 Summary
Prion diseases such as scrapie in sheep, bovine spongiform encephalopathy (BSE)
in cattle or Creutzfeldt-Jakob disease (CJD) in humans are fatal neurodegenerative
disorders characterized by brain lesions and the accumulation of a disease-associated
protein, designated PrPSc. How prions proceed to damage neurons and whether all
or only subsets of neurons have to be affected for the onset of the clinical disease
is still elusive. The manifestation of clinical prion disease is characterized by motor
dysfunctions, dementia and death. Furthermore loss of motor neurons (MN) in the
spinal cord is a constant finding in different mouse models of prion disease, suggesting
that MN are vulnerable cells for triggering the onset of clinical symptoms.
To determine whether the protection of MN against prion induced dysfunctions is
an approach for holding the disease at the sub-clinical level, we established a novel
conditional model for Cre-mediated expression of a dominant-negative PrP mutant
(PrPQ167R) in the cells of interest. Dominant-negative PrP mutants provide protection of
prion induced dysfunctions by inhibiting prion replication. Transgenic mice were gener-
ated carrying a floxed LacZ marker gene followed by the coding sequence of PrPQ167R
under control of the human ubiquitin C promoter. Two Cre strains have been used to
direct PrPQ167R expression either to a subset of MN of the spinal cord (Hb9-Cre) or to
various neuronal cell populations of the spinal cord and brain (NF-L-Cre). Transgenic
mice were infected with mouse-adapted prions via different inoculation routes (intran-
erval, intracerebral and intraperitoneal) and monitored for effects on incubation time
and pathology. Tg floxed LacZ-PrPQ167R/NF-L-Cre mice showed about 15% prolonged
survival upon intraperitoneal low dose prion infection, whereas survival of Tg floxed
LacZ-PrPQ167R/Hb9-Cre mice was comparable to control littermates. The results sug-
gest that the protection of spinal MN prolongs the incubation period but is not sufficient
to completely inhibit clinical prion disease.
In a second approach, Cre was transferred into the hind limb muscles of transgenic
mice via a double-stranded adeno-associated virus vector (dsAAV2-Cre). The goal of
this strategy was to target a broader cell population and thus to enhance expression
levels of protective PrPQ167R in the spinal cord of Tg floxed-LacZ-PrPQ167R mice.
After intramuscular (i.m.) application of dsAAV2-Cre, exhibiting a physical titer of
5x1010 GP/ml, recombinant transgenic DNA was detected only in the muscle tissue,
pointing out that functional Cre-recombinase was expressed at the side of virus ap-
plication. However, dsAAV2-Cre did neither induce recombination of transgenic DNA
in the spinal cord or brain nor expression of dominant-negative PrPQ167R. In conclu-
sion the dsAAV2-Cre vectors system needs further improvement to achieve efficient
transport from muscle tissue to the central nervous system (CNS).
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The lymphoreticular system (LRS) is an early site of prion replication. In splenic
tissue prion infectivity is associated with follicular dendritic cells (FDC) as well as with B-
and T-lymphocytes. However, it is still unknown if those cell types are able to replicate
the infectious agent or if other PrP-expressing cell types are engaged.
To investigate if neurons and in particular MN are involved, transgenic mice carrying
one allele of floxed Prnp (lox2+/−) and either one allele of Hb9-Cre or NF-L-Cre were
generated on a Prnp0/0 background. Therefore a conditional PrP knockout was estab-
lished in a subset of MN of the spinal cord (Hb9-Cre) or in various neuronal populations
of the spinal cord and brain (NF-L-Cre). Transgenic mice were inoculated with prions
to study the accumulation of PrPSc and prion infectivity in spleen and spinal cord at an
early time point after infection.
The findings show that PrPSc accumulation in mice with MN-specific PrP depletion
(lox2+/−/ Hb9-Cre) was comparable to control littermates, while pan-neuronal PrP de-
ficient mice (lox2+/−/NF-L-Cre) were not able to accumulate PrPSc in splenic tissue
until 50 days post inoculation. Moreover spleens of lox2+/−/NF-L-Cre mice exhibited
a clearly reduced prion infectivity titer, suggesting that accumulation of prions in the
spleen is dependent on PrP expression in the nervous tissue.
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8 Zusammenfassung
Prionenerkrankungen, wie Scrapie beim Schaf, die bovine spongiforme Enzephalo-
pathie (BSE) beim Rind oder die Creutzfeldt-Jakob-Krankheit (CJD) beim Menschen
sind letale, neurodegenerative Erkrankungen des zentralen Nervensystems (ZNS). Ty-
pische Merkmale der Erkrankung sind neben Neuronenverlust die Akkumulation des
mit der Krankheit assoziierten Proteins PrPSc im Gehirn infizierter Individuen. Wie die
Akkumulation von Prionen zu Neurodegeneration führt und welche Regionen des ZNS
für die klinische Erkrankung verantwortlich sind, ist bisher unbekannt. Charakteristi-
sche, klinische Symptome von Prionenkrankheiten sind motorische Störungen sowie
Demenz in einem späten Stadium der Erkrankung. Außerdem ist der Verlust von Mo-
toneuronen (MN) im Rückenmark ein konstanter Befund im Tiermodell, was eine Rolle
des motorischen Nervensystems bei der Prionpathogenese vermuten lässt.
In dieser Arbeit sollte daher untersucht werden, ob der Schutz von MN vor Prio-
nen induzierten Dysfunktionen den Ausbruch der klinischen Erkrankung verzögern
kann. Dazu wurde ein konditionales Mausmodell mit Cre-induzierbarer Expression ei-
ner dom- inant-negativen PrP-Mutante (PrPQ167R) hergestellt. Dominant-negative PrP
Mutanten schützen vor Prionen induzierten Schädigungen, indem sie die Replikation
von Prionen inhibieren. Das Transgen besteht aus dem humanen Ubiquitin C Promoter,
einem „gefloxten” LacZ Markergen und der kodierenden Sequenz von PrPQ167R. Die
Kreuzung von Tg floxed LacZ-PrPQ167R Mäusen mit der Hb9-Cre Linie bewirkt eine MN-
spezifische Expression von PrPQ167R im Rückenmark, während das Einkreuzen eines
NF-L-Cre Allels die Expression von PrPQ167R in den meisten Neuronen des Rücken-
marks sowie in verschiedenen motorischen Kerngebieten des Gehirns zur Folge hat.
Transgenen Mäuse wurden auf verschiedenen Routen (intranerval, intrazerebral und
intraperitoneal) mit Maus-adaptierten Prionen infiziert und der Effekt von PrPQ167R auf
die Inkubationszeit und Pathologie der Tiere untersucht. Während Tg floxed LacZ-
PrPQ167R/NF-L-Cre Mäuse eine um 15% verlängerte Inkubationszeit aufwiesen, war
bei Tg floxed LacZ-PrPQ167R/Hb9-Cre Mäusen kein Überlebensvorteil zu beobachten.
Somit verlängert der Schutz von MN des Rückenmarks zwar die Inkubationszeit, ist
aber nicht ausreichend, um den klinischen Ausbruch der Erkrankung zu verhindern.
Um eine größere Zellpopulation im Rückenmark von Tg floxed LacZ-PrPQ167R Mäu-
sen und so eine stärkere Expression von PrPQ167R zu erreichen, wurde ein viraler
Gentransfer von Cre-Rekombinase durchgeführt. Dazu wurden doppelsträngige, Cre-
exprimierende Adeno-assoziierte Virus Vektoren (dsAAV2-Cre) bilateral in die Musku-
latur der Hinterbeine von Tg floxed LacZ-PrPQ167R Mäusen injiziert.
Die Applikation von dsAAV2-Cre, mit einem physikalischen Virus-Titer von 5x1010
GP/ml, führte ausschließlich im Muskelgewebe zur Expression von enzymatisch aktiver
Cre-Rekombinase und folglich zur Rekombination der transgenen DNA. Im Rücken-
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mark oder Gehirn war keine rekombinante DNA detektierbar. Auch auf Protein-Ebene
konnte die Expression von PrPQ167R weder im Muskel noch im Rückenmark oder Ge-
hirn nachgewiesen werden. Um den Transport von dsAAV2-Cre vom Applikationsort
bis in das ZNS zu gewährleisten und Cre stabil zu exprimieren, ist demnach eine wei-
tere Optimierung des dsAAV2-Cre Vektorsystems notwendig.
Prionen replizieren im lymphoretikulären System (LRS) bereits in einem frühen Sta-
dium der Erkrankung. In der Milz ist Prionen-Infektiosität in follikulär dendritischen Zel-
len (FDC) sowie in B- und T-Lymphozyten lokalisiert. Ob noch andere PrP exprimie-
rende Zellen an der Prionen-Replikation im LRS beteiligt sind, ist unklar.
Um die Beteiligung von Neuronen und MN an der Akkumulation von Prionen im
LRS zu untersuchen, wurden transgene, neuronal PrP defiziente Mäuse generiert.
Ein Neuronen-spezifischer bzw. MN-spezifischer Knockout von PrP wurde durch Kreu-
zung von transgenen lox2+/− Mäusen, welche ein „gefloxtes“ Prnp Allel Prnp auf ei-
nem Prnp0/0 Hintergrund tragen, mit NF-L-Cre oder Hb9-Cre Mäusen erreicht. Nach
Prionen-Infektion von lox2+/−/NF-L-Cre und lox2+/−/Hb9-Cre Mäusen wurde die Ak-
kumulation von PrPSc und Prionen-Infektiosität in der Milz und im Rückenmark am Tag
50 nach der Infektion analysiert.
Während die Replikation von PrPSc in der Milz von Mäusen mit MN-spezifischem
PrP Knockout (lox2+/−/Hb9-Cre) nicht beeinträchtigt war, war in pan-neuronal PrP de-
fizienten Mäusen (lox2+/−/NF-L-Cre) keine Akkumulation von PrPSc nachweisbar. Zu-
dem war die Prionen-Infektiosität in der Milz von lox2+/−/NF-L-Cre Mäusen deutlich
reduziert. Die Ergebnisse weisen darauf hin, dass die Akkumulation von PrPSc und
Prionen-Infektiosität in der Milz abhängig von neuronaler PrP Expression ist.
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9 Supplement
9.1 Abbreviations
aa Amino acid HSV Herpes simplex virus
AAV Adeno-associated virus i.c. Intracerebral
Ad Adeno virus i.m. Intramuscular
Aβ Alzheimer´s peptide i.n. Intranerval
β-gal β-galactosidase i.p. Intraperitoneal
BSE Bovine spongiform
encephalopathies
IHC
iCJD
Immunohistochemistry
Iatrogenic CJD
CJD Creutzfeldt-Jakob disease ITR Inverted terminal repeat
CMV Cytomegalo virus LCR Locus control region
CNS Central nervous system LRS Lymphoreticular system
Cre Cre-recombinase LTP Long term potentiation
CTA Clinical target area MBM Meat-and-bone-meal
CWD Chronic wasting disease MN Motor neuron
DC Dendritic cell n Number of measurements
DNA Deoxyribonucleic acid N2a Neuroblastoma cells
dpi Days post inoculation neo Neomycin
ds Double stranded NeuN Neuronal neuclei
E Embryonic stage NF-L Neurofilament light chain
e.g. for example (Latin: exempli gratia) NLS Nuclear localization signal
ER Endoplasmatic reticulum NMR Nuclear magnetic resonance
FACS Fluorescence activated cell sorting NTP Nucleotide triphosphate
fCJD Familiar Creutzfeldt-Jakob disease OD Optical density
FDC Follicular dendritic cell PAGE Polyacrylamide gel electrophoresis
FFI Fatal familiar insomnia PCR Polymerase chain reaction
FSE Feline spongiform
encephalopathies
PK
PMCA
Proteinase K
Protein misfolding cyclic amplification
GALT Gut-associated lymphoid tissue PNS Peripheral nervous system
GFAP Glial fibrillary acidic protein prion Proteinaceous infectious particles
GFP Green fluorescent protein Prnp PrP gene
GPI Glycophosphatidylinositol anchor PrP Prion protein
GSS Gerstmann-Sträussler-Scheinker
syndrome
PrPC
PrPSc
cellular form of PrP
infectious form of PrP, PrP-scrapie
HA Haemagglutinin tag PSPr Protease-sensitive prionopathy
Hb9 Homeobox gene PVDF Polyvinylidene difluoride membrane
HE Hematoxylin-eosin qrt Quantitative real time
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HEK Human embryonic kidney cells RML Rocky mountain laboratory
HRP Horse radish Peroxidase RNA Ribonucleic acid
sCJD Sporadic CJD TME Transmissible mink encephalopathies
SD Standard deviation trs Terminal resolution site
SDS
SOD
Sodium dodecyl sulfate
Superoxide dismutase
TSE Transmissible spongiform
encephalopathies
ss Single stranded UbiC Human ubiquitin C promoter
STE Stop transfer region UK United Kingdom
Tg Trangenic vCJD Variant CJD
TM Transmembrane sequence WFA Wisteria floribunda agglutinin
9.2 Units
SI Base quantity Name Symbol SI base unit
length meter m m
mass kilogram kg kg
time second s s
electric current ampere A A
thermodynamic temperature kelvin K K
amount of substance mole mol mol
luminous intensity candela cd cd
SI Derived quantity
electric potential difference volt V m2 kg s−3 A−1
Celsius temperature degree Celsius °C K
Non SI quantity
minute min 1 min = 60 s
hour h 1 h = 60 min = 3600 s
day d 1 d = 24 h = 86400 s
liter L 1 L = 1 dm−3 = 10−3m3
Molarity (concentration) M (c) mol L−1
Mass-volume percentage % (w/v)
Volume-volume percentage % (v/v)
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SI prefixes
Factor Name Symbol Factor Name Symbol
1024 yotta Y 10−1 deci d
1021 zetta Z 10−2 centi c
1018 exa E 10−3 milli m
1015 peta P 10−6 micro µ
1012 tera T 10−9 nano n
109 giga G 10−12 pico p
106 mega M 10−15 femto f
103 kilo k 10−18 atto a
102 hecto h 10−21 zepto z
101 deka da 10−24 yocto y
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